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Acinetobacter baumannii is an emerging multiresistant pathogen increasingly known 
to cause infections in the immuno-compromised patients. Carbapenems and colistin 
are considered to be the last resorts in treatment of i fections involving multidrug 
resistant strains of A. baumannii. Resistance to carbapenems is well known due to the 
presence of intrinsic carbapenemase gene blaOXA-51-like, which may be governed by 
insertion elements, or by acquired carbapenemases like blaOXA-23-like, blaOXA-58-like or 
blaOXA-40-like genes, most of which are frequently associated with insertion elements.  
 
The acquired carbapenemases can be integrated with the host chromosome making 
the bacterium strongly resistant to a range of antibiotics. Recent reports also suggest 
that the ubiquitous and intrinsic enzymes encoded by the blaOXA-51-like gene can be 
mobilized on a plasmid. 
 
In this thesis, the prevalence of antibiotic resistance was examined for 96 strains 
isolated from various parts of the world. The resistances to aminoglycosides, 
fluoroquinolones and cephalosporins were studied with a major focus on resistance to 
carbapenems. 
 
Section 1 shows the transposition of ISAba1 and its varied influence in controlling the 
blaOXA-51-like gene and the blaADC gene. It explains how ISAba1 being a strong factor in 
influencing antibiotic resistance genes contributes to the plasticity of the organism 
 
Section 2 is related with a novel insertion element ISAba125 controlling the blaADC 
gene and as an element providing high resistance to f azidime in comparison to 
ISAba1. 
 
Section 3 analyses the multi-drug resistant profile f strains isolated from 
Cochabamba, Bolivia. Besides the classification of carbapenem resistance for the 
clinical strains, the aminoglycoside resistance and ciprofloxacin mechanisms are 
examined in this project 
 
Section 4 relates with the pattern of resistance in strains isolated from the Aberdeen 
Royal Infirmary. It describes two novel variants of the blaOXA-51-like gene, namely 
blaOXA-216  and blaOXA-217 and also the acquisition of the blaOXA-23-like gene in two 
isolates from different years and deemed identical by their PFGE pattern. 
 
Section 5 describes the influence of ISAba825 in controlling the blaOXA-51-like gene and 
the blaOXA-58-like from clinical isolates 
 
Section 6 is related with the insertional inactivation of the blaOXA-132 gene and the 
carbapenem resistance caused by the activation of the blaOXA-58 gene in isolate Ab244 
 
Section 7 describes the influence of insertion elemnts in strains having high 
ciprofloxacin resistance. This project is concerned with the role of efflux pump 
control system adeRS and how they influence the adeABC operon causing increased 
and decreased expression of the genes. 
 
Section 8 describes the multi drug resistant pattern of 36 strains each isolated from 
Europe and the United States  
 
In conclusion, there are various factors that influence the resistance profile of multi-
drug resistant A. baumannii isolates with insertion sequences such as ISAba1, 
ISAba2, ISAba3, ISAba825, IS1008, ISAba125, ISAba16 governing the expression or 
providing alternate mechanisms of resistance for the better fitness of the bacterium. 
Mutations in the genes identified in this study also have a crucial role in imparting 
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1.0 INTRODUCTION  
1.1 The genus Acinetobacter 
1.1.1 An historical perspective 
The genus Acinetobacter has a complex history, and only recently it has become 
possible to distinguish various species within the genus. Phylogenetic classification 
places the genus Acinetobacter in the group of Gammaproteobacteria of the 
Proteobacteria (Juni, 2005). The history of the genus Acinetobacter begins in 1911 
when the Dutch microbiologist Beijerinck isolated a micro-organism from soil by 
enrichment in calcium acetate containing minimal medium (Beijerinck, 1911). This 
organism was named as Micrococcus calco-aceticus. Over the following decades 
similar organisms were described and assigned to different genera and species, e.g; 
Achromobacter anitratus (Brisou, 1953),  Achromobacter mucosus (Mannheim and 
Stenzel, 1962), Alcaligenes haemolysans (Henriksen, 1973), Bacterium anitratum 
(Schaub and Hauber, 1948) , Diplococcus mucosus (von Lingelsheim, 1908), Herellea 
vaginicola (DeBord, 1942), Mima polymorpha (DeBord, 1939), Moraxella lwoffi 
(Audureau, 1940), Neisseria winogradskyi (Lemoigne et al., 1952). The genus 
Acinetobacter (greek- akinetos, i.e nonmotile) was proposed by Brisou and Prévot in 
1954 to separate the non-motile micro-organisms from the motile ones within the 
genus Achromobacter. Baumann et al (1968) published a comprehensive survey and 
concluded that the species listed above belonged to the proposed Acinetobacter genus. 
They also concluded that further phenotypic classification of various species was not 
possible (Baumann et al., 1968). By the end of 1980 the names A. calcoaceticus for 
strains producing acids from sugars and A. lwoffii for non acid- producing strains were 
approved (Skerman et al., 1980)  
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1.1.2 Taxonomic classification of Acinetobacter species 
The genus Acinetobacter has been revised extensively since 1986. It comprises of 33 
different species of which 22 are named (Table 1) (Dijkshoorn et al., 2007, Nemec et 
al., 2009, Nemec et al., 2011) and further 28 groups have been identified. The genus 
Acinetobacter, as currently defined, comprises of Gram-negative, strictly aerobic, 
non-fermenting, non-fastidious, non-motile, catalase-positive, oxidase-negative 
bacteria with DNA G+C content of 39% to 47% (reviewed by Peleg et al., 2008). It 
was proposed in 1991 that the members of the genus Acinetobacter should be 
classified in the new family Moraxellaceae within the order Gammaproteobacteria, 
which includes the genera Moraxella, Acinetobacter, Psychrobacter and other related 
organisms (Rossau et al., 1991). Twelve Acinetobacter genospecies were delineated 
on the basis of DNA-DNA hybridization (Bouvet and Grimont, 1986). Further work 
done by Bouvet and Jeanjean, Tjernberg and Ursing, and Nishimura et al added to the 
description of further Acinetobacter genomic species (Bouvet and Jeanjean., 1989, 
Tjernberg and Ursing, 1989, and Nishimura et al., 1988). A. calcoaceticus, A. 
baumannii, Acinetobacter genomic species 3, and Acinetobacter genomic species 13 
TU are very closely related, it is very difficult to distinguish them from each other by 
phenotypic characteristics and these species are referred to as the A. calcoaceticus- A. 
baumannii complex (Grener-Smidt, 1992, Grener-Smidt et al., 1991). Further studies 
are essential to assess the relatedness of species clusters in more detail.   
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Table 1. Classification of the genus Acinetobacter 
(Dijkshoorn et al., 2007, Nemec et al., 2009, Nemec et al., 2010, Nemec et al., 2011) 
Named species Genomic species Source 
Acinetobacter calcoaceticus 1 Soil and humans (including clinical specimens) 
Acinetobacter baumannii 2 Humans (including clinical specimens), soil, meat 
and vegetables 
Acinetobacter haemolyticus 4 Humans (including clinical specimens) 
Acinetobacter junii 5 Humans (including clinical specimens) 
Acinetobacter johnsonii 7 Humans (including clinical specimens) and animals 
Acinetobacter lwoffii 8,9 Humans (including clinical specimens) and animals 
Acinetobacter radioresistens 12 Humans (including clinical specimens), soil and 
cotton 
Acinetobacter ursingii  Humans (including clinical specimens) 
Acinetobacter schindleri  Humans (including clinical specimens) 
Acinetobacter parvus  Humans (including clinical specimens) and animals 
Acinetobacter baylyi  Activated sludge and soil 
Acinetobacter bouvetii  Activated sludge 
Acinetobacter towneri  Activated sludge 
Acinetobacter tandoii  Activated sludge 
Acinetobacter grimontii  Activated sludge 
Acinetobacter tjernbergiae  Activated sludge 
Acinetobacter gerneri  Activated sludge 
Acinetobacter venetianus  Sea water 
Acinetobacter pittii 3 Humans (including clinical specimens), soil and 
vegetables 
Acinetobacter nosocomialis 13TU Humans (including clinical specimens) 
 6 Humans (including clinical specimens) 
Acinetobacter bereziniae 10 Humans (including clinical specimens), soil and 
vegetables 
Acinetobacter guillouiae 11 Humans (including clinical specimens) and animals 
 13BJ, 14TU Humans (including clinical specimens) 
 14BJ Humans (including clinical specimens) 
 15BJ Humans (including clinical specimens) 
 16 Humans (including clinical specimens) and 
vegetables 
 17 Humans (including clinical specimens) and soil 
 15TU Humans (including clinical specimens) and animals 
 ‘Between 1 and 3’ Humans (clinical specimens) 
 ‘Close to 13TU’ Humans (clinical specimens) 
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1.1.3 Importance of Acinetobacter species 
Acinetobacter baumannii has emerged as one of the most troublesome pathogens for 
health care institutions globally (reviewed by Peleg et al., 2008). It has a very high 
incidence in most hospitals and the misuse of broad-spectrum antibiotics has led to an 
increase in multi-drug resistance of this bacterium. Also the natural resistance of 
Acinetobacter spp. to several β-lactam antibiotics has caused an increase in its 
resistance profile (Amyes and Young, 1996). A. baumannii strains resistant to all 
known antibiotics have now been reported, signifying a sentinel event that should be 
acted on promptly by the international health care community (reviewed by Peleg et
al., 2008). Acting in synergy with this emerging resistance profile is the uncanny 
ability of A. baumannii to survive for prolonged periods, thus potentiating its ability 
to spread. The organism mostly targets the vulnerabl  hospitalized patients who are 
critically ill with breaches in skin integrity and airway protection (reviewed by Peleg 
et al., 2008). The most common infection caused by this organism is hospital-
acquired pneumonia (Glew et al., 1977). Although, recent reports suggest that it can 
also cause central nervous system and skin and soft tissue infections (reviewed by 
Peleg et al., 2008). 
 
1.1.4 Identification and typing of Acinetobacter species 
Acinetobacters may be identified presumptively as Gram-negative, catalase-positive, 
oxidase-negative, nonmotile and nonfermenting coccoba illi (reviewed by Peleg et 
al., 2008). The scheme proposed by Bouvet and Grimont in 1987 included growth at 
37, 41 and 44°C; production of acid from glucose; gelatine hydrolysis; and 
assimilation of 14 different carbon sources (Bouvet and Grimont, 1987). This system 
correctly identified 136 Acinetobacter spp (95.6%) to the species level (Seifert et al., 
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1997). Since this method of identification is laborious it is far from being suitable for 
routine laboratory microbiology testing in the labs. Species identification of 
acinetobacters for laboratory diagnostic purposes i currently done by systems such as 
API 20NE, VITEK 2, Phoenix, and MicroScan WalkAway. These phenotypic systems 
can be problematic. The four species belonging to A. calcoaceticus- baumannii 
complex can only be distinguished by molecular methods. Table 2 describes the 
genotypic methods available for Acinetobacter species identification (Seifert and 
Dijkshoorn, 2008) 
 
Table 2. Genotypic methods for Acinetobacter species identification 
(Seifert and Dijkshoorn, 2008) 
Method Target structure 
AFLPTM analysis Whole genome 
tRNA spacer fingerprinting tRNA spacer 
PCR-RFLP 16S rDNA sequence (in ADRA analysis) 
 recA 
 16-23S spacer rDNA 
Ribotyping rDNA and adjacent regions 
Hybridization with oligonucleotide probe 16-23S spacer rDNA 
DNA sequence analysis 16S rDNA 






Amplified rDNA restriction analysis (ADRA) and amplified fragment length 
polymorphism (AFLP) are currently the most widely accepted and validated reference 
methods for species identification of acinetobacters with a large library of profiles 
available for both reference and clinical strains (reviewed by Peleg et al., 2008).  
ADRA is similar to the PCR-RFLP methods. The 16S rDNA sequence is amplified 
and separated by agarose electrophoresis after digestion with five different restriction 
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enzymes each. The combined patterns generated with the five enzymes are then 
compared to a library of profiles of strains of all known species (Seifert and 
Dijkshoorn, 2008). The ADRA combined with phenotypic characterization, i.e., 
consensus identification can compensate for the limitations of each of the two 
approaches (Nemec et al., 2000).  AFLP analysis is a high resolution whole genomic 
fingerprinting method by which restriction fragments are selectively amplified (Vos et 
al., 1995). A simplified protocol as compared to the original procedure was set up at 
Leiden University Medical Center (LUMC). In this procedure, EcoRI and MseI are 
used for restriction and the DNA is ligated to adapters in a single step, after which 
selective amplification is achieved with an Mse-C primer and a Cy-5 labeled Eco-A 
primer. Amplified fragments are separated electrophoretically on a sequencing 
machine and the banding patterns are analyzed by cluster analysis with dedicated 
software. 
 
More recent developments include the identification of A. baumannii by detection of 
the blaOXA-51-like intrinsic to this species (Brown et al., 2005, Turton et al., 2006b).  
 
1.1.5 Natural habitat of Acinetobacter species 
Acinetobacter species are generally isolated from environmental samples such as soil 
and sludge, vegetables or from clinical human samples (Table 1). 
 
Many members of the genus are generally considered to be environmental organisms 
as they are ubiquitously present in the environment (r viewed by Peleg et al., 2008). 
This holds true for the genus Acinetobacter, as they can be recovered from virtually 
all samples obtained from soil or surface water after enrichment (Baumann, 1968) but 
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not all species of the genus Acinetobacter have their natural habitat in the 
environment.  
 
Acinetobacters are part of the human skin flora. In an epidemiological survey 
performed to investigate the colonization of human ski  and mucous membranes with 
Acinetobacter species, up to 43% of non-hospitalized individuals tested positive 
(Seifert et al., 1997). The most frequently isolated species were A. lwoffii (58%), A. 
johnsonii (20%), A. junii (10%), and A. pittii  (previosuly genomospecies 3) (6%). In a 
similar study, a carrier rate of 44% was found in healthy volunteers, with A. lwoffii 
(61%), Acinetobacter genomic species 15BJ (12%), A. radioresistens (8%), and 
Acinetobacter pittii (5%) being the most prevalent species (Berlau et al., 1999). In 
patients hospitalized on a regular ward, the carriage r te with these species was even 
higher, at 75% (Seifert et al., 1997). The faecal carriage of Acinetobacter was 25% 
among healthy individuals, with A. johnsonii and Acinetobacter genomic species 11 
predominantly present (Dijkshoorn et al., 2005). A total of 226 samples were 
examined. 
 
In a study of the microbial communities from the extr me environments of six 
Andean lakes, a total of five different acinetobacters were isolated, one of which was 
A. johnsonii (Ordonez et al., 2009). Members of the species A. calcoaceticus have 
been isolated from the soil surrounding plant roots and have been shown to promote 
plant growth in vitro (Peix et al., 2009). A. baylyi, another organism isolated from the 
soil, has been shown to be able to acquire plant DNA through horizontal gene transfer 
or by conjugation (Pontiroli et al., 2009). An A. baumannii solate from petroleum-
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contaminated desert soil in Kuwait has been shown t be able to degrade crude oil 
(Obuekwe et al., 2009). 
 
A. baumannii, the most important nosocomial Acinetobacter spp, was found only 
rarely on human skin and in human faeces, and Acinetobacter nosocomialis could not 
be detected at all (Seifert e al., 1997; Berlau et al., 1999; Dijkshoorn et al., 2005). 
A. baumannii was occasionally found as aetiological agents in infected animals 
(Francey et al., 2000; Vaneechoutte et al., 2000). A. baumannii was recovered from 
22% of body lice sampled from homeless people (La Scola and Raoult, 2004). It has 
been speculated that this finding might result from clinically silent bacteraemia in this 
group; the clinical implication of this observation, however, is not yet clear. In Hong 
Kong, 51% of local vegetables were found to be contaminated with acinetobacters, 
the majority of which were A. pittii (75%), but one sample grew A. baumannii 
(Houang et al., 2001). In particular, it has to be demonstrated that it is not human 
handling of vegetables that are the source of A. pittii. Acinetobacters were found in 22 
of 60 soil samples collected in Hong Kong, and the most frequent species were A. 
pittii  (27%) and A. baumannii (23%); only one sample yielded A. calcoaceticus 
(Houang et al., 2001). 
 
Infected animals and surface contaminated vegetables nd water can act as a source of 
transmission for Acinetobacter spp, allowing it to freely enter the human food chain.  
Furthermore silent carriers and fomites may also be responsible for the spread of this 
pathogenic bacterium.  
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A study of skin carriage among healthy individuals in UK showed an Acinetobacter 
carriage rate of 44% , with A. lwoffii accounting for 61% of isolates, Acinetobacter 
genospecies 15BJ accounting for 12.5%, and A. radioresistens accounting for 8% 
(Berlau et al., 1999). The percentage of Acinetobacters in a group of healthy people 
was 42.5%, mainly A. lwoffii, followed by A. johnsonii, and to a lesser extent of A.
junii (Seifert et al., 1997). In a study performed in Hong Kong, it was found that 53% 
of medical students and new nurses colonized with acinetobacters in summer versus 
32% in winter (Chu et al., 1999).  A seasonal variation in the frequency of 
Acinetobacter infections was also observed in USA and attributed to increased 
humidity in the summer months (Retailliau et al., 1979; McDonald et al., 1999). 
 
In conclusion, A. baumannii, A. pittii and A. nosocomialis may be found rarely in 
environmental samples, but they are emerging pathogens in the hospital environment 
and are frequently isolated from various clinical sources. More studies need to be 
performed to get a better understanding of the distribution of Acinetobacter species in 
the environment, in humans, and in animals. Systematic surveys in different 
geographical settings and under different climatic conditions should be carried out for 
detailed investigation purposes. 
 
1.2 Clinical manifestations of infections caused by A. baumannii. 
Acinetobacter baumannii is rapidly emerging as a multiresistant bacterium and today 
it can be considered as the paradigm of antibiotic resistant bacteria. The major 
problems confronting the clinicians in the ICUs arerelated to the severity of the 
clinical situation and multi-drug resistance (Bergogne- Bérézin, 2008). Acinetobacters 
are commonly found in the hospital environment, as colonizers of the patient’s skin 
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and mucous membranes and they are responsible for the spread of nosocomial 
infections. The three major factors responsible for the strength of this bacterium are 
resistance to major antimicrobial agents, resistance to dessication and to disinfectants 
(Seifert and Dijkshoorn, 2008). 
 
1.2.1 Urinary tract infections 
A. baumannii rarely causes UTI with just 1.6% of ICU-acquired UTI, mainly catheter 
associated infection or colonization. Although, there has been a gradual increase in 
UTI caused by A. baumannii (Gaynes and Edwards, 2005). The use of endotracheal 
tubes, intravascular, ventricular, or urinary catheters often leads to opportunistic 
bacteria colonizing the site (Joly-Guillou, 2008). It is not unusual for this bacterium to 
cause uncomplicated UTI in healthy outpatients (reviewed by Peleg et al., 2008). 
 
1.2.2 Meningitis 
Acinetobacter is a rare cause of meningitis althoug post-neurosurgical A. baumannii 
meningitis is becoming an increasingly important entity with mortality rates as high as 
64% been reported in patients with meningitis due to A. baumannii (Garcia-
Garmendia et al., 2001). Sporadic cases have been reported following neurosurgical 
procedures (Chen et al., 2005). An outbreak of Acinetobacter meningitis was 
described in a group of children with leukaemia following administration of 
intrathecal methotrexate due to inappropriately steriliz d needles which lead to death 
of three children. Risk factors for meningitis include the presence of a continuous 
connection between the ventricles and the external vironment, a ventriculostomy, a 
CSF fistula, presence of an indwelling ventricular c theter for more than 5 days, and 
the use of antimicrobial agent. A wide prevalence of multiresistant Acinetobacter 
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causing meningitis in neurosurgical patients has been seen in Turkey (Metan et al., 
2007). The surveillance of local pathogens in neuros rgical wards should guide the 





1.2.3 Suppurative infections 
In recent times, acinetobacter infections involving skin and soft tissue have become 
very problematic. This may be because strains of Acinetobacter species are the only 
group of Gram-negative bacteria that may be present naturally on the human skin 
(Seifert et al., 1997). It was reported by Gaynes and Edwards (2005) that 
Acinetobacter was responsible for 2.1% of ICU-acquired skin/soft tissue infection. It 
is a very difficult pathogen to eradicate from a burns unit (Trottier et al., 2007). 
A. baumannii s commonly isolated from wounds of combat casualties from Iraq or 
Afghanistan (reviewed by Peleg t al., 2008). It was the most commonly isolated 
pathogen from patients with open tibial fractures, but due to its low pathogenicity at 
this site, it was completely eradicated (Johnson et al., 2007). 
 
1.2.4 Bloodstream infections 
A. baumannii was the 10th most common aetiologic agent, responsible for 1.3% of all 
nosocomial bloodstream infections in the United States (reviewed by Peleg et al., 
2008). A. baumannii was a more common cause of ICU-acquired bloodstream 
infection than of non-ICU-ward infection (1.6% versus 0.9% of bloodstream 
infections, respectively, in those locations). Crude mortality overall from A. 
baumannii bloodstream infection was 34.0% to 43.4% in the ICU and 16.3% outside 
the ICU. A. baumannii bloodstream infection had the third highest crude mortality 
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rate in the ICU, exceeded only by infections caused by P. aeruginosa and Candida 
spp. A. baumannii nfections were the latest of all bloodstream infections to occur 
during hospitalization, occurring at a mean of 26 days from the time of hospital 
admission (reviewed by Peleg t al., 2008). It is therefore not certain if the high crude 
mortality rate represents its occurrence in patients wi h ongoing underlying critical 
illness or whether the organism does have significat attributable mortality. It is 
notable that 102 patients had bloodstream infections at sites treating U.S. military 
members injured in Iraq or Afghanistan from 1 January 2002 and 31 August 2004 
(reviewed by Peleg et al., 2008). Recent report suggests that A. baumannii s resistant 
to a range of antibiotics and, most importantly, A. baumannii bacteraemia has a worse 
prognosis than bacteraemia due to non-A. baumannii solates (Lee et al., 2010). 
 
1.2.5 Hospital acquired infections 
A. baumannii nfection is a pathogen of considerable importance associated with high 
mortality in patients with pneumonia (Fagon et al., 1989). It is one of the most 
important causes of nosocomial pneumonia especially after the use of a mechanical 
ventilator. The incidence of nosocomial pneumonia ifections caused by A. 
baumannii between 1976 and 1990 increased from 0.64% to 6.4% (McDonald et al., 
1999). In a review from the CDC, 7% of ICU-acquired pneumonias were due to 
Acinetobacter in 2003, compared to 4% in 1986 (Gaynes and Edwards, 2005). The 
majority of A. baumannii solates were from the respiratory tracts of hospitalized 
patients. In many circumstances, it is very difficult to distinguish upper airway 
colonization from true pneumonia although there is no doubt that A. baumannii does 
cause ventilator-associated pneumonia (VAP). In large surveillance studies from the 
United States, between 5 and 10% of cases of ICU-acquired pneumonia were due to 
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A. baumannii (Gaynes and Edwards, 2005). The number of ICU-acquired pneumonia 
is very much a cause of concern today. Infections are associated with 
immunocompromised patients, with infection rates often being highest in intensive 
care units (ICUs) and surgical wards. It has been rported that 15% of all nosocomial 
infections were hospital-acquired pneumonia with the mortality rate exceeding 30% 
(Timsit et al., 1996). However, mechanical ventilation is a criti al risk factor for 
developing hospital acquired pneumonia in patients who require prolonged 
mechanical ventilation (>48hrs); hospital acquired pneumonia occurs within 48hrs of 
incubation (Rello et al., 1999). A. baumannii is directly responsible for patient death, 
and therefore the risk factors for colonization between ventilation associated 
pneumonia due to A. baumannii nfection could differ from other bacteria responsible 
for similar infection (Baraibar and Colleges, 1997). Patients with A. baumannii 
infections have had prolonged ICU stays, although in outbreak situations, earlier 
acquisition of infection may occur (reviewed by Peleg et al., 2008). Prolonged 
survival of A. baumannii n a clinical setting, i.e. on patients bed rails, has been found 
associated with an ongoing outbreak in an intensive car  unit and illustrates that dry 
vectors can be secondary reservoirs where A. baumannii can survive (Catalano et al., 
1999). 
 
The proportion of individuals with previous MDR A. baumannii solation who remain 
carriers for prolonged periods was substantial in an Israeli hospital. Surveillance 
cultures involved six different body sites including ostrils, pharynx, skin, rectum, 
wounds, and endotracheal aspirates (Marchaim et al., 2007). It remains to be 
determined if long-term carriage of MDR A. baumannii n an individual patient may 
contribute to transmission of these organisms within and outside the hospital.  
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Epidemiological surveys involving acinetobacters have identified A. baumannii to be 
by far, the most frequent cause of infection, though there are reports of higher rates of 
isolation of A. pittii (Lim et al., 2007, Boo et al., 2009). While A. pittii and A. 
nosocomialis tend to cause infections sporadically they are usually relatively 
susceptible to antibiotics but the same cannot be said of A. baumannii. Mortality rates 
for Acinetobacter species other than A. baumannii have been found to be low, with 
values between 7% and 18% being reported (Seifert t al., 1994, Choi et al., 2006). 
However, crude mortality rates of between 8% and 43% have been reported for A.
baumannii (Falagas et al., 2006). Additionally, the length of stay in hospital 
associated with A. baumannii nfection was significantly longer than that for other 
Acinetobacter species (Choi et al., 2006).  
 
1.2.6 Community acquired infections 
Community-acquired pneumonia due to A. baumannii has been described for tropical 
regions of Australia and Asia (reviewed by Peleg et al., 2008). The source of infection 
may be throat carriage, which occurs in up to 10% of community residents with 
excessive alcohol consumption (Anstey et al., 2002).The infection is seen mainly in 
people with a history of alcohol abuse and may sometimes require admission to an 
ICU (Anstey et al., 2002). It is generally a fulminating infection or a secondary 






1.2.7 Other manifestations 
Endocarditis due to Acinetobacter is a rare pathology with high mortality, reported 
mainly in hospitalized patients with predisposing risk factors (Valero et al, 1999). 
Acinetobacter spp. may cause endophthalmitis or keratitis, sometimes related to 
contact lens use or following eye surgery (Corrigan et al., 2001). Acinetobacter has 
been implicated in isolated infections following invasive ocular surgeries. Although 
ocular infections are rare, a recent study did associate Acinetobacter with adverse 
ocular responses in patients who wore extended-wear soft contact lenses (Corrigan et 
al., 2001).  A. baumannii was also reported to cause preseptal and orbital cellulitis in a 
39 year old woman (Miller, 2005). A case report also exists of a Shiga toxin-2 
producing A. haemolyticus train, which was associated with bloody diarrhoea in  3-
month-old infant in Pereira Rossell Pediatric Hospital, Uruguay (Grotiuz et al., 2006).  
 
1.3 Molecular basis of Acinetobacter infections 
A pathogen is a microorganism that is able to cause disease. Pathogenicity refers to 
the ability of microorganism to cause disease in a host organism. The pathogenicity of 
a microbe is expressed by its virulence, a term which refers to the degree of 
pathogenicity of the microbe. It has pathogenic determinants or virulence factors that 
enable it to infection the host. Virulence is the pathogenicity degree of a 
microorganism that can vary between the members of a same species of pathogens 
(Braun, 2008). The survival rates of Acinetobacters are very high with A. 
radioresistens surviving for an average of 157 days (Jawad et al., 1998) and A. 
baumannii beyond 30 days while A. lwoffii up to 21 days in the UK hospitals (Houang 
et al., 1998). This clearly shows that Acinetobacter spp can survive desiccation 
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persisting in the environment for many days. Acinetobacter also has been shown to 
survive better than other Gram-negative bacteria such as E. coli (Jawad et al., 1996). 
 
1.3.1 Acinetobacter adhesins and fimbriae 
The first step of infection is the ability of microorganism to penetrate the host and 
initiate the infection. It depends on the capacity of the microorganism to adhere and 
survive on the host mucosal surfaces. Bacterial adhesins are cell surface components 
that facilitate the adhesion of bacteria to inanimate surfaces; these include the 
fimbriae (pili), capsular polysaccharides, or cell wall components (Braun, 2008). The 
adherence of A. baumannii to the bladder tissue is a natural attribute of different 
strains, a comparable trait found in an uropathogenic strain of Escherichia coli 
(Sepulveda et al., 1998). Bacteria that express type 1 fimbriae are characterized by the 
ability to agglutinate erythrocytes in the absence of D-mannose. Fimbrial structures 
were observed in A. baumannii by transmission electron microscopy. The 
haemagglutining activity of the strains was not inhibited by either D-mannose or D-
galactose (Sepulveda et al., 1998).The two types of adherence of A. baumannii to 
human bronchial epithelial cells were dispersed adherence of bacteria to the surface of 
the cell and adherence of clusters of bacteria at loc lized areas of the cell to form 
microcolonies. Scanning electron microscopy showed thin fimbrial-like extensions on 
the bacterial surface that were firmly anchored to the membrane surface of the cells. 
There were no significant quantitative differences in adherence between outbreak and 
non-outbreak strains (Lee et al., 2006b). The expression of a chaperone usher 
secretion system is required for fimbriae formation and the concomitant attachment to 
plastic surfaces and the ensuing formation of biofilms (Tomaras et al., 2003). It has 
been hypothesized that there exists a correlation between the PER-1 gene that codes 
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for a beta-lactamase and Caco 2 cell adhesion in Aci etobacter strains (Sechi et al., 
2004). 
 
1.3.2 Toxins and enzymes 
Many bacteria synthesize enzymes or toxins or have cellular constituents that play a 
role in toxic action or direct necrosis under inflammatory cells and other components 
of the host immune system (Braun, 2008).  The presence of lipopolysaccharide (LPS) 
in a bacterium can influence the pathogenicity by causing macrophage activation, 
fever, and cardiovascular changes leading to shock and death (Peterson, 1996). The O 
polysaccharide of Acinetobacter baumannii and its antibodies have been investigated 
intensively (Haseley and Wilkinson, 1998). They are sp cific for a given serotype 
(Pantophlet et al., 2002). About the lipidic fraction, the chemical omposition of lipid 
A of A. calcoaceticus exhibits unusual features, but its toxic and other biological 
properties are similar to those of enterobacterial ndotoxin (Brade and Galanos, 
1983). The endotoxins of both A. baumannii and Acinetobacter ‘genomospecies 9’ are 
potent stimulators of inflammatory signalling in human monocytic cells and that 
responses to these bacteria are dependent on both TLR2 and TLR4.  An exaggerated 
innate immune response to the endotoxins of these organisms may contribute to the 
pathology of Acinetobacter infection. Hence Acinetobacter baumannii 
lipopolysaccharides are potent stimulators of human o ocyte activation via Toll-like 
receptor 4 signalling (Erridge t al., 2007). Acinetobacter baumannii outer membrane 
protein A (AbOmpA) induced early-onset apoptosis and delayed-onset necrosis in 
dendritic cells. AbOmpA targeted the mitochondria and induced the production of 
reactive oxygen species (ROS). ROS are directly responsible for both apoptosis and 
necrosis of AbOmpA-treated dendritic cells. These results demonstrate that the 
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AbOmpA secreted by outer membrane vesicles from A. baumannii nduces dendritic 
cell death, which may impair T cell biology to induce adaptive immune responses 
against A. baumannii. AbOmpA is a potential virulence factor that induces epithelial 
cell death (Lee at al., 2010). The ability of A. baumannii to produce esterase and 
urease may be responsible for damaging the lipid tissues and colonize the 
hypochlorhydric or achlorhydric walls of the stomach, thus inducing inflammation 
(Braun, 2008). 
 
1.3.3 Surface and mitochondrial porins 
Gram-negative bacteria are resistant to a large number of toxic agents as a result of 
the effective permeability barrier function of their outer membrane (OM) (reviewed 
by Vaara, 1992). 
 
The OM is impermeable to macromolecules and allows nly limited diffusion of 
hydrophobic substances through its LPS-covered surface (reviewed by Vaara, 1992). 
The small number and sizes of the different porins when coupled with efflux provide 
a significant barrier to the uptake of antibiotics in A. baumannii (Vila et al., 2007). 
Porins play a variety of roles depending on the bacterial species, including the 
maintenance of cellular structural integrity, bacterial conjugation and bacteriophage 
binding, antimicrobial resistance and pore formation  allow the penetration of small 
molecules (Braun, 2008). The outer membrane structures are integral part of the 
efflux assembly responsible for extrusion of toxic compounds from the cell. It is 
worth mentioning that even in the presence of a fully nctional acrAB efflux pump, 
the loss of integrity of the outer membrane protein r sults in no resistance being seen 
in E. coli cells (Nikaido, 2001). This may not be entirely true for Acinetobacter 
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baumannii. Several studies state that a decrease in porin expression is associated with 
antimicrobial resistance in A. baumannii (Mussi et al., 2005; Siroy et al., 2006). It has 
been reported by Clark (1996) that imipenem resistance in A. baumannii s due to 
reduced expression of 33-36 kDa outer membrane protin. I  has also been reported 
that a loss of 29 kDa outer membrane protein is associated with resistance to 
imipenem in strains having no carbapenemase activity (Limansky et al., 2002). The 
major band of outer membrane proteins (OMPs) of A. baumannii on SDS-
polyacrylamide gel electrophoresis is a 38 kDa mitochondrial porin. Omp38 localizes 
to the mitochondria and induces a release of cytochrome c and apoptosis-inducing 
factor (AIF) into cytosol, which mediates caspase dependent and AIF-dependent 
apoptosis in epithelial cells. The cytotoxic effects of A. baumannii were investigated 
in human laryngeal HEp-2 cells, and the findings indicate that this bacterium induces 
apoptosis of HEp-2 in vitro through both caspase-dependent cascades, which are 
mediated by cell surface signalling and mitochondrial d sintegration, and the AIF-
dependent pathway. Purified Omp38 also induced apoptosis of human bronchial 
epithelial cells and human monocyte cells. Apoptosis f epithelial cells may disrupt 
the mucosal lining and allow the access of bacteria or bacterial products into the deep 
tissues (Choi et al., 2005). Mucins secreted by epithelial cells may offer a protective 
role and act as a barrier protecting against bacteri l infections (Derrien et al., 2010). 
 
1.3.4 The role of siderophores 
Acinetobacter synthesizes siderophores which are relatively low-molecular weight 
agents, capable of converting polymeric ferric oxy-hydroxides to soluble iron chelates 
under low iron stress (Neilands, 1995). The ability of bacteria to assimilate iron is 
known to be related to invasiveness. The lung and systemic infections, where there is 
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iron restriction, suggest the presence of an iron uptake system in Acinetobacter. The 
presence of iron chelator 2, 3-dihydroxybenzoic acid (DHBA) and iron-repressible 
outer membrane proteins was detected in the culture sup rnatant of A. calcoaceticus 
(Smith et al., 1990). The A. baumannii clinical strains were able to grow under iron-
deficient conditions, and some of them excreted an iron-regulated catechol 
siderophore into the culture supernatants (Echeniqu et al., 1992, Actis et al., 1993).  
 
This siderophore was different from DHBA and other bacterial catechol-type 
siderophores (Braun, 2008). The structure of acinetobactin, a novel siderophore with 
both catechol and hydroxamate functional groups, isolated from A. baumannii ATCC 
19606 was elucidated (Yamamoto et al., 1994). The same study proved that there 
exists strain-to-strain variation in the ability to produce acinetobactin (Yamamoto et 
al., 1994). The chemical structure of this siderophore is highly related to the iron 
chelator anguibactin produced by the fish pathogen Vibrio anguillarum (Dorsey et al., 
2004).  
 
Iron-regulated proteins are present in both inner ad outer membranes of clinical 
strains of A. baumannii. The presence of two iron-regulated proteins localized in the 
inner membrane was reported (Echenique et al., 1992). The Fur protein responsible 
for iron uptake in A. baumannii was found to bear 63% similarity with that of E. coli 
(Daniel et al., 1999). Since Fur and Fur-like repressors are known t  regulate some 
virulence determinant genes in other bacteria, the A. baumannii Fur-like repressor 




1.3.5 Host- pathogen interactions 
Many factors like strain virulence, host factors and bacterial load are responsible for 
the host-pathogen interactions. They play a crucial role in progression of disease in an 
infected host and can have detrimental effects on the host. A significant number of 
identified genes encoding resistance to antibiotics, heavy metals, and antiseptics likely 
originated in other highly pathogenic organisms (Fournier et al., 2006). A comparison 
between the whole genome of A. baumannii 17978 and the non pathogenic species A. 
baylyi, revealed 28 gene clusters unique to A. baumannii, with 16 having a potential 
role in virulence (Smith et al., 2007). The csu polycistronic operon involves five 
genes, some of which are homologous to genes that encod  proteins related to 
chaperones and involved in pilus assembly in Gram-negative bacteria (Tomars et al., 
2003).  It has been shown that biofilm formation in A. baumannii s phenotypically 
associated with exopolysaccharide production and pilus formation (Tomars et al., 
2003). This may explain the success of A. baumannii to form biofilms on inanimate 
objects in hospital environment. Adherence of A. baumannii to human bronchial 
epithelial cells and erythrocytes has also been demonstrated, with similar pilus-like 
structures (Gospodarek t al., 1998). Quorum sensing also has been shown to regulat  
a wide array of virulence mechanisms in many Gram-negative organisms. The 
quorum sensing molecules of the N-acyl homoserine lactones (AHSL) have been 
identified in Acinetobacter, indicating that this may be a central mechanism for auto-
induction of various virulence factors (Gonzalez et al., 2001; Joly Guillou, 2005). The 
three molecules identified are 3-oxo substituted with acyl chain length from 4 to 12 
carbons; 3- unsubstituted AHSL (with the exception of C4) and 3- hydroxyl AHSL 
(C6, C8 and C10) (Gonzalez t al., 2001). 
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Apart from biofilm formation, exopolysaccharide production is also thought to protect 
bacteria from host defenses (Joly Guillou, 2005). Recent studies have described the 
innate immune response to A. baumannii and the importance of Toll-like receptor 
(TLR) signaling (Knapp et al., 2006; Erridge et al., 2007). In a mouse pneumonia 
model, TLR4 gene-deficient mice showed increased bacteri l counts, increased 
bacteraemia, impaired cytokine/chemokine responses, and delayed onset of lung 
inflammation compared to wild-type mice (Knapp et al., 2006).  A. baumannii 
lipopolysaccharide (LPS) was also identified as the major stimulatory factor for 
triggering immune response (Knapp et al., 2006). This was further illustrated by the 
attenuated effects of A. baumannii on mice deficient in CD14, an important molecule 
that enables LPS binding to TLR4 (Knapp et al., 2006). These findings were 
confirmed using human cells but, in contrast to the mouse model, TLR2 was also 
identified as an important signaling pathway potent endotoxic potential of A. 
baumannii LPS, which stimulated the inflammatory cytokines interleukin-8 and 
tumour necrosis factor alpha equally to the stimulation by E. coli LPS at similar 
concentrations (Erridge t al., 2007). These studies suggest that A. baumannii 
endotoxin may incite a strong inflammatory response during infection.  
 
Humoral immune responses have also been described for Acinetobacter infection, 
with antibodies being targeted toward iron-repressable OMPs and the O 
polysaccharide component of LPS (Smith and Alpar, 1991). Mouse-derived 
monoclonal antibodies directed at A. baumannii OMPs expressed in an iron-depleted 
environment have bactericidal and opsonizing effect, blocking the iron uptake (Goel 
and Kapil, 2001). Deliberately induced infections in well-defined animal models 
provide much useful information about disease processes. The results of experimental 
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infections should be interpreted carefully as they do provide information about 
disease processes in the natural context (Joly-Guillou and Wolff, 2008). 
 
1.4 Resistance mechanisms in A. baumannii 
Acinetobacter spp. have an extraordinary ability to develop multiple resistance 
mechanisms against major antibiotic classes – they have become resistant to broad 
spectrum β-lactams; third generation cephalosporins, carboxypenicillins, and 
increasingly to carbapenems. They produce a wide range of aminoglycoside-
inactivating enzymes and most strains are resistant to fluoroquinolones (Bergone-
Bérézin, 2008). The rapid global emergence of A. baumannii strains resistant to all 
β-lactams, including carbapenems, illustrates the pot ntial of this organism to respond 
swiftly to changes in selective environmental pressure (reviewed by Peleg et al., 
2008). 
 
There are various mechanisms of resistance that makes A. baumannii a successful 
pathogen of the 21st century. They include the class A β-lactamases which may also 
be extended spectrum β-lactamases (Nagano et al., 2004; Naiemi et al., 2005; 
Pasteran et al., 2006), class B β-lactamases which have metal ions governing the 
active site, hence they are also known as metallo β-lactamases (Chu et al., 2001; Lee 
et al.,2003; Lee et al., 2005); class C β-lactamases which are acinetobacter-derived 
cephalosporinases or the chromosomally-encoded AmpC enzymes (Bou and 
Martinez-Beltran, 2000), and class D β-lactamases which are mainly oxacillinases 
involved in resistance to carbapenems (Paton e  al., 1993, reviewed by Peleg et al., 
2008,).    
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Other enzymatic mechanisms of resistance include the aminoglycoside-modifying 
enzymes like acetyltransferases, nucleotidyltransfera es and phosphotransferases 
(reviewed by Peleg et al., 2008). Besides all these resistance mechanisms efflux
pumps like AdeABC (Magnet et al., 2001), AdeIJK (Damier-Piolle t al., 2008), 
AdeXYZ (Roca et al., 2011) AdeM (Su et al., 2005) and the tetracycline-specific 
efflux pumps Tet(A) and Tet(B) also play an important role in conferring resistance to 
various other antimicrobials (Guardabassi et al., 2000; Ribera et al., 2003a; Ribera et 
al., 2003b). 
 
1.4.1 Antimicrobial agents 
The modern era of chemotherapy began with the work of the German physician Paul 
Ehrlich. He coined the term ‘chemotherapy’ in the early 20th century in a search for 
compounds to act as ‘‘magic bullets’’ to treat bacterial infections (reviewed by Freter 
and Perry, 2008). According to the American Biochemist and Microbiologist Selman 
Waksman, ‘It was the knowledge of the great abundance d wide distribution of 
actinomycetes, which dated back nearly three decades, nd the recognition of the 
marked activity of this group of organisms against other organisms that led me in 
1939 to undertake a systematic study of their ability to produce antibiotics.’ He coined 
the term "antibiotic" in 1942 to describe any substance produced by a microorganism 
that is antagonistic to the growth of other microorganisms in high dilution (Waksman, 
1947). Antibiotics are chemicals produced by or derived from microoganisms that 
inhibit the growth of other microorganisms. The term antibiotic is now widely used to 





Alexander Fleming recognized the antibacterial activity of a substance secreted by 
Penicillium notatum on a contaminated culture plate in 1929 and thus discovered 
penicillin (Bush, 2010).  
 
Penicillin (Figure 1) impairs cell wall synthesis by preventing cross-linking of the 
peptidoglycan polymers necessary for cell wall formation and does this by binding to 
the penicillin-binding proteins (PBPs) (carboxypeptidases, endopeptidases, and 
transpeptidases) that participate in cell wall synthesis (Tomaz, 1979). Allergy to any 
of the penicillins is the only absolute contraindicat on to the use of a penicillin agent. 
Allergic reactions occur in up to 10% of patients, with 0.001% dying from 
anaphylaxis (Lin, 1992).  
 
1.4.1.2 Cephalosporins 
The first cephalosporin (Figure 2) was discovered in 1948 by Guiseppe Brotzu, who 
observed that the fungus Cephalosporium acremonium produced a substance that 
inhibited the growth of S. aureus and other bacteria (reviewed by Griffith and Black, 
1964). The cephamycins were created by adding a methoxy group on the β-lactam 
ring of the original compound, based on the structure of cefoxitin, produced by 
Streptomyces lactamdurans. By altering the chemical groups substituted on the basic 
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molecule, greater antimicrobial activity and longer half-lives have been obtained 
(Kees and Grobecker, 1995)  
 
Cephalosporins are β-lactams that have the β-lactam ring fused with a dihydrothiazine 
ring. Cephalosporins inhibit bacterial cell wall synthesis by blocking the 
transpeptidases and other PBPs involved in the synthesis and cross-linking of 
peptidoglycan (Wise, 1990; Fontana et al., 2000). Resistance to cephalosporins may 
result from mutations in the penicillin-binding proteins resulting in altered binding 
site or due to the production of extended-spectrum beta-lactamases responsible for the 
hydrolysis of the drug or both (Koch, 2000). Recently developed cephalosporins 
include ceftaroline and ceftobiprole which are regaded as 5th generation 
cephalosporins (Kollef, 2009).  
 
1.4.1.3 Carbapenems 
Carbapenems (Figure 3) which include meropenem, imipenem, biapenem, doripenem, 
razupenem and ertapenem are parenteral synthetic β-lactams derived from 
thienamycin, an antibiotic produced by Streptomyces cattleya (Kahan et al., 1979; 
Chen and Livermore, 1994; Livermore et al., 2009). Carbapenems have a lactam ring, 
like the penicillins and cephalosporins, but have a methylene moiety in the ring 
replacing sulphur in position 1 in the lactam ring hence the name carbapenem. 




Like other β-lactams, the carbapenems inhibit mucopeptide synthesis in the bacterial 
cell wall by binding to PBPs, leading to lysis and cell death. Carbapenems have the 
ability to retain activity against Gram-negative bacteria either with an extended 
spectrum of β-lactamases or those which hyperproduce the AmpC tye 
cephalosporinase (reviewed by Livermore, 1995). Bacterial resistance may occur due 
to carbapenemases, which may be intrinsic or acquired and are responsible for the 
hydrolysis of carbapenems. Another source of resistance is the lack of the outer 
membrane porin, thus inhibiting the transport of the drug into the cell (Rybak, 2004). 
 
1.4.1.4 Monobactams 
Monobactams have a single β-lactam ring which is not fused with other ring, henc  
then name monobactam. (Ennis and Cobbs, 1995). The monobactam aztreonam was 




It is now manufactured as a synthetic antibiotic (Durán et al., 2010). As with other 
β-lactams, aztreonam (Figure 4) inhibits mucopeptide synthesis in the bacterial cell 
wall by binding to the penicillin-binding protein (PBP) 3 of Gram-negative bacteria, 
leading to the lysis of the cell. It also has mild affinity for PBP-1a. It has been shown 
to have a synergistic effect with aminoglycosides (Georgopapadakou et al., 1982). 
 
1.4.1.5 Aminoglycosides 
The aminoglycosides were discovered during the 1940s during an extensive study of 
Actinomycetes for possible antimicrobial by-products. It was found that 
Micromonospora purpurea (suffix-micin) and Streptomyces griseus ( uffix-mycin) 
produced inhibitory molecules Streptomycin (Figure 5) and Gentamicin (Figure 6) 
respectively. Streptomycin, discovered in the labortory of Selman Walksman was the 
first aminoglycoside to be developed (Begg and Barclay, 1995). 
 
 
An aminoglycoside is a molecule composed of amino-modified sugars. The 
aminoglycosides have two main effects on the bacteri l cell that ultimately result in 
cell death. These agents bind to the negative charges in the outer phospholipid 
membrane, displacing the cations that link the phoslipids leading to disruption of 
the integral cell membrane. The aminoglycosides also inhibit protein synthesis by 
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binding to the 30S subunit of the ribosome, causing miscoding and termination 
(Moellering Jr, 1983). 
 
1.4.1.6 Macrolides 
The original macrolide (Figure 7), erythromycin, was discovered in 1952 by J.M. 
McGuire and marketed under the brand name Ilotycin (McGuire et al., 1952).  
It is produced by Saccharopolyspora erythraea (formerly known as Streptomyces 
erythreus) (Labeda, 1987). Semisynthetic derivatives like clarithromycin and 
azithromycin have been produced from erythromycin, w th modifications that 




The macrolides are bacteriostatic, inhibiting protein synthesis by binding at the 50S 
ribosomal unit and by blocking transpeptidation andtranslocation. At high 
concentrations or with rapid bacterial growth, the eff cts may be bactericidal 
(Kanatani and Guglielmo, 1994).  
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1.4.1.7 Quinolones 
The first quinolone, nalidixic acid (Figure 8) was formed as a result of chloroquine 
synthesis and introduced in 1962. As with other classes of synthetic and semisynthetic 
antimicrobials, alterations of side chains affect antimicrobial activity and 
pharmacokinetics (Andersson and MacGowan, 2003) 
 
Quinolones cause bacterial cell death by inhibiting DNA synthesis. They inhibit DNA 
gyrase and DNA topoisomerase, enzymes that mediate DNA supercoiling, 
transcription, and repair (Drlica and Zhao, 1997). Bacterial resistance develops as a 
result of spontaneous mutations that change the binding sites for quinolones on the 
DNA gyrase and the DNA topoisomerase (Willmott and Maxwell, 1993).  
 
1.4.1.8 Sulphonamides 
Sulfonamides are azo dyes derivatives which were discovered by Gerhard Domagk, 
who was awarded the Nobel Prize in the year 1939. The first agent was 
sulfachrysoidine, used in 1935, which released sulfanilamide in vivo (Woods, 1940). 
In bacteria, sulphonamides act as competitive inhibtors of the enzyme 
dihydropteroate synthetase, an enzyme involved in folate synthesis. Trimethoprim 
was discovered by George Hitchings during the 1940s and he was the Nobel laureate 
for medicine in the year 1988. Trimethoprim is a bacteriostatic antibiotic and acts by 
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interfering with the action of bacterial dihydrofolate reductase, inhibiting synthesis of 
tetrahydrofolic acid. Folic acid is an essential precursor in the de novo synthesis of the 
DNA nucleosides thymidine and deoxyuridine. Trimethoprim (Figure 9) and 
sulfamethoxazole (Figure 10) have a greater effect when given together; the reason is 
because they inhibit successive steps in the folate synthesis pathway (Burchall, 1973).  
 
 
The synergy between trimethoprim and sulfamethoxazole was first described in a 
series of in vitro and in vivo experiments published in the late 1960s (Bushby and 
Hitchings, 1968; Böhni, 1969 ).  
 
1.4.1.9 Tetracyclines 
Chlortetracycline or Aureomycin, the first tetracycline (Figure 11), was developed in 
1948 from Streptomyces aureofaciens by Benjamin Duggar (Duggar, 1948).  
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Doxycycline and minocycline are semisynthetic derivatives of tetracycline (Smith and 
Leyden, 2005). Tetracyclines bind to the 30S ribosomal subunit, blocking the binding 
of aminoacyl t-RNA resulting in the inhibition of protein synthesis. It has a 
bacteriostatic effect (Craven et al., 1969). 
 
1.4.1.10 Polymyxins 
Polymyxins are antibiotics produced by Bacillus polymyxa which act by disrupting 
the lipopolysaccharide bilayer (Dixon and Chopra, 1986).  
 
Polymyxin B (Figure 12) has been extensively used for topical applications (Kohonen 
and Tarkanen, 1969). Colistin or Polymyxin E (Figure 13) is a multicomponent 
polypeptide antibiotic, comprised mainly of colistin A and B that became available 
for clinical use in the 1960s, but was replaced in the 1970s by antibiotics considered 
less toxic (Li et al., 2006b).  
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Colistin is produced by Bacillus polymyxa var. colistinus, and is now considered to be 
the last resort for serious infections involving multi-drug resistant isolates of 
Pseudomonas aeruginosa, Acinetobacter baumannii or Klebsiella pneumoniae 
(Falagas et al., 2008). 
 
1.4.1.11 Tigecycline 
Tigecycline is the first glycylcycline antibiotic and was discovered by Francis Tally 
(Projan, 2010). It was developed in order to overcome bacterial mechanisms of 
tetracycline resistance such as ribosomal protection and efflux pumps. 
 
The primary backbone consists of minocycline with an N-alkyl-glycylamido group 
substituted at position nine and this gives this drug its broad spectrum of activity and 
protection from resistance mechanisms. Tigecycline is generally bacteriostatic, but 
some in vitro studies have reported bactericidal activity against Streptococcus 
pneumoniae, Haemophilus influenzae, nd Neisseria gonorrhoeae (Meagher et al., 
2005; Noskin, 2005). 
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This drug binds to the 30S ribosomal subunit of bacteria and blocks entry of amino-
acyl t-RNA into the A site of the ribosome (Noskin, 2005). Tigecycline was 
efficacious both against NDM-1-producing K. pneumoniae and E. coli (Docobo-Pérez 























1.4.2 Mechanisms of resistance to antibiotics in A. baumannii 











Figure 15: General mechanism of hydrolysis by serine β-lactamase.    
β-lactamases (EC 3.5.2.6), are enzymes produced by bacteria, which destroy β-lactam 
ring of antibiotics. The β-lactam agent becomes changed in its chemical structure and 
is no longer recognized by the enzymes responsible for making the peptidoglycan or 
the murein layer of the bacterial cell wall (Frere, 1995). Enzymes of class A, C, and D 
have at their active site a serine residue but class B enzymes utilize a Zn2+ ion to 
attack the β-lactam ring. The mechanism of hydrolysis by a serine β-lactamase is 
depicted in figure 15 (reviewed by Livermore, 1995). Table 3 gives a systematic 
classification of β-lactamases and their functional groups according to Ambler and 
Bush scheme (reviewed by Livermore, 1995). Figure 16 gives the mode of action of 












Table 3: Classification of β-lactamases and their functional groups (reviewed by Livermore, 1995). 
 





Penicillin Carbenicillin Oxacillin Cephaloridine Cefotaxime Aztreonam Imipenem 
Inhibited by clavulanate 
Serine-β 
lactamases 
         
A 2a +++ + - +/- - - - ++ 
 2b +++ + + ++ - - - ++ 
 2be +++ + + ++ ++ ++ - ++ 
 2br +++ + + + - - - - 
 2c ++ +++ + + - - - + 
 2e ++ ++ - ++ ++ ++ - ++ 
 2f ++ + ? + + ++ ++ + 
C 1 ++ +/- Inhibitor +++ + Inhibitor - - 
D 2d ++ + +++ + - - - +/- 
Undeterminedc 4c ++ ++ ++ V V - - - 
          
Zinc-β 
lactamases 
         
B 3 ++ ++ ++ ++ ++ - ++ - 
b +++, preferred substrate (highest Vmax); ++, good substrate; +, hydrolyzed; +/-, barely hydrolyzed; -, stable; V, variable within group; ?, uncertain. 
c None of Bush’s group 4 enzymes has yet been sequenced; they are assumed to be serine types because they lack carbapenemase activity 
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1.4.2.1.1.1 Class A β-Lactamases and ESBLs 
The class A enzymes have the ability to hydrolyze a bro d spectrum of antibiotics 
including 3rd generation cephalosporins, penicillins, carbapenems and monobactams. 
They are inhibited by β-lactamase inhibitors such as clavulanic acid and tzobactam 
(Gin et al., 2007; Thomson, 2010). This group of enzymes includes the majority of 
the extended-spectrum β-lactamases (ESBLs) as it encompasses the KPC, GES, 
NMC, SME, IMI, TEM, SHV, PER, VEB, CTX-M ESBL families (Poirel and 
Nordman, 2008; Thomson, 2010). The gene encoding the enzyme PER-1 has been 
found in many isolates of A. baumannii n the USA, Korea and Turkey (Poirel et al., 
2005a; Hujer et al., 2006, Kim et al., 2008), and a significant number of isolates from 
Belgium and France encode the gene for the VEB-1 enzyme (Naas et al., 2006a, Naas 
et al., 2006b). The emerging group of ESBLs in Enterobacteriaceae, which are of the 
CTX-M- type, have been identified rarely in A. baumannii. A strain producing 
CTX-M-2 was identified in Japan, which is a country where the first CTX-M-type 
enzymes were identified more than 15 years ago (Nagano et al., 2004). TEM, SHV 
type enzymes have also been described in Ac etobacter (Hujer et al., 2006; Naas et 
al., 2007). The expression of ESBLs in A. baumannii may contribute significantly to 
its resistance to expanded-spectrum β-lactams and to the increasingly observed 
multidrug resistance profile in this species. Due to generally widespread high-levels 
of resistance in A. baumannii to the penicillins and cephalosporins conferred by the 
intrinsic class C β-lactamases, these drugs are not usually considered appropriate for 
treatment of A. baumannii infections. Clinical detection of ESBL producers may be 
difficult since combined mechanisms of resistance are often associated in those 
multidrug-resistant A. baumannii solates. A combined over-expression of the 
naturally occurring cephalosporinase may be antagonized by addition of cloxacillin, 
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oxacillin or boronic acid that inhibits the cephalosp rinase activity making such 
ESBL detection easier (Coudron, 2005; Poirel and Nordmann, 2008). The prevalence 
of the class A β-lactamases in A. baumannii may not be a very major problem in 
comparison to other carbapenemases in this species; however the potential of this 
species to act as a reservoir for mobilisable resistance genes in the hospital may be 
alarming. 
 
1.4.2.1.1.2 Class B β-Lactamases (metallo-β-lactamases) 
The first classification of molecular class B enzymes was by Ambler in 1980 
distinguishing them from serine β-lactamases. He also proposed that β-lactamases 
have a polyphyletic origin (Ambler, 1980); since thn an alternative categorization 
was suggested by Bush in 1989, placing them into separate groups according to their 
functional enzymes (Bush et al., 1995). The molecular class B enzymes are 
metallo-β-lactamases (MBL), which require two divalent cations, usually zinc as 
metal cofactors for the enzyme activity. They have the ability to hydrolyse penicillin, 
cephalosporins and carbapenems, and are not inhibited y β-lactamase inhibitors and 
monobactams (Walsh et al., 2005). They are inhibited by EDTA or 
mercaptopropionic acid (Arakawa et al., 2000; Yong et al., 2002). It is interesting to 
note that they are not hydrolysed by aztreonam particularly well; however in animal 
pneumonia model studies it was observed that infection aused by P. aeruginosa 
producing VIM-2, could not be eradicated with aztreonam even when the animals 
were given high drug doses (Bellais et al., 2002). To date, nine families of acquired 
MBLs enzymes have been identified – IMP (Imipenemase fir t discovered in Japan), 
VIM (Verona MBL), SIM (Seoul MBL), SPM (São Paulo imipenemase), GIM 
(German MBL), DIM (Dutch imipenemase) (Poirel et al., 2010a), KHM (Kyorin 
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university hospital imipenemase, Japan) (Poirel et al., 2010a), AIM (Australian 
imipenemase) (Poirel t al., 2010a) and the most recent NDM (New Delhi MBL) 
(Poirel and Nordmann, 2008, Yong et al., 2009). 
 
The IMP, VIM and SIM have been identified in A. baumannii with several variants of 
the IMP and VIM families found in Hong Kong, Canada, T iwan, Japan and in Italy 
France, Greece, Korea, Spain, Portugal, Poland and other countries (Walsh et al., 
2005). The SPM enzyme was first discovered in P. aeruginosa in Brazil (Toleman et 
al., 2002). The GIM enzyme was also first identified n P. aeruginosa (Castanheira et 
al., 2004). Interspecies spread of SPM and GIM enzyme has not yet been reported. 
Since their initial discoveries, SPM, GIM, and SIM metallo-β-lactamases have not 
spread beyond their countries of origin. Genetic analysis of the surrounding genes 
identified in A. baumannii shows similar structures since the gene families of VIM, 
IMP and SIM have been included in the class-1 integron structure. The dissemination 
of these genes among the strains of A. baumannii and P. aeruginosa in specific areas 
has been clarified by the plasmid location of MBL genes (Livermore and Woodford, 
2006). The NDM enzyme, first found in K. pneumoniae is now also prevalent in A. 
baumannii in India (Yong et al., 2009; Karthikeyan et al., 2010). To date, 33 variants 
of IMP, 33 variants of VIM and 6 variants of NDM have been reported 
(http://www.lahey.org/Studies/other.asp, Last accessed on 12/03/12). It is clear that 
VIM and IMP family are growing at an equal rate butit is also a matter of concern 
that the blaNDM-1 gene first identified on plasmid can be integrated on the chromosome 
in certain E. coli strains as the surrounding genetic structures may facilitate its 
integration (Pfeifer et al., 2011). Recent reports by Walsh et al. (2011) suggest the 
integration of blaNDM-1 in the chromosomes of Aeromonas caviae and Vibrio cholerae. 
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1.4.2.1.1.3 Class C β-Lactamases (ampC’s) 
AmpC-type β -lactamases constitute molecular class C in Ambler’s classification 
scheme and are commonly found encoded on the chromoso e in Gram-negative 
organisms. As well as these intrinsic enzymes, there are several families of plasmid-
borne ampC genes that are spreading particularly within the Enterobacteriaceae 
(Jacoby, 2009). In Acinetobacter species these genes are known as Acinetobacter-
derived cephalosporinases (ADC) (Hujer et al., 2005). As this name implies, these 
enzymes are able to hydrolyse penicillins and the narrow-spectrum cephalosporins. 
When over-expressed, the enzymes can confer resistance o the extended-spectrum 
cephalosporins. AmpC enzymes were considered as exclusively chromosomal until 
1989, when MIR-1, the first plasmid-encoded AmpC enzyme, was discovered 
(Papanicolaou et al., 1990). In other Gram-negative bacteria the expression of the 
cephalosporinase gene is inducible but, in A. baumannii, the ampC is expressed at a 
basal level but the expression is enhanced when the i sertion sequence ISAba1or 
ISAba125 inserts upstream of the gene providing a better promoter for gene 
expression (Corvec et al.,2003; Lopes et al., 2011. P601, ECCMID). The widespread 
nature of the blaADC genes is the major reason for high levels of resistance in A. 
baumannii to the penicillins and cephalosporins and as such these drugs are generally 








1.4.2.1.1.4 Class D β-Lactamases (oxacillinases) 
Oxacillinases are peculiar β-lactamases that are grouped in a heterogeneous class of 
enzymes either regarding their structural or their biochemical properties (Poirel and 
Nordman, 2008). The OXA group mainly occurs in Acinetobacter and Pseudomonas 
species with naturally occuring variants in many Gram-negative non fermentors. The 
OXA β-lactamases hydrolyze amoxicillin, methicillin, cephaloridine and, to some 
extent, cefalotin. They usually hydrolyze oxacillin more efficiently than 
benzylpenicillin (Poirel and Nordmann 2008, Girlich et al., 2004). The OXA group 
enzymes are generally not regarded as ESBLs, becaus they do not hydrolyse the 
extended-spectrum cephalosporins, although certain exceptions like OXA-37 from A. 
baumannii and OXA-20 from P. aeruginosa can be seen (Naas et al., 1998; Navia et 
al., 2002; Girlich et al., 2004). Currently, over 232 different variants of OXA 
enzymes have been identified on the protein level 
(http://www.lahey.org/Studies/other.asp, last accessed 12/03/12). The class D 
oxacillinases have been found both on plasmids and chromosome (Heritier et al., 
2005b; Corvec et al., 2007). The naturally occurring class-D oxacillinase OXA-50 is 
expressed constitutively in P. aeruginosa (Girlich et al., 2004). The genes blaOXA-51-
like, blaOXA-23-like and blaOXA-134 for instance, are present intrinsically in A. 
baumannii, A. radioresistens and A. lwoffii, respectively (Brown et al., 2005; Poirel et 
al., 2008; Figueiredo et al., 2010).  
 
1.4.2.1.1.4.1 OXA-23-like β-Lactamases 
OXA-23, originally named ARI-1 for "Acinetobacter esistant to imipenem" was 
identified in Scotland and then renamed OXA-23 based on its genetic 
characterization. It was isolated from the plasmid of a strain of A. baumannii solated 
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in 1985 which possessed an MIC of imipenem of 16 mg/L (Paton et al., 1993). The 
OXA-23-like enzyme OXA-27, isolated from Singapore, shares 99% identity with 
OXA-23 (Afzal-Shah et al., 2004). Another variant, OXA-49, was isolated in China 
from a carbapenem resistant A. baumannii strains (Brown et al., 2005). The OXA-23 
enzymes have been identified in A. baumannii n various parts of the world like, 
Brazil (Dalla-Costa et al., 2003), China (Yu et al., 2004), London (Coelho et al., 
2004) and Singapore (Koh et al., 2007). They can be present on both plasmid and 
chromosome (Paton et al., 1993; Bonnet et al., 2002). In vivo the OXA-23 
β-lactamase contributes towards resistance to amoxicillin, ticarcillin, meropenem and 
imipenem. When, a naturally-occurring plasmid containing the blaOXA-23 gene is 
electro-transformed into the same recipient strains, moderate to high MICs are 
achieved of 16 to >32 mg/L of carbapenems, with the highest values again found in 
the recipient over-expressing the AdeABC efflux pum, indicating the involvement of 
other genetic factors associated with the blaOXA-23 gene in conferring resistance 
(Héritier et al., 2005c). Other variants of OXA-23 enzymes are OXA-27, OXA-102, 
OXA-103, OXA-105, and OXA-133. NCBI blast search reveals that OXA-146 
(FJ194494), OXA-165 (HM488986), OXA-165 (HM488987), OXA-
166(HM488988), OXA-167 (HM488989), OXA-168 (HM488990), OXA-169 
(HM488991), OXA-170 (HM488992), OXA-171 (HM488992) and OXA-225 
(JN638887) are also OXA-23-like carbapenemases. OXA-133 has been fou d in A. 
radioresistens (Mendes et al., 2009; reviewed by Poirel t al., 2010b). OXA-134 is 
found to be present intrinsically in A. lwoffii and it could act as a source of 
dissemination of OXA-23-like enzymes (Figueiredo et al., 2010). Chomosomally 
encoded OXA-23 enzyme has also been shown to be pres nt in Proteus mirabilis 
(Bonnet et al., 2002). OXA-73, an acquired OXA-23- like carbapenemase, has also 
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been found in K. peumoniae (reviewed by Poirel et al., 2010b). Recent reports point 
to the increase in carbapenem-resistant A. baumannii solates encoding OXA-23 from 
South America and South-East Asia (Villegas et al., 2007, Fu et al., 2010). A study of 
A. baumannii solates from Colombian institutions found an averag  of 33.6% of 
isolates resistant to a carbapenem, and in a subset of 66 of these resistant isolates, 65 
were positive by PCR for blaOXA-23 . It was observed that one clone was present in two 
hospitals within one city, while another had spread between two hospitals in different 
cities (Villegas et al., 2007). In a Chinese teaching hospital, the rates of carbapenem 
resistance have increased from 5% to 50% from 1999 to 2005 in isolates from ICU 
wards and 20% in non-ICU isolates in 2004; and a subsequent study of 221 resistant 
isolates from 11 institutions, including 117 isolates from the same teaching hospital, 
found 97.7% were positive for blaOXA-23 gene (Wang et al., 2007). Recent report 
identifies Tn2008 having ISAba1 upstream and ATPase gene downstream of the 
blaOXA-23, as a major vehicle carrying blaOXA-23 in Acinetobacter baumannii in China 
(Wang et al., 2011). 
 
1.4.2.1.1.4.2 OXA-40-like β-Lactamases 
The OXA-40 β-lactamase has a mainly narrow-spectrum hydrolytic profile including 
ceftazidime and imipenem. Its activity is resistant to inhibition by clavulanic acid, 
tazobactam, sulbactam. Like most of the other carbapenem-hydrolyzing oxacillinases, 
the OXA-40 enzyme is not inhibited by NaCl (Héritier et al., 2003).The OXA-40 
enzyme, originally named OXA-24, was identified in Spain in a highly carbapenem 
resistant A. baumannii strain and it shares 63% and 60% amino acid identity with 
OXA-51/69 and OXA-23 respectively (Bou et al., 2000a). This group also includes 
the variants OXA-24, OXA-25, OXA-26, OXA-33 (AY008291), OXA-72 OXA- 139 
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(AM991978) and OXA-160 (Tian et al., 2011). The variants OXA-25, OXA- 26 were 
identified in strains from Spain and Belgium subsequently (Afzal-Shah et al., 2001), 
while OXA-72 was identified in A. baumannii strains were identified from Thailand 
(Walther-Rasmussen and Høiby, 2006). The blaOXA-33 has also been found to be co-
present with the carbapenemase gene blaOXA-62 on the integron of Pandoraea 
pnomenusa (Schneider et al., 2006). 
 
Kinetic studies carried out on OXA-40-like enzymes d monstrate that these enzymes 
are capable of hydrolysing penicillins, have weak activity against carbapenems, and 
very weak activity against some cephalosporins (Bou et al., 2000a; Afzal-Shah et al., 
2001; Heritier et al., 2003). It is observed that in vivo the OXA-40 enzyme confers 
resistance to carbapenems as well as increased MICs of penicillins and cephalosporins 
(Héritier et al., 2005c). Despite having only weak hydrolytic activity against the 
carbapenems of the purified enzyme, isolates encodig an OXA-40-like β-lactamase 
had an imipenem MIC of >128mg/L (Ruiz et al., 2007). When transformed into 
susceptible reference A. baumannii strains, the enzyme only confers intermediate to 
low level resistance, with the higher of these values associated with an isolate over-
expressing the AdeABC efflux pump, suggesting that other resistance mechanisms are 
required to achieve the high levels of resistance seen in clinical isolates (Héritier t 
al., 2005c).  
 
The blaOXA-40-like genes have been found in other Acinetobacter spp as well as in 
Pseudomonas aeruginosa, and to be both chromosomally and plasmid encoded 
(Quinteira et al., 2007; Lee et al., 2009a; Sevillano et al., 2009). Isolates encoding the 
enzymes have been reported in Spain and in Asia (Ruiz et al., 2007, Wang et al., 
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2007, Lee et al., 2009a), but Spain and Portugal are the main countries where it has 
been widely disseminated, and this is because therewas evidence of its plasmid 
location in several isolates (Lopez-Otsoa et l., 2002; Quinteira et al., 2007; Ruiz et 
al., 2007). High prevalence of blaOXA-40-like has been seen on the Iberian Peninsula and 
it appears to be the hot spot for the dissemination of these genes (Da Silva et al., 
2004). A recent study of 83 imipenem resistant A. baumannii solates from 12 
hospitals in Spain found 42% of isolates were positive for a blaOXA-40-like gene (Ruiz et 
al., 2007). A second recent study from a hospital in Portugal found that of 222 
imipenem-resistant A. baumannii collected over the period of January 2001 to 
October 2004, 36.6% carried a blaOXA-40-like gene, the majority of which were 
associated with plasmid DNA, which was also found in Acinetobacter haemolyticus 
isolates in the same institution (Quinteira et al., 2007). The identification of a high 
percentage of blaOXA-40-like genes presents a worrying possibility of these genes 
becoming more globally established thereby hampering t eatment options in 
compromised patients. 
 
Recently two new carbapenemases, OXA-143 and OXA-182 have been identified. 
The OXA-182 carbapenemase has 93% amino acid identity wi h OXA-143 and 89% 
with OXA-40 (Kim et al., 2010). The OXA-143 carbapenemase has 88% amino ac d 







1.4.2.1.1.4.3 OXA-51-like β-Lactamases 
The OXA-51-like β-lactamases are an enzyme group that are intrinsic a d ubiquitous 
in A. baumannii (Brown et al., 2005; Merkier and Centron, 2006; Turton et al., 2006). 
The first report of OXA-51, was in 2005 in isolates obtained from Argentina in 1996 
(Brown et al., 2005), and a large number of variants of enzymes have since been 
discovered. OXA-51 shares < 63% amino acid identity w h subgroups 1 
(OXA-23-like enzymes), subgroup 2 (OXA-40-like enzymes) and <50% with 
subgroup 4 (OXA-58-like enzymes). They are less effici ntly inhibited by clavulanate 
or tazobactam and their activity is inhibited by NaCl (Héritier et al. 2005b; Poirel and 
Nordmann, 2008).The OXA-51-like enzymes currently represent one of the largest 
groups of β-lactamases, with 81 enzymes currently identified 
(http://www.lahey.org/Studies/ Last accessed on 12/03/12).  
 
The blaOXA-51-like genes have generally been found to be chromosomally encoded and 
non-transferable. However, recent reports and PCR analysis for blaOXA-51-like genes 
indicate plasmid as well as chromosomal location of the blaOXA-51-like genes (Chen et 
al., 2010). A second report mentions that the investigators were able to transfer a 
blaOXA-87, a blaOXA-51-like gene, to E. coli DH5α, indicating that blaOXA-51-like variants 
might jump to plasmids as well (Vahaboglu et al., 2006). 
 
The blaOXA-51-like genes have been identified in A. baumannii, except blaOXA-138 , which 
has been identified in A. nosocomialis from Taiwan, further suggesting that there is 
the potential for these genes to be mobilised within e A. baumannii- calcoaceticus 
complex (Lee et al., 2009b ). The G+C content of the blaOXA-51-like  gene blaOXA-69 was 
found to be 39.3%, which compares with the G+C content of the A. baumannii 
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genome (38.8%) lending further weight to the suggestion that these genes are native 
to A. baumannii (Héritier et al. 2005b). Kinetic analysis has only been performed on 
OXA-51 and OXA-69 enzymes (Brown et al., 2005, Heritier et al., 2005b) and they 
both demonstrate poor hydrolysis of oxacillin and cloxacillin, a feature that has been 
observed in carbapenem-hydrolysing oxacillinases (Bou et al., 2000a ; Afzal-Shah et 
al., 2001).The contribution of the enzymes to carbapenem resistance is difficult to 
determine. It has been suggested that the blaOXA-51-like genes are generally poorly 
expressed and that they may only confer resistance when they have high levels of 
expression with the insertion of an element such as ISAba1 upstream of the gene, 
providing a better promoter (Turton et al., 2006a). The large group of enzymes 
clustered around the OXA-66 enzymes are found in isolates belonging to an A. 
baumannii lineage including the prevalent European clone 2, while those clustered 
around the OXA-69 enzyme are found in another lineage encompassing European 
clone 1. The OXA-71 enzyme is associated with European clone 3. The most 
commonly identified enzymes are those of the OXA-66 cluster, which are particularly 
highly represented in South America and Asia (Merkier and Centron, 2006; Koh et
al., 2007; Wang et al., 2007; Evans et al., 2008). Enzymes of the OXA-69 cluster are 
also common, particularly in Eastern Europe and of OXA-71, associated with 
European clone 3 have been widely identified in isolates from the Iberian Peninsula 
(Evans et al., 2008). To date, the OXA-51-like group comprises of OXA-51, OXA-64 
to OXA-71, OXA-75 to OXA-80, OXA-82 to OXA-84, OXA-86 to OXA-95, OXA-
98 to OXA-100 (AM231720), OXA-104, OXA-106 to OXA-113, OXA-115 to OXA-
117, OXA-120 to OXA-127, OXA-138, OXA-144 (FJ872530), OXA-148 to OXA-
150 (GQ853679 to GQ853681), OXA-172 to OXA-180 (HM113558 to HM570036) 
OXA-194 to OXA-197 (HQ425492 to HQ425495), OXA-200 to OXA-202 
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(HQ734811 to HQ734813), OXA-208 (FR853176), OXA-216 (FR865168), OXA-217 
(JN603240), OXA-219 (JN215211), OXA-223 (JN248564). These enzymes have 
been identified according to the data cited by Brown & Amyes, 2005; Evans et al, 
2007; reviewed by Poirel t al., 2010b; Lee et al., 2009b and by personal 
communication with B. A. Evans. 
 
1.4.2.1.1.4.4 OXA-58-like β-Lactamases 
The blaOXA-58 gene was first identified in France from a strain isolated in Toulouse in 
2003 (Poirel et al., 2005b). It hydrolyses penicillins, oxacillin, and imipenem but not 
expanded-spectrum cephalosporins. The blaOXA-58 gene was located on a 30-kb non-
self-transferable plasmid. It was electrotransformed in the A. baumannii reference 
strain and was shown to conferred reduced susceptibility to carbapenems (Poirel t 
al., 2005b). Kinetic analysis of OXA-58 has shown that it has similar properties to the 
other OXA-type carbapenemases of A. baumannii; however, it hydrolyses imipenem 
twice as efficiently as OXA-40. The purified enzyme has weak activity against 
penicillins and imipenem, very weak activity against meropenem, and some activity 
against cephalothin and cefpirome, but not against ceftazidime or cefotaxime (Poirel 
et al., 2005b). The blaOXA-58 gene, which has been identified only in Acinetobacter 
spp. isolates, has been associated with a variety of different genetic structures. It has 
been shown to confer high level of carbapenem resistance only when insertion 
sequences provide a strong promoter in the expression of the gene along with 
synergistic over-expression of the AdeABC efflux pump (reviewed by Peleg et al., 
2008). OXA-58 has a low percentage of amino acid identity compared with the other 
oxacillinases (Brown and Amyes, 2006). Genes encodig OXA-58-like enzymes have 
been found in a range of Acinetobacter species and are usually plasmid borne, though 
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a chromosomal location has also been described (Bogaerts et al., 2006, Poirel et al., 
2005b; Poirel and Nordmann, 2006a). Isolates carrying blaOXA-58-like genes are most 
frequently reported from Europe, though the genes have been reported in isolates from 
South America, North America, Anatolia, Asia and Australia (Marqué et al., 2005; 
Bogaerts et al., 2006; Coelho et al., 2006; reviewed by Peleg et al., 2006; Koh et al., 
2007; Wang et al., 2007; Gur et al., 2008; Merkier et al., 2008; Zarrilli et al., 2008; 
Lee et al., 2009a; Mendes et al., 2009). In addition to being dependent on IS elemnts, 
the level of expression of the blaOXA-58 gene may be related to the gene copy number, 
as exemplified in one Italian clone exhibiting various levels of resistance to imipenem 
as a consequence of the blaOXA-58 copy number (Bertini et al., 2007). It has been 
shown recently that the blaOXA-58 has been duplicated in one isolate of A. pittii 
conferring intermediate level of resistance to carbapenems (Evans et al., 2010). Other 
variants of OXA-58 found in Acinetobacter spp are OXA-96, OXA-97 and OXA-164 
(Gene bank accession number, GU831575) (reviewed by Poirel et al., 2010b) 
 
1.4.2.1.2 Outer membrane proteins 
A tough outer membrane, low numbers of protein-porins, and several other 
constitutive characteristics play a role in behaviour f Acinetobacter with regards to 
the capacity of resistance and survival in the enviro ment. The small number and 
sizes of the different porins when coupled with efflux provide a significant barrier to 
the uptake of antibiotics in A. baumannii (Hooper, 2005; Vila et al., 2007). Several 
studies state that a decrease in porin expression is associated with antimicrobial 
resistance in A. baumannii (Bou et al., 2000b; Fernandez-Cuenca et al., 2003; Mussi 
et al., 2005; Siroy et al., 2006).  
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The major outer membrane protein in Acinetobacter spp is HMP-AB, a member of the 
OmpA-like family and is a heat-modifiable protein (Dupont et al., 2005; Walzer et al., 
2006). It shares sequence identity and structural simi arities with OprF in P. 
aeruginosa and with OmpA in E. coli and is sized at 37 kDa, but heating shifts this to 
45 kDa (Gribun et al., 2003). The HMP-AB protein has been shown to allow the 
penetration of β-lactams and saccharides up to 800 Da, but has a significantly lower 
efficiency than the OmpF protein in E. coli (Gribun et al., 2003). The OmpA-like 
protein contributes poorly to membrane permeability and it is possible that it may 
work in association with one of the clinically relevant efflux pumps such as AdeAB 
and AbeM although this link has not been established experimentally. Recent report 
shows that OmpA of A. baumannii 19606 plays a partial role in the development of 
robust biofilms on plastic and it is essential for bacterial attachment to Candida 
albicans filaments and A549 human alveolar epithelial cells. The interaction with 
biotic surfaces is independent of the CsuA/BABCDE-mediated pili and the interaction 
of A. baumannii 19606 with fungal and epithelial cells results in their apoptotic death. 
Furthermore, the bacterial adhesion phenotype correlates with the ability of bacteria to 
invade A549 epithelial cells. The same study also proves that the killing activity of 
cell-free culture supernatants is protease and temperature sensitive, suggesting that its 
cytotoxic activity is due to secreted proteins, some of which are different from OmpA 
(Gaddy et al., 2009). 
 
The 33-36 kDa outer membrane protein has been implicated in several studies 
involving carbapenem resistance in clinical strains (Clark, 1996; del Mar Tomas et al., 
2005). The levels of the 33-36 kDa outer membrane protein were decreased in a 
carbapenem-resistant isolate of A. baumannii and cloning and over-expression of the 
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gene encoding this outer membrane protein restored a β-lactam sensitive phenotype to 
the previously resistant isolate. N-terminal sequencing of this protein shows that it 
shares homology with outer membrane proteins from Ralstonia spp. and OmpF from 
Serratia marcescens (del Mar Tomas et al., 2005). 
 
The CarO protein, another heat-modifiable protein, co-migrates on SDS-PAGE gels 
with the HMP-AB protein. When heated, the size of the protein changes from 25 to 
29kDa (Mussi et al., 2005). The mature protein comprises 228 residues is found to be 
approximately 24 kDa. Amino-terminal sequencing analysis shows that it shares a 
100% similarity with the CarO protein in the Swiss-Prot database. Blast analysis 
indicates that this protein is highly similar to ACIAD2598 (70% identity to outer 
membrane protein CarO precursor) and Omp25 in A. baumannii ATCC19606 
(Accession No: CAI 79415) (Schneiders et al., 2008). The loss or disruption of this 
protein results in carbapenem resistance as indicated by other studied but no binding 
site for imipenem has been identified suggesting that i  might function as a 
nonspecific monomeric channel (Siroy et al., 2005). 
 
1.4.2.1.3 Efflux mechanisms 
In A. baumannii, pumps of the resistance nodulation cell-division (RND), multidrug 
and toxic compound extrusion (MATE), and major facilitator superfamily (MFS) have 
been associated with antimicrobial resistance (Magnet et al., 2001; Marchand et al., 
2004; Su et al., 2005). Many studies have shown that efflux pumps play a crucial role 
in bacterial pathogenesis and in the survival of the pathogen in the host where the 
deletion of the transporter genes has resulted in reduced survival and virulence 
potential of the organism (Hirakata et al., 2002; Su et al., 2005; Piddock, 2006). 
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Studies on P. aeruginosa lacking efflux pumps show that the bacteria were unable to 
invade canine-kidney epithelial cells but the invasion potential was restored upon 
complementation with the mexAB-oprM genes (Hirakata et al., 2002).  
 
It is likely that the RND-type efflux pumps, AdeABC, AdeDE, AdeIJK, and 
AdeXYZ, contribute to the virulence and fitness of Acinetobacter spp. Although 
described as independent pumps, AdeIJK and AdeXYZ share 93% identity at the 
nucleotide level and 99% similarity at the protein l vel. AdeIJK and AdeXYZ 
represent the same pump belonging to Acinetobacter genomic DNA groups 2, 3, and 
13TU. AdeABC pump has been described and characterized in a non-Acinetobacter 
baumannii strain and all three pumps can coexist (Roca et l., 2011). The 
retrospective analysis of the active efflux systems show that the AdeAB efflux pump 
was specific to A. baumannii and both AdeE and AdeY were only found in 
Acinetobacter genomospecies 3 (Chau et al., 2004; Chu et al., 2006).  
 
It has been shown that AdeAB is controlled by a twocomponent regulatory system 
AdeR (regulator) and AdeS (sensor kinase). AdeA is the membrane fusion protein, 
AdeB is the multidrug transporter and AdeC is the outer membrane protein. The lack 
of the AdeC gene in A. baumannii ATCC17978 in contrast to BM4454 suggests that 
AdeAB efflux pump might use alternative outer membrane proteins to export 
substrates, however when AdeB gene was disrupted in BM4454 the bacterium 
became susceptible to a vast range of antibiotics (Magnet et al., 2001; Schneiders et 
al., 2008). This is consistent with the observation that not all structural components of 
the AdeABC pump are required to be encoded by members of the same genomic 
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DNA group and that AdeC does not contribute significantly to the multidrug 
resistance phenotype (Marchand et al., 2004).  
 
AbeM is an H+-dependent drug antiporter and member of the MATE family. It is 
shown to confer resistance to gentamicin and hydrophilic quinolones (Chau et al., 
2004). The tet(A) or tet(B) genes encode for membrane-associated efflux proteins 
(Marti et al., 2006). These proteins belong to the MF superfamily and exchange a 
proton for the tetracycline cation complex (Roberts, 1996). When expressed, the tet 
(A) gene confers resistance to tetracycline and the tet (B) gene confers resistance to 
both tetracycline and minocycline (Roberts, 1996). 
 
The cmlA gene encodes an efflux pump that confers resistance to hloramphenicol 
and is a part of the gene cluster that harbours tet(R) and tet(A). It belongs to the MF 
superfamily and was found to be located within the pathogenicity island present in the 
epidemic multidrug resistant A. baumannii AYE strain. The AYE strain also 
harboured the qacE∆1 gene responsible for resistance to quarternary ammonium 
compounds (Fournier et al., 2006). 
 
1.4.2.2 Antibiotic resistance 
1.4.2.2.1 Aminoglycosides 
All of the major classes of enzymes conferring resistance to amino-glycosides have 
been described; these include acetyltransferases, nucleotidyltransferases, and 
phosphotransferases (Noppe-Leclercq et al., 1999; Nemec et al., 2004; Hujer et al., 
2006). One of the most important mechanisms of aminoglycoside resistance is post-
transcriptional rRNA methylation by 16S rRNA methylases. 16S rRNA methylation 
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by the armA gene has described for A. baumannii strains from Japan, Korea, and 
North America (Yamane t al., 2005; Lee et al., 2006a; Doi et al., 2007). The genetic 
surroundings of armA appear very similar across Gram-negative organisms, as it is 
plasmid-borne and within a transposon (Tn1548) (Doi et al., 2007). Other 16S rRNA 
methylase genes like rmtA, rmtB, rmtC and rmtD have also been described in the 
Enterobacteriaceae family (Yokoyama et al., 2003; Yamane t al., 2005). They are the 
cause of high-levels of resistance to all clinically useful aminoglycosides, including 
gentamicin, tobramycin, and amikacin. 
 
1.4.2.2.2 Fluoroquinolones 
The two target proteins of the quinolones are the DNA gyrase (topoisomerase II) and 
topoisomerase IV. DNA gyrase is a tetrameric enzyme with two subunits A and two 
subunits B, encoded in the gyrA and gyrB genes, respectively. Topoisomerase IV is 
also a tetrameric enzyme, which also has two A and two B subunits, encoded in the 
parC and parE genes, respectively (Vila and Pachón, 2008). Modifications of the 
DNA gyrase and topoisomerase IV, due to the mutations n the gyrA and parC genes, 
have been well described for A. baumannii and they interfere with the binding of the 
target site (Hamouda and Amyes, 2004; Higgins et al., 2004., reviewed by Peleg t
al., 2008). 
 
Both aminoglycosides, and quinolones have been shown as the substrates for 
multidrug efflux pumps (Ribera et al., 2002), including the AdeABC and AbeM 
(Magnet et al., 2001; Higgins et al., 2004; Su et al., 2005). The plasmid genes qnrA, 
qnrB and qnrS conferring quinolone resistance are not widespread with only a single 
report on identification of the qnrA gene in A. baumannii strain recovered in Algeria 
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(Touati et al., 2008). QepA plasmid mediated quinolone resistance by fluoroquinolone 




According to the recent reports in vitro resistance and heteroresistance to the 
polymyxins in A. baumannii s increasing with the underlying mechanism still unclear 
(Li et al., 2006a). Mutations in PmrAB system have shown to confer colistin 
resistance (Adams et al., 2009). It has previously been shown that reduced bin ing to 
the lipopolysaccharide (LPS) target site can lead to resistance in E. coli, Salmonella 
spp., and P. aeruginosa (Peterson et al., 1987; Conrad and Galanos, 1989). Changes 
in outer membrane proteins have shown to cause reduced susceptibility to polymyxins 
in P. aeruginosa (Nicas et al., 1980). These factors may have implications in the 
contribution of colistin resistance in A. baumannii strains. 
 
1.4.2.2.4 Trimethoprim-sulfamethoxazole 
The prevalence of trimethoprim-sulfamethoxazole resistance in A. baumannii s high 
in China and Europe (Van Looveren t al., 2004; Gu et al., 2007). Integrons are very 
common in multidrug resistant A. baumannii strains. The 3’-conserved region of an 
integron mostly contains a qac gene fused to a sul gene, conferring resistance to 
antiseptics and sulphonamides, respectively (reviewed by Peleg et al., 2008). 
Consequently, sulphonamide resistance has been shown to be highly predictive of 
integron-carrying strains of A. baumannii (Gu et al., 2007). Similarly dhfr genes 
coding for trimethoprim resistance and cat genes coding for chloramphenicol 
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resistance have also been reported within integron structures in A. baumannii (Gu et 
al., 2007; reviewed by Peleg et al., 2008). 
 
1.4.2.2.5 Tigecycline  
Tigecycline is an extended-spectrum antibiotic with activity against Acinetobacter 
spp, an increasingly common cause of nosocomial pneumonia. It is one of the last 
resorts for the treatmeant of multi-resistant Acinetobacter baumannii infections 
(Koomanachai et al., 2009). High resistance rates to tigecycline, in multiple clones of 
MDR A. baumannii have been reported in Tel Aviv medical centre, Israel (Navon-
Venezia et al., 2007). These findings are worrying. 
 
Other mechanisms like alteration of drug targets (penicillin-binding proteins), 
permeability problems, resistance to tetracyclines and carbapenems have also been 














Integrons are assembly platforms that incorporate exog nous open reading frames 
(ORFs) by site-specific recombination and convert them to functional genes (Figure 
17). All integrons characterized to date are composed of three main elements 
necessary for the capture of exogenous genes: a gene intI encoding an integrase 
belonging to the tyrosine-recombinase family; a primary recombination site attI; and 
an outward- orientated promoter (Pc) that directs transcription of the captured genes 
(Mazel, 2006). At present, five classes of integrons are known to have a role in the 
dissemination of antibiotic resistance genes. These classes have been defined based on 
the sequence of the encoded integrases, which show 40–58% identity (Mazel, 2006). 
All five classes are physically linked to mobile DNA elements, such as insertion 
sequences, transposons and conjugative plasmids, all of which can serve as vehicles 
for the intraspecies and interspecies transmission of genetic material (Mazel, 2006). 
Three classes of integrons are ‘historical’ classes that are involved in the multiple-
antibiotic-resistance phenotype. Class 1 integrons are associated with functional and 
non-functional transposons derived from transposon Tn402 that can be embedded in 
larger transposons, such as Tn21 (Rådström et al., 1994; Brown et al., 1996; Mazel, 
2006). Class 2 integrons are exclusively associated with Tn7 derivatives (Sundström 
et al., 1991; Rådström et al., 1994). The class 3 integrons are thought to be located in 
a transposon inserted in as-yet-uncharacterized plasmids (Collis et al., 2002; Mazel, 
2006). The other two classes of mobile integrons, class 4 and class 5 have been 




Figure 17: Structural comparison of a 'classical' mobile integron and a 
superintegron from Vibrio cholerae strain N16961. 
 a) A schematic representation of the class 1 integron In40. The various resistance-
gene cassettes carry different attC sites. The following antibiotic-resistance cassettes 
confer resistance to the following compounds: aacA4, aminoglycosides; cmlA2, 
chloramphenicol; oxa-9, β-lactams; qacF and qacE, quarternary ammonium 
compounds. The sul gene, which confers resistance to sulphonamides, is not a gene 
cassette.  
b) A schematic representation of the chromosomal superintegron in V. cholerae; the 
open reading frames are separated by highly homologous sequences, the V. cholerae 
repeats (VCRs). infC, encodes translation initiation factor IF3; rpmI and rplT encode 




To date only class 1 and class 2 integrons have been reported in A. baumannii, class 1 
being the most common (Seward and Towner, 1999) and c  confer resistance to the 
aminoglycosides, sulphonamides, chloramphenicol, trimethoprim and β-lactams 
(Seward and Towner, 1999; Ploy et al., 2000; Koeleman et al., 2001; Nemec., 2004; 
Gu et al 2007). Genes encoding metallo-β-lactamase such as IMP and VIM have also 
been reported A. baumannii from isolates in Italy and Korea (Riccio et al., 2000; Yum 
et al., 2002). Horizontal transfer of the resistance genes can be achieved when an 
integron containing one or more such genes is incorporated into a broad-host-range 
plasmid. Likewise, single cassettes integrated at secondary sites in a broad-host-range 
















1.4.2.4 Insertion Sequences 
The IS finder database (www-is.biotoul.fr/is.html, last accessed 12/3/2012) reveals the 
presence of 35 insertion sequences, 23 of which have been associated with A.
baumannii (Table 4). 
Table 4: Insertion elements found in various Acinetobacter spp 
N0 Name Family Origin Accession 
number 
1 IS1007 IS6 Acinetobacter sp. LS56-7 AJ250860 
2 IS18 IS30 Acinetobacter sp. 13 BM2716  AF043676 
3 IS1236 IS3 Acinetobacter calcoaceticus U03772 
4 ISAca1 IS3 Acinetobacter calcoaceticus  AF121266 
5 IS1008 IS6 Acinetobacter calcoaceticus  AJ251307 
6 IS17 IS5 Acinetobacter haemolyticus  U95013 
7 ISAha1 IS5 Acinetobacter haemolyticus   
8 ISAha2 IS5 Acinetobacter haemolyticus   
9 ISAlw1 IS5 Acinetobacter lwoffii   
10 IS1006 IS6 Acinetobacter junii  NC_004361 
11 ISAba1 IS4 Acinetobacter baumannii  AY758396 
12 ISAba2 IS3 Acinetobacter baumannii  AY665723 
13 ISAba3 IS1 Acinetobacter baumannii  AY665723 
14 ISAba4 IS982 Acinetobacter baumannii  EF059914 
15 ISAba5 IS5 Acinetobacter baumannii  CU459140 
16 ISAba6 IS982 Acinetobacter baumannii  CU468230 
17 ISAba7 IS5 Acinetobacter baumannii  CU468230 
18 ISAba8 IS21 Acinetobacter baumannii  EF102240 
19 ISAba9 IS982 Acinetobacter baumannii  EU850412 
20 ISAba10 IS5 Acinetobacter baumannii  GQ379223 
21 ISAba11 IS701 Acinetobacter baumannii  CP000521 
22 ISAba12 IS5 Acinetobacter baumannii  NC_009085 
23 IS18 IS30 Acinetobacter baumannii EU294228 
24 ISAba125 IS30 Acinetobacter baumannii  AY751533 
25 ISAba825 IS982 Acinetobacter baumannii  AY751532 
26 ISAba13 IS5 Acinetobacter baumannii  CP001182 
27 ISAba14 IS3 Acinetobacter baumannii  CP001921 
28 ISAba15 IS5 Acinetobacter baumannii  JN187417 
29 ISAba16 IS66 Acinetobacter baumannii  JN415682 
30 ISAba17 IS66 Acinetobacter baumannii   
31 ISAba18 IS3 Acinetobacter baumannii  CP000521 
32 ISAba19 IS3 Acinetobacter baumannii   
33 ISAba20 IS3 Acinetobacter baumannii   
34 ISAcsp1 Tn3 Acinetobacter species EB104  




Barbara McClintock's discovery of jumping genes early in her career earned her the 
Nobel Prize in 1983. She records her discovery of transposable elements which have 
either a "copy and paste" or "cut and paste" mechanism (McClintock, 1950).  An 
insertion sequence (Figure 18) is a short DNA sequence that acts as a simple 
transposable element. The two major characteristics of insertion elements are: they are 
smaller in length (upto 2500bp) relative to other transposable elements and only code 
for proteins implicated in the transposition activity (Campbell and Reece, 2002). 
These proteins are usually the transposase which catalyses the enzymatic reaction 
allowing the IS to move, and also one regulatory protein which either stimulates or 
inhibits the transposition activity (Campbell and Reece, 2002). The coding region in 
an insertion sequence is usually flanked by inverted epeats (Figure 18). For example, 
the well-known IS911 is flanked by two 36 bp inverted repeats and the coding region 
have two partially overlapping genes orfA and orfAB, coding for the transposase 
(OrfAB) and a regulatory protein (OrfA)(Campbell and Reece, 2002).  
 
Insertion sequences have a very specific role to play with respect to the expression of 
oxacillinases in A. baumannii. ISAba1 has been shown to cause the over-expression of 
the naturally occurring blaOXA-51-like gene leading to carbapenem resistance in A.
baumannii (Turton et al., 2006a). ISAba825 has been found upstream of the 
blaOXA-51-like and is responsible for the expression of the blaOXA-51-like  gene (Lopes and 
Amyes, unpublished observations). It has also been shown that ISAba1 controls the 
expression of the blaADC (Corvec et al., 2003). Recent observations also show the role 
of ISAba125 in providing a better promoter than ISAba1 in the over-expression of the 
blaADC gene (Lopes et al., 2011. P601, ECCMID). It has been reported that insertion 
sequences ISAba1, ISAba2, ISAba3 and IS18 are associated with the blaOXA-58 gene 
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expression (Poirel and Nordmann, 2006b). The same study also identified a composite 
transposon-like structure formed by ISAba3 and it concluded that the acquisition of 
the blaOXA-58 gene was not the result of a transposition process but due to homologous 
recombination (Poirel and Nordmann, 2006b). ISAba1 and ISAba4 have been 
associated with expression of the blaOXA-23 gene (Corvec et al., 2007; Bogaerts et al., 
2008). Insertion sequences in A. baumannii have also been involved in altering the 
copy number of the blaOXA-58 gene. The best known example is of the duplication of 
the blaOXA-58 gene, mediated by the IS26 element. The study reports three clonally-
related strains, resistant to imipenem having one, two and three copies of the blaOXA-58 
gene (Bertini et al., 2007). This study shows that IS26 element is able to duplicate the 
entire ISAba2/ISAba3- blaOXA-58-ISAba3 region by imperfect duplicative 
transposition, starting with the cointegrate fusion and duplication of the element but 
lacking the resolution of the cointegrate providing better promoters for the expression 










Figure 18: General structure of an insertion element having the transposase gene 
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Recent studies also demonstrate the acquisition of plasmid-located ISAba1-blaOXA-51-
like genes as a result of one ended transposition (Chen et al., 2010). It is clear by these 
studies that the ‘‘intrinsic’’ genes can confer high levels of resistance and can be 
freely mobilised interspecifically in Acinetobacter spp. The acquisition of the blaOXA-
138 (a gene of the blaOXA-51-like cluster) in A. nosocomialis may have occurred by a 
similar process. Insertion sequences such as ISAba125 and ISAba825 have also been 
involved in the disruption of the carO gene leading to a multi-drug resistant 
phenotype in A. baumannii (Mussi et al., 2005). ISAba825-ISAba3-like hybrid 
promoter has also been shown to cause the over-expression of the blaOXA-58 gene in A. 




In the Acinetobacter calcoaceticus- baumannii complex, Acinetobacter baumannii is 
an emerging multi-drug resistant nosocomial pathogen, with other members of the 
complex A. pittii and A. nosocomialis also emerging along side. 
 
A. baumannii has caused serious problems like ventilator associated pneumonia and 
septicaemia associated with a steady rise in infections seen in immuno-compromised 
patients over the past few decades. 
 
A. baumannii s a major problem due to its evolving multi-drug resistant profile and is 
developing increasing antibiotic resistance to almost all classes of antimicrobials, 
parallel to the development of different antibacterial drugs.  
 
Carbapenems are regarded as the last sustainable resort for treatment of A. baumannii 
infections but resistance to the carbapenems is an established problem in A. 
baumannii with different mechanisms of innate and acquired resistance phenotype in 
this species.  
 
Carbapenem resistance due to presence of insertion sequences like ISAba1 present 
upstream of the intrinsic blaOXA-51-like gene has been observed in A. baumannii 
 
A. baumannii has developed numerous mechanisms that make it a very strong 
nosocomial pathogen. These include IS elements governing the expression of 
carbapenemase genes, insertional inactivation or modifications of the outer membrane 
proteins, acquisition of metallo-carbapenemases leading to carbapenem resistance, 
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over-expression of acinetobacter derived cephalosporinases, over-expression of the 
efflux pumps and more recently it marks the beginning of emergence of resistance to 
colistin. 
 67 
1.6 Aims and Objectives of this project 
 To prove the importance of transposition of ISAba1 and its role in control of 
antibiotic resistance genes. 
 To identify any novel insertion elements governing the blaADC gene expression 
 To analyze multi-drug resistant profile of the isolates isolated from 
Cochabamba, Bolivia. 
 To monitor and assess the trends in Aberdeen Royal Infirmary and to identify 
any novel blaOXA-51-like variants. 
 To identify any novel insertion elements governing the blaOXA-51-like gene in 
isolates from the US 
 To study the insertional inactivation of the blaOXA-51-like  gene and to 
understand the mechanism of carbapenem resistance in Acinetobacter 
baumannii strain isolated in Carnaxide, Portugal 
 To study the mechanism of ciprofloxacin resistance and the role of insertion 
sequences involved in the disruption or promotion of various genes involved 
in efflux pump regulation. 

















2.0 MATERIALS AND METHODS 
2.1 Strain collection and identification 
A total of 96 Acinetobacter baumannii solates were used in this study. Thirty-six 
isolates each were from the collections of Benjamin Evans (Europe) and Susan Brown 
(United States), fifteen isolates from Bolivia (Lucía Gallego, University of the Basque 
Country, Bizkaia, Spain) and nine isolates from Aberde n Royal Infirmary (Ian 
Gould). 
 
The isolates had been previously identified by 16S-23  rRNA restriction analysis 
(Dolzani et al., 1995) or by the intrinsic blaOXA-51-like gene PCR (Héritier et al., 2005b) 
or by the rpoB gene sequencing (La Scola et al., 2006). They were reconfirmed by me 
by at least two of the above method. 
 
The isolates were sub-cultured on MacConkey agar (Oxoid, Basingstoke) and 
incubated at 37oC for 24hrs. A single colony was inoculated in IST broth and grown 
overnight at 37oC in an orbital shaker. 900µL of the overnight culture was added to 
100µL sterile glycerol in a cryovial and were stored at -85oC for long-term storage. 
  
2.2 Chemicals and Media 
All the chemicals and antibiotics were purchased from Sigma-Aldrich Company 
(Poole, UK) Ltd unless otherwise stated. All media were purchased in powdered form 
from Oxoid (Basingstoke, UK). The broths and agar pl tes were prepared according 
to the manufacturer’s instructions. They were sterilis d at 121oC/15psi for 15 minutes 
by autoclaving. Normal saline was prepared by dissolving 0.85 g of NaCl in 100mL 
of D/W and sterilized by autoclaving. 
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2.3 10X TAE buffer 
48.44g of Trizma base (Sigma) and 3.72g of EDTA (Ethylene diamine tetra acetic 
acid) disodium salt dehydrate 99% were dissolved in D/W with the addition of 11.4 
ml glacial acetic acid to give a final volume of one litre. The pH was adjusted to 8.0 
and the solution was sterilized. For running the gels, 1:10 dilution was made to a final 
concentration of 1X and used for gel electrophoresis. 
 
2.4 Gel electrophoresis and staining 
1.5% gels (Gensieve LE agarose, Flowgen, UK) were prepared in 1X TAE buffer and 
used for running at 100V. 0.7% gels were prepared for the running of plasmid DNA 
and they were run at 60V for 19hrs for better resoluti n. All the gels were stained in a 
100 mL of gel red (Biotium, US) staining solution (50 µL gel red dissolved in 100ml 
of 0.1M NaCl) and visualized by the Gel Doc system. 
 
2.5 10X TBE buffer 
Tris-base (108g) and 55g of boric acid were dissolved with 40mL of 20mM EDTA in 
one litre of D/W. The pH was adjusted to 8.0 with and the solution was sterilized. 
0.5X TBE buffer was used for running of the PFGE gels. 
 
2.6 Pulsed-Field Gel Electrophoresis (PFGE) 
PFGE was performed on Acinetobacter baumannii strains isolated from the Aberdeen 
Royal Infirmary according to the procedure described y Seifert et al. (2005). The 
isolates were inoculated onto Iso-Sensitest agar (Oxoid, Basingstoke) and incubated 
overnight at 37°C in ambient air. A loopful of bacteria was removed from the agar 
surface with a sterile plastic loop and suspended in a glass or polystyrene round-
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bottomed tube containing 2.5 ml of cell suspension buffer (100 mM Tris, 100 mM 
EDTA, pH 8.0). Each cell suspension was adjusted to give a cell density of 
approximately 109 cells/ml. This was performed by using the spectrophotometer. The 
pellet was resuspended by vortexing, and the cell suspension was incubated at 55°C 
for 10 min a water bath. An aliquot of 25 µL proteinase K (20-mg/ml stock solution in 
ultrapure water) was added, and the suspension was mixed gently by inverting the 
tube two to four times. An equal volume of melted 1% CHEF genomic agarose (Bio-
Rad, UK)-1% sodium dodecyl sulphate(Fisher Scientific, UK) in TE buffer (10 mM 
Tris, 1 mM EDTA, pH 8.0) was added to the cell suspension, and the suspension was 
mixed gently by inverting the tube 10 to 12 times. The agarose-cell suspension 
mixture was immediately dispensed into the wells of reusable plug moulds. The 
agarose plugs were allowed to solidify at room temprature for 5 min and at 4°C for 
another 5 min. A single plug was then transferred to isposable screw-cap 50-ml 
polypropylene tubes containing 5 ml of cell lysis buffer (50 mM Tris, 50 mM EDTA 
[pH 8.0], 1% sarcosine) and 25 µL of proteinase K (20 mg/ml stock solution). Lysis 
was performed at 55°C in a water bath for two hours with. After lysis, the buffer was 
carefully removed and the plugs were washed five tim s (15 min/wash) at 55°C (two 
times with sterile ultrapure water and three times with TE buffer; 10 ml for each 
washing step) in a water bath. The water and TE buffer were preheated at 50 to 55°C 
before each washing step. After the last wash, the TE buffer was poured off and 10 ml 
of fresh TE buffer was added to each tube. If the plugs were not used on the same day 
then they were refrigerated. For the restriction of the genomic DNA a single slice of 
the plug (4.0 by 5.5 mm) was cut with a scalpel or razor blade and transferred to a 
microcentrifuge tube containing 200 µL of the restriction buffer with 30 U ApaI 
(Promega, Southampton, UK). The plug slices were incubated at 37°C for 24 hours in 
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a water bath. 1.0% gels were prepared in 0.5X TBE buffer for PFGE and the gels 
were run with the plugs in CHEF apparatus with initial pulse 5 and final pulse 25 for 
20 hours. The gel was stained with gel red on the completion of run. Cluster analysis 
was performed by the unweighted pair group method with mathematical averaging 
(UPGMA), and DNA relatedness was calculated by using the band-based Dice 
coefficient with a tolerance setting of 1.5% band tolerance and 1.5% optimization 
setting for the whole profile. Gel analysis was performed using the BioNumerics v4.0 
software (Applied Maths, Sint-Martins-Latem, Belgium). The banding patterns were 
interpreted according to the criteria suggested by Tenover et al., 1995. A value of 80-
85% was chosen as the threshold for the establishment of clonal relatedness of 
unknown isolates.  
 
2.7 Determination of the minimum inhibitory concentration 
The isolates were tested for their susceptibility to either some or all the antibiotics. 
The antibiotics used in this study were imipenem (IPM) (Merck, Sharp & Dohme Ltd, 
Hertfordshire, UK), meropenem (MEM) (AstraZeneca, Cheshire, UK), ceftazidime 
(CAZ) (Sigma), cefepime (FEP) (Bristol Myers Squibb, US), ciprofloxacin (CIP) 
(Bayer AG, Germany), gatifloxacin (GAT) (Sigma), gentamicin (CN) (Sigma), 
piperacillin/tazobactam (PIP/TZ) (Cyanamid, Gosport, UK). 
 
The efflux pump inhibitor 1-(1-napthylmethyl) piperazine (NMP) was used at a 
concentration of 100 mg/L to check for the action of the efflux-mediated 
ciprofloxacin resistance in some strains. 
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Following overnight culture on MacConkey agar plates, a single colony was 
suspended in 5 mL of Iso-sensitest broth (Oxoid, Basingstoke) and grown overnight at 
37°C/180 rpm in an orbital shaker. Minimum inhibitory concentrations (MICs) were 
determined by the agar double dilution technique in Iso-sensitest agar according to the 
British Society for Antimicrobial Chemotherapy (BSAC) methodology (British 
Society for Antimicrobial Chemotherapy, Version 6.1). The results were interpreted 
according to the BSAC guidelines. Pseudomonas aeruginosa NCTC 10662, 
Escherichia coli NCTC 10418 and Staphylococcus aureus NCTC 6571 were used as 
control strains. 
 
2.8 Extraction of DNA 
Following overnight sub-culture on MacConkey agar at 37oC, DNA extraction was 
performed by boiling 5 identical colonies in 50 µL of sterile distilled water for about 
15-20 minutes. The eppendorf tubes were centrifuged and the supernatant was used as 
the DNA template. 
 
2.9 Amplification of genes by Polymerase chain reaction (PCR) 
All the PCR’s were performed in a total volume of 50 µL, with reagents supplied by 
Promega (Promega, Southampton, UK) according to the manufacturer’s guidelines. 
The primers used in this study were supplied by Eurofins MWG operon, UK. They 
were diluted to a concentration of 100 pmol/µL as stock standards. 12.5 pmol of 
primer was used for each PCR reaction. 
All the primers used in this study were either from previously published papers or 
were designed using the biotools software  
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi, Last accessed, 9/8/2011) 
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2.10 The aims of the PCR reaction and purpose of the primers (5’-3’) used in this 
study.  
 
 A PCR described by Dolzani et al. (1995) using the primers 16S-23S primer 1 
and 16S-23S primer 2, was used to re-identify and confirm the identity of 
some A. baumannii strains. The 975bp product amplified for Acinetobacter 
genospecies 2 was restricted with the enzymes AluI and NdeII. Restriction of 
the product by the enzyme AluI produced fragments of 50, 125, 135, 165, 175 
and 330 bp specific to A. baumannii. Restriction of the same product produced 
fragment sizes 50, 110,145, 330 and 360 bp by the enzyme NdeII, specific to 
A. baumannii. The primers and expected fragment size were 
16S-23S primer 1 
16S-23S primer 2 
 TTG TAC ACA CCG CCC GTC A 
GGT ACT TAG ATG TTT CAG TTC     
975bp 
 
 A PCR described by La Scola et al. (2006) was used for the rpoB gene 
detection and sequencing for the molecular identification of Acinetobacter 
species. The primers and expected fragment size wer 
Ac696F 
Ac1093R 
TAY CGY AAA GAY TTG AAA GAA G 
CMA CAC CYT TGT TMC CRT GA 
350bp 
            
           Y= C, T; M= A, C; R= A, G      
 Multiplex PCR for detection of oxacillinases was performed according to the 
method of Woodford et al. (2006).  The primers listed below were used for the 













TAA TGC TTT GAT CGG CCT TG 
TGG ATT GCA CTT CAT CTT GG 
GAT CGG ATT GGA GAA CCA GA 
ATT TCT GAC CGC ATT TCC AT 
GGT TAG TTG GCC CCC TTA AA 
AGT TGA GCG AAA AGG GGA TT 
AAG TAT TGG GGC TTG TGC TG 









 PCR for the detection of blaOXA-143 was performed using the primers OXA-
143F and OXA-143R. The primers and expected fragment size were 
OXA-143F 
OXA-143R 
TTC TGT CAG TGC ATG CTC ATC 
CAG GCA TTC CTT GCT TCA TT 
728bp 
            PCR conditions were                                                                                                                                             
Function Temperature  Time  Cycle/s 
Pre-denaturation 94°C 5 min 1 
Denaturation 94°C 30 sec 
Annealing 57°C 40 sec 
Extension 72°C 50 sec 
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 PCR for the detection of the blaOXA-51-like gene and the upstream insertion, if 
any, was performed according to Héritier et al, (2005b). The primers used for 
this PCR anneal at the intergenic regions upstream and downstream of the 
blaOXA-51-like gene and hence are able to map the blaOXA-51-like gene and any 
insertion if present upstream of the blaOXA-51-like gene. The primers Oxa69-A 




CTA ATA ATT GAT CTA CTC AAG 
CCA GTG GAT GGA TGG ATA GAT TAT C 
975bp 
 
 PCR for the detection of the intergenic region downstream of the blaOXA-51-like 
gene were performed using the IntoxaF and IntaceR primers. The PCR was 
performed only for strains which were found to be positive for an insert 
upstream of the blaOXA-51-like gene (This study). The primers and expected 
fragment size were 
IntoxaF 
IntaceR 
GGA ATA CCT AGC TCT GTT CG 
GTT TTA CCC ACG CTG GTA CT 
250bp 
            PCR conditions were 
Function Temperature  Time  Cycle/s 
Pre-denaturation 94°C 5 min 1 
Denaturation 94°C 30 sec 
Annealing 57°C 40 sec 
Extension 72°C 50 sec 
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 PCR for the analysis of the region upstream blaOXA-51-like gene was also 
performed by using the primers FxOxaF and FxOxaR (This study). The 
primers and expected fragment size were 
FxOxaF 
FxOxaR 
GAT ACC AGA CCT GGC AAC AT 
GCA CGA GCA AGA TCA TTA CC 
889bp 
            PCR conditions were 
Function Temperature  Time  Cycle/s 
Pre-denaturation 94°C 7 min 1 
Denaturation 94°C 1 min 
Annealing 57°C 1 min 
Extension 72°C 2 min 
 
35 
Final extension 72°C 7 min 1 
Cooling 4°C 
 








ATC CGG CTA ACA CAG CCT TA 
 
GAC CTG GCC TGA TTT AAA GC 
 
AGG CAC TGA TCC AAG GTT TG 
 





 PCR for the detection of the entire blaOXA-58-like gene was performed using the 
primers preOxa-58prom+ and preOXA-58B designed by Héritier et al. 
(2005a). The primers and expected fragment size wer
preOXA-58prom+ 
preOXA-58B 
TTA TCA AAA TCC AAT CGG C 
TAA CCT CAA ACT TCT AAT TC 
934bp 
 
 PCR for the detection of upstream sequences of the blaOXA-58-like gene in 
certain A. baumannii strains was performed using a combination of primers, 
SM2 and OXA-58-like R. The primers are listed indivi ually by Poirel and 
Nordmann (2006) and Woodford et al. (2006) respectively. The walk-58R 




AAG TGT CTA TAT TCT CAC C 
CAG CAC AAG CCC CAA TAC TT 
Variable 
            PCR conditions were 
Function Temperature  Time  Cycle/s 
Pre-denaturation 94°C 5 min 1 
Denaturation 94°C 30 sec 
Annealing 55°C 40 sec 
Extension 72°C 50 sec 
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 PCR were performed for the detection of the whole b aOXA-40-like gene 
according to the primers described Afzal-Shah et al., (2001) using the Oxa-
24A and Oxa-24B primers. The primers and expected fragment size were 
Oxa-24A 
Oxa-24B 
GTA CTA ATC AAA GTT GTG AA 
TTC CCC TAA CAT GAA TTT GT 
1023bp 
 
 The blaOXA-40-like gene PCR was repeated for samples negative by Oxa-24A 
and Oxa-24B but positive by multiplex PCR, using the primers Oxa-24F and 




TTA AAT GAT TCC AAG ATT TTC TAG C 
825bp 
 
 The blaOXA-23-like gene PCR was performed using the primers 23A and 23B 




GAT GTG TCA TAG TAT TCG TCG 
TCA CAA CAA CTA AAA GCA CTG 
1062bp 
 
 PCR for the detection of ISAba1 upstream of blaOXA-23-like gene was performed 
using a combination of primers, ISADC1 and Oxa-23R described individually 
by Ruiz et al. (2007) and Woodford et al. (2006) (This study). The primers 
and expected fragment size were 
ISADC1 
Oxa-23R 
GTT GCA CTT GGT CGA ATG AAA A 




           PCR conditions were 
Function Temperature  Time  Cycle/s 
Pre-denaturation 94°C 5 min 1 
Denaturation 94°C 30 sec 
Annealing 55°C 40 sec 
Extension 72°C 50 sec 
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Final extension 72°C 6 min 1 
Cooling 4°C 
 
 PCR for the detection of ISAba1 upstream of the blaOXA-51-like gene was 
performed using ISAba1F and OxaR primers (This study). The primers and 
expected fragment size were 
ISAba1F
OxaR 
TCA GGG TTC TGC CTT CTT AA 
GCA CGA GCA AGA TCA TTA CC 
1365bp 
            PCR conditions were 
Function Temperature  Time  Cycle/s 
Pre-denaturation 94°C 5 min 1 
Denaturation 94°C 30 sec 
Annealing 57°C 40 sec 
Extension 72°C 50 sec 
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 PCR for the detection of any insertion sequences upstream and downstream of 
blaADC was performed using the primers FU, RU (annealing upstream of 
blaADC) and FD, RD (annealing downstream of blaADC) respectively (This 












            PCR conditions were 
Function Temperature  Time  Cycle/s 
Pre-denaturation 94°C 5 min 1 
Denaturation 94°C 30 sec 
Annealing 57°C 40 sec 
Extension 72°C 50 sec 
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Final extension 72°C 6 min 1 
Cooling 4°C 
 
 PCR for the detection of ISAba1 upstream of the blaADC gene was performed 
according to Ruiz et al. (2007) using the ISADC1 and ISADC2 primers. The 
primers and expected fragment size were 
ISADC1 
ISADC2 
GTT GCA CTT GGT CGA ATG AAA A 




 PCR for the detection of ADC (AmpC) was performed according to Ruiz et al. 
(2007) using the ADC1 and ADC2 primers. The primers and expected 
fragment size were 
ADC1 
ADC2 
CCG CGA CAG CAG GTG GAT A 
TCG GCT GAT TTT CTT GGT T 
420bp 
 
 A multiplex PCR for the detection of integrons was performed using the 
primers previously described by Dillon et al. (2005) using the primers int1F, 








CAG TGG ACA TAA GCC TGT TC 
CCC GAG GCA TAG ACT GTA 
GTA GCA AAC GAG TGA CGA AAT G 
CAC GGA TAT GCG ACA AAA AGG T 
GCC TCC GGC AGC GAC TTT CAG 







 The primers CSa and CSb describer earlier by Lévesque et al. (1995) were 
used for the detection of conserved regions in class I integrons. 
CSa 
CSb 
GGC ATC CAA GCA GCA AG 
AAG CAG ACT TGA CCT GA 
Variable 
 
 A multiplex PCR for the detection of metallo-β-lactamases was performed 
using the primers previously described by Ellington et al., (2007) using the 
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GGA ATA GAG TGG CTT AAY TCT C 
CCA AAC YAC TAS GTT ATC T 
GAT GGT GTT TGG TCG CAT A 
CGA ATG CGC AGC ACC AG 
TCG ACA CAC CTT GGT CTG AA 
AAC TTC CAA CTT TGC CAT GC 
TAC AAG GGA TTC GGC ATC G 
TAA TGG CCT GTT CCC ATG TG 
AAA ATC TGG GTA CGC AAA CG 











 Insertion causing disruption of the carO gene (29kDa OMP) was checked, 
using the established primers carOF and carOR describ d earlier by Mussi et 
al. (2005). The primers and expected fragment size wer   
carOF 
carOR 
CCA TGG CTG ACG AWG CAG TCG TAC ATG A 
CCA TGG CAA AAG TAT TAA AAG TTT TAG CAG T 
700bp 
 
 The efflux genes were amplified with the primers listed in the table below 
(This study). They were also used to record the levls of gene expression in 
strains having high antibiotic efflux, mainly to fluoroquinolones. The primers 
and expected fragment sizes were 
adeS-F 
adeS-R 
TGC CGC CAA ATT CTT TAT TC 























CGC TCT AGT GCA TCG CTA TC 
GCA TTA CGC ATA GGT GCA GA 
CGC AAG TCG GAG GTA TCA TT 
TAT ACC TGA GGC TCG CCA CT 
CCC TAA TCA AGG ACG TAT GC 
TAG AGT GCA GCC AAG ACA AG 
AGC CTG CCA TTA CAT CTC AT 
TGG CAC TTC ACT ATC AAT AC 
ATC GCG CTT GTT GGT TGT AG 
 
AAG CAC CAG CCG TTA CTG AA 
 
CTG GTG CTA TGG GCG TTA GT 
 
CGG AAT TGA CCA GCT TTC AT 
 
CAC AGA ACA ACC AGC TTC CA 
 














            PCR conditions were 
Function Temperature  Time  Cycle/s 
Pre-denaturation 94°C 5 min 1 
Denaturation 94°C 30 sec 
Annealing 57°C 40 sec 
Extension 72°C 50 sec 
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 The intergenic regions of adeR and adeS, adeR and adeA and the adeA and 
adeB were amplified using the primers listed in the table elow (This study). 







GCA TTA CGC ATA GGT GCA GA 
GAG GTC GCC GTG ACT AAT TT 
TCA CGG GAG TCT GAG CTT TT 
AAT AGG CGC TCG AAC TGT TG 
CAA CAG TTC GAG CGC CT ATT 






            PCR conditions were 
Function Temperature  Time  Cycle/s 
Pre-denaturation 94°C 5 min 1 
Denaturation 94°C 30 sec 
Annealing 57°C 40 sec 
Extension 72°C 50 sec 
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Final extension 72°C 6 min 1 
Cooling 4°C 
 
 The primers described previously by Noppe-Leclercq et al. (1999) were used 
for the amplification of aminoglycoside resistance g nes. The primers and 




























































 The primers described previously by Valentine et al. (2008) were used for the 







 Primers were used for the detection of blaTEM genes (Weill et al., 2004), 
blaCTX-M families (Woodford et al., 2005), blaSHV (Findlay et al., 2012). The 
primers for blaPER, blaVEB and blaGES were also used (This study). The primers 






























           
 
 
























ATA AAA TTC TTG AAG ACG AAA 
GAC AGT TAC CAA TGC TTA ATC 
AAA AAT CAC TGC GCC AGT TC  
AGC TTA TTC ATC GCC ACG TT 
CGA CGC TAC CCC TGC TAT  T  
CCA GCG TCA GAT TTT TCA GG  
CAA AGA GAG TGC AAC GGA TG 
ATT GGA AAG CGT TCA TCA CC 
TCG CGT TAA GCG GAT GAT GC 
GCA CGA TGA CAT TCG GG 
AAC CCA CGA TGT GGG TAG C  
CGC CGG GTT ATT CTT ATT TG 
CCA CGT TTA TGG CGT TAC CT 
CCT GAC GAT CTG GAA CCT TT 
GCA ACC TGC GCA ATG ATA GC 
ATT TCC CGA TGC AAA GCG T 
CCA ACA GCG ATG AAC AAA CT 
ATG CGC TTC ATT CAC GCA C 





















           PCR conditions for the amplification of blaPER, blaVEB and blaGES were 
Function Temperature  Time  Cycle/s 
Pre-denaturation 94°C 5 min 1 
Denaturation 94°C 30 sec 
Annealing 57°C 40 sec 
Extension 72°C 50 sec 
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Final extension 72°C 6 min 1 
Cooling 4°C 
 
2.11 Primers used for analysis of gene expression 
OXA-58-like F and OXA-58-like R primers described earlier by Woodford et al. 
(2006) were used for the expression analysis of the blaOXA-58-like gene. 
 
Primers for the gene expression of the blaADC gene (AmpC) were ADC1 and ADC2 
primers, as mentioned earlier by Ruiz et al. (2007). 
 
Primers 51-F and 51-R described earlier by Lopes et al. (2010). were used for the 






TTT CAG CCT GCT CAC CTT 
TTC CCT TGA GGC TGA ACA AC 
CTC GTG CTT CGA CCG AGT AT 






Primers 16S-F and 16S-R, described earlier by Lin et al., (2009) were used as internal 
control primers for the constitutively expressed 16S-23S gene in A. baumannii. The 
primers and expected fragment size were  
16S-F 
16S-R 
GAC GTA CTC GCA GAA TAA GC 
TTA GTC TTG CGA CCG TAC TC 
426bp 
 
2.12 Sequencing of the genes 
The PCR products were purified by Qiagen PCR purification kit, UK and 5 µL of 
DNA was used with 1 µL of 3.2 pmol of primer for forward or reverse sequencing of 
the genes. 
 
The PCR products were sequenced to check for any novel genes or mutations by the 
Sanger method using an ABI 373A DNA sequencer (PE Applied Biosystems, 
Warrington, UK). The BLAST and FASTA programs of the National Centre for 
Biotechnology Information (http://www.ncbi.nlm.nhi.gov) were used to search 
databases for similar nucleotide and amino acid similarities. The amino acid 
sequences were translated using the EXPASY translate tool 
(http://www.expasy.ch/tools/dna.html). Alignment of the DNA or amino acid 
sequences was performed with the Multalin tool to check for any changes in the 
sequences (http://www.toulouse.inra.fr/multalin.html). 
 
2.13 Gradient plate technique 
Some of the strains used in this study were treated with the frame-shift mutagen 
acriflavine after overnight growth in nutrient broth. The mutants were isolated using 
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the gradient plate technique as described previously by Hunt and Sandham (1969) 
using a concentration range between 0.03- 0.3 % . 
A single colony at the highest concentration was select d and tested for further 
analysis.  
 
2.14 Strain serial subculture  
Strain subculture was performed daily on MacConkey agar for over 150 days in order 
to check for changes in the outer membrane proteins and the stability of ISAba1. 
 
2.15 RNA extraction 
Bacterial cultures were grown to an optical density of 0.5-0.8 at OD600 and the total 
RNA was extracted with RiboPureTM-Bacteria Kit according to the manufacturer’s 
instructions (Ambion, UK). Sterilization of the benches, gloves and the pipettes was 
done using RNAZAP (Ambion, UK). The RNA was measured using nanodrop 
spectrophotometer, ND-1000. 1500ng of RNA was taken forward and treated with 
DNase I at 37°C for 30 minutes to remove any traces of genomic DNA. 
 
2.16 Reverse transcription 
The treated RNA was re-estimated and 100ng of it was taken forward in order to 
perform reverse transcription. RNA was reverse transcribed to cDNA by incubation at 
45 oC/1 hr, followed by specific PCR gene amplification according to the 
manufacturer’s guidelines (Access RT-PCR System Kit, Promega). The reverse 





2.17 Determination of outer membrane proteins (OMPs) by Sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) 
 
The outer membrane proteins were extracted according to the method described by 
Bossi and Bossi. (2007). Briefly, bacterial cells were grown in 5 ml of LB to OD600 of 
0.4 and collected by centrifugation at 3000 g (Sorvall RT 6000D) for 15 minutes at 
4°C. The pellet was re-suspended in 1 ml of 10 mM Tris pH 8.0 and sonicated with 
cooling, using three pulses of 20 s with 30 s resting intervals (MSE Soniprep 150, 
MSE instruments, Crawley). The lysate was centrifuged at 7000 g for 5 minutes. The 
supernatant was recovered and centrifuged at 13 000 rpm for 45 minutes at room 
temperature. The pellet was re-suspended in 0.5 ml of freshly made 10 mM Tris-HCl 
pH 8.0, 10 mM MgCl2, 2% (v/v) Triton X-100. Furthermore, the suspension was 
incubated at 37°C for 30 minutes, and then centrifuged at 16000 g for 45 minutes at 
20°C. Finally, the pellet was re-suspended in 50 µl of 100 mM Tris-HCl pH 8.0, 2% 












2.18 Polyacrylamide gel electrophoresis 
The percentages of separating and stacking gels were calculated as shown below. 
(http://www.changbioscience.com/calculator/sdspc.htm, Last accessed, 6/6/2010) 
 
Stacking gel (4%) 
Total 
Volume 




Polyacrylamide (40%) 625 Polyacrylamide (40%) 3750 





TEMED 12 TEMED 22 
D/W 3650 D/W 3550 
10% SDS 50 10% SDS 100 
 
 
Ammonium persulfate and TEMED were the last components to be added just before 
pouring the gel. The separating solution was poured into the pre-assembled Bio-Rad 
gel apparatus. Addition of ethanol ensured a fine uiform surface, which was allowed 
to solidify by cross-linking after which the stacking gel was added and a comb was 
placed in order to make wells to load the samples. The gel was allowed to polymerise 
for 30-45 mins in the presence of light. 
 
The protein concentration was estimated using NanoDrop spectrophotometer (ND-
1000) for the samples to be loaded. Approximately 50 to 100 µg of protein was mixed 
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in equal volume with the loading dye made up of 950µl of Bio-Rad buffer and 50 µl 
β-mercaptoethanol. 5 µl of the protein sample was mixed with 5 µl dye and was 
heated at 100 ºC for 10 mins, cooled on ice in order to denature proteins. 
 
Molecular weight markers (Bio Rad) were used for estimation of band size. The gel 
was inserted into a gel electrophoresis apparatus (Protean II, Bio Rad) and was  
electrophoresed at 150 V for approximately 90 minutes in 1X Tris-Glycine buffer. 
 
The stacking gel was cut off and the separating gel was stained in 0.1% w/v 
Coomassie blue R-250, in 50% v/v ethanol, 1% v/v acetic acid in distilled water, for 
50 minutes. Destaining of the membrane was carried out with the destaining solution 
(50% v/v ethanol, 1% v/v acetic acid in distilled water) for 50 minutes. The gel was 
washed in distilled water for 10 mins or left over-night followed by viewing under 
illuminated light surface. 
 
2.19 Efflux assay 
The efflux assays were either performed as described pr viously by Pannek et al. 
(2006). Bacterial cells were grown overnight on LB or IST agar plates and diluted in 1 
mL of PBS + 0.4% glucose (pH 7.4) until an OD at 600 nm of 1 was reached. The 
cells were then transferred to a 96-well plate, and NMP (1mg/L) was added. 
Thereafter, EtBr was added to a final concentration of 1 mg/L, and the relative 
fluorescence intensity was measured over time at 37° C with a fluorescence 
spectrophotometer (Polarstar optima, BMG, labtech). Excitation and emission 
wavelengths of 544 and 612nm were used. 
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2.20 Detection of extended spectrum β-lactamases (ESBLs) 
Some of the isolates were screened for ESBL production using the cephalosporin and 
co-amoxiclav synergy disc method as described previously by Livermore and Brown 
(2001). Discs containing co-amoxiclav (30µg) and ceftazidime (30µg) are applied 25-
30 mm apart on IST agar swabbed with the test culture. A disc containing a different 
cephalosporin can be placed on the opposite side of the co-amoxiclav disc. The plate 
is incubated overnight at 37oC and ESBL production was inferred when the 
cephalosporin zone was expanded by clavulanate. This method is cost-effective and 
the disadvantage is that the optimal separation of the discs may vary with the 
individual strain. The cephalosporins discs used for this assay were of ceftazidime, 
cefotaxime, cefpodoxime and cefepime. 
 
2.21 Conjugation assay 
Transconjugation assays were performed with E.coli J62.2 as the recipient as 
described earlier by Findlay et al. (2012). Overnight cultures of the recipient (E. coli 
J62.2) and donor strains were mixed in a 1:4 ratio, and cells were colle ted by 
centrifugation and resuspended in 30 µL of cold saline. Five microlitre aliquots of the 
resuspension were spotted onto a nutrient agar plate and incubated at 37°C for 6 h. 
Growth was collected and resuspended in cold saline and inoculated onto nutrient 
agar plates containing rifampicin at 16 mg/L and one of the selective antibiotics, 
ceftazidime or meropenem, at a range of concentrations. 
 
2.22 S1-nuclease digestion 
S1 nuclease is an endonuclease that is more active against DNA than RNA. Its 
reaction products are oligonucleotides or single nucleotides with 5' phosphoryl 
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groups. It is usually nicks the plasmid DNA and linearises it to form a distinct band.  
S1 nuclease digestion was performed for the PFGE plugs according to the 
manufacturer’s instructions. A total of 10 units per lug were used for digestion with 
incubation at 37°C /45 mins. The plasmids were stained with gel red and visualized 
by the gel-doc system. 
 
2.23 Plasmid curing 
Plasmid curing is the selective removal of plasmids present in a specific species of 
bacteria. Plasmid curing can help in determining the presence of resistance genes, 
spreading in various bacterial species. Plasmid curing was performed using one or 
more of the curing agents like acriflavine (0.2-2%), SDS (4%) or ethidium bromide 
(1-2%) assisted with elevated temperature of incubation (reviewed by Trevors, 1986). 
The strains were serially subcultured for 14 days or m re at 47°C. 
 
2.24 Plasmid isolation (Joly, 1996) 
A single well isolated colony was grown in 5mL IST broth at 37° C/24hrs. The 
culture was centrifuged and the supernatant was decant d. It was suspended in 100µL 
of bacterial resuspension solution [50 mM glucose, 50 mM Tris-HCI, pH 8.0, 
10mMEDTA]. 200 µL of lysis solution (200 mM NaOH, 1% SDS) was added and the 
mixture was gently iverted and left at room temperature for 3 minutes. 150 µL of 
neutralizing solution (3M potassium/5M acetate soluti n) was then added and 
centrifuged at maximum speed for 5 minuted. The liquid phase was removed and 
transferred to another set of tubes containing chilled iso-propanol. The precipitate 
formed was recoved by centrifuging the tubes at maxi um speed. Finally it was 
washed with 70% ethanol and resuspended in TE buffer (10 mM TrisHCI, pH 8.0,1 
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mMEDTA). Chromosomal DNA was removed with 4M ammonium acetate and 
















3.0 RESULTS AND DISCUSSION 
3.1 SECTION 1:  
ISAba1 transposition and control of resistance genes in A. baumannii. 
3.1.1 Aims and objectives 
To check if ISAba1 can transpose in the Acinetobacter baumannii genome using the 
frame-shift mutagen acriflavine. 
To check if strain subculture leads to attenuation or weakening and whether this 
affects transposition of the ISAba1 element. 
To observe any changes in the outer membrane protein profile which leads to 
resistance to carbapenems. 
 
3.1.2 Identification and PCR amplification 
The strains used in this study were previously identifi d as A. baumannii by Benjamin 
Evans in this laboratory and were designated as AB153, AB1225 (parent), AB153M, 
AB1225M (acriflavine derived mutant) and AB1225s (MacConkey agar serially sub-
cultured strain for 150 days). 
 
A PCR described by Dolzani et al. (1995) using the primers 16S-23S primer1 and 
16S-23S primer 2, was used to re-identify and confirm the identity. The 975bp 
product amplified for Acinetobacter genospecies 2 was restricted with the enzymes 
AluI and NdeII. Restriction of the product by the enzyme AluI produced fragments of 
50, 125, 135, 165, 175 and 330 bp specific to A. baumannii. Restriction of the same 
product produced fragment sizes 50, 110,145, 330 and 360 bp by the enzyme NdeII, 
specific to A baumannii.  
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They were reconfirmed by the blaOXA-51-like PCR using the 69A and 69B primers 
described earlier by Héritier et al (2005b). A product of 2155bp was AB1225 and 
AB1225s strains. Sequencing the fragment revealed th  presence of ISAba1 upstream 
of the blaOXA-66 gene. A fragment of 975bp was amplified for the strain AB153. 
Sequencing revealed the presence of the blaOXA-110 gene in AB1225 and AB1225s 
strain 
 
Primers ADC1 and ADC2 were used for the detection of blaADC gene. AB153, 
AB1225 and AB1225s showed the presence of the blaADC gene. Primers ISADC1 and 
ISADC2 detected the presence of insertion sequence ISAba1 upstream of the blaADC 
gene in Ab1225 (Figure 20). They were described earlier by Ruiz et al. (2007). 
 
After AB153 and AB1225 were treated with the frame-shift mutagen and isolated by 
the gradient plate technique, they were designated s AB153M and AB1225M. It was 
observed that isolate AB153M had gained ISAba1 upstream of the blaOXA-66 gene 
whereas isolate AB1225M had lost the ISAba1 sequence. The genetic rearrangement 










Figure 19: PCR for the detection of insertion element upstream of the blaOXA-51-
like gene 
 
N=negative control, M=1kb ladder, 1=AB153 parent, 2= AB153M (acriflavine 
mutant), 3= AB1225 parent 4=AB1225M (acriflavine mutant), 5=AB1225s, serial 
sub-cultured strain. The blaOXA-51-like gene in each mutant strain was sequenced in 
order to confirm its identity with the parent strain. 
 
ISAba1 movement was seen upstream of blaADC gene in the acriflavine treated 
AB153M but its loss was observed in the similarly tea ed strain AB1225M.  ISAba1 
movement was not seen in AB1225s (sub-cultured) and its features remained identical 
with respect to its parent strain AB1225 (Figure 20). The ISAba1 sequence of strain 










Figure 20: PCR for the detection of insertion element upstream of the blaADC 
gene 
 
N=negative control, M=100bp ladder, 1=AB153 parent, 2= AB153M (acriflavine 
mutant), 3= AB1225 parent 4=AB1225M (acriflavine mutant), 5=AB1225s, serial 
sub-cultured strain. 
 
3.1.3 Antimicrobial susceptibility testing 
Table 5 shows changes in MICs of IPM, MEM, PIP/TZ and CAZ in A. baumannii 
parent, mutants and the serially sub-cultured strain. An 8-fold rise in MICs to 
imipenem was seen in AB153M and a 4-fold decrease was seen in AB1225M strains 
with respect to the parent strains, AB153 and AB1225. A 4-fold and 2–fold decrease 
in MIC of imipenem and meropenem was seen in AB1225s with respect to AB1225. 
There was negligible difference seen in MIC values of CAZ. No major difference was 
seen in the MIC values of PIP/TZ except that a 4-fold decrease was seen in isolate 
AB1225s compared to AB1225 parent strain. Furthermore as no ISAba1 change was 
observed in AB1225s strain, it was important to seeif there were any significant 
changes related to the outer membrane proteins of this s rain as it had a 4-fold and 2-
fold decrease in MIC of imipenem and meropenem.    
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Table 5: MIC’s of various antibiotics and the levels of gene expression in clinical 
isolates of A. baumannii. 
 
● Fold increase/decrease (±Standard Deviation) 
 
3.1.4 Gene expression analysis 
The expression of the blaOXA-51-like and blaADC genes were analysed by RT-PCR 
(Promega) (Figure 21). The products obtained were quantified using Bio-Rad quantity 
one software 4.6.1. A 2.7-fold increase in expression of the blaADC gene was recorded 
in AB153M in comparison with AB153. There was a 1.2-fold decrease seen in the 
expression of the blaADC gene between AB1225M compared to AB1225. A negligible 
difference was seen in expression of the blaADC gene between AB1225 and AB1225s. 
It was observed that there was a 2.5-fold increased expression of blaOXA-51-like gene in 
AB153M in comparison to AB153 and a 5-fold decreased expression of blaOXA-51-like 
gene seen in AB1225M in comparison to AB1225. There was 4-fold decrease in 
expression of blaOXA-51-like gene seen in AB1225s as compared with AB1225. The 
expression was confirmed thrice using separate RNA preps and the results recorded 
are based on the average mean increase or decrease of individual strains. Structural 
organization of blaOXA-51-like and blaADC genes in A. baumannii genome is shown in 
Figure 22a and 22b. 
Strain MIC (mg/L)  
  IPM MEM PIP/TZ CAZ 
Expression of  
blaOXA-51 like gene● 
Expression of 
blaADC gene● 
AB153 0.25 1 32 32 0 0 
AB153M 2 4 64 128 +2.5 ± 0.11 + 2.7 ± 0.105 
AB1225 2 4 64 128       0  ± 0.057       0 ± 0.057 
AB1225M 0.25 1 64 64     5.0 ± 0.106 -1.2 ± 0.57 
AB1225s 0.5 2 16 128  -4.0 ± 0.15 0 
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Figure 21: Analysis of gene expression  
 
oxa-51: Expression analysis of the blaOXA-51 like gene in A. baumannii using 51F and 
51R internal primers, adc: Expression analysis of the blaADC gene in A. baumannii 
using the ADC1 and ADC2 primers, 16S: PCR for 16S-23S rRNA gene in A.
baumannii using 16S-F and 16S-R primers. 
1= Ab153 (Parent strain), 2= Ab153M (acriflavine mutant strain), 3= Ab1225 (Parent 
strain) 4= Ab1225M (acriflavine mutant), 5= Ab1225s (serial sub-cultured strain). 
 
mcrA, gyrB or rpoB genes can also be used as 16S is highly abundant and widely 








Figure 22: Structural organization of blaOXA-51-like (a) and blaADC (b) genes in A. 
baumannii (Not to scale). ISAba1 (insertion element), fxsA (phage exclusion 








3.1.5 Analysis of OMP profiles 
Figure 23 shows the OMP profiles obtained for the A. baumannii used in this study. 
The analyses reveal significant differences between th  AB153 parent and AB153M. 
Reduced expression of 17kDa, 23kDa and 25kDa OMPs was seen in the AB153M 
strain, which also had increased MIC values. AB1225M and AB1225s exhibited an 
increase in the expression of 17kDa, 23kDa, 25kDa and 27kDa OMPs and had a 
decrease in MICs values, rendering them more susceptible to some antibiotics. The 
outer membrane pattern produced by AB1225s showed significant over expression of 
a 43kDa OMP. 
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Figure 23: Outer Membrane profiles of Acinetobacter baumannii solates. 
 
 
1=AB153 parent, 2=AB1225 parent, 3=AB153M (acriflavine mutant), 4=AB1225M 
(acriflavine mutant), 5=AB1225s (serial sub-cultured strain). 
 
3.1.6 DISCUSSION: 
The different resistance profiles of A. baumannii correlate with the movement of 
ISAba1 upstream of the blaOXA-51-like gene or the blaADC gene. The MIC values of 
AB153 and AB1225 parent and mutant strains suggest that ISAba1 may act as a 
promoter for blaOXA-51-like gene or the blaADC gene. It is noteworthy to say that the 
functionality of ISAba1 depends on it acting as a promoter rather than just being 
present upstream of an antibiotic resistance gene. This addresses the fact that ISAba1 
may have a preferential role with respect to specific antibiotic resistance genes like 
blaOXA or ampC. Resistance mechanisms to various antibiotics also depend on the 
usage of antibiotics in specific hospitals and hence the bacterium may recruit insertion 
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sequences like ISAba1, which leads to over-expression of antibiotic resistance genes. 
This is also an important defence mechanism employed b  the bacterium for its 
survival in the host and ability to resist antibiotic pressure. The selection of the gene 
for over-expression is pre-determined by the ability to hydrolyse antibiotics at a basal 
level first and second by strengthening its control by insertion elements, which are, at 
least, partly responsible for the multiresistant profile of A. baumannii. 
 
Strain AB1225s had a negligible difference on expression of the blaADC gene with 
respect to AB1225, both of which retained ISAba1 upstream of the gene. This is 
supported by the fact that resistance to oxyiminocephalosporins is mainly due to 
hyperproduction of Amp-C-type-β lactamases (Rodríguez-Martínez t al, 2010).   
 
AB1225s had a 4-fold decrease in blaOXA-51-like gene expression concurring with lower 
MICs of carbapenems. The increased expression of OMPs in AB1225s can also be a 
factor that led to 4-fold decrease in the MIC of imipenem, a 2-fold decrease in the 
MIC of meropenem and 4-fold decrease in the MIC of piperacillin/tazobactam 
causing strain attenuation. It can be said that OMPs do play a role in antibiotic 
resistance depending on the stress load of the compound and they might be important 
for transport of the compound across the cell wall in either direction.  
 
All the A. baumannii strains were resistant to ceftazidime and it can be said that 
ISAba1 may play a preferential role in increased expression of the blaADC gene 
making carbapenems the last resort for treatment of patients. This concurs with the 
fact that genetic organization of genes and their control is likely to play a crucial role 
in antibiotic resistance. 
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It was also observed that there was over-expression of OMPs in AB1225M, which 
correlated with a drop in MIC values of different antibiotics. Strains AB153 and 
AB153M also had changes with respect to their outer m mbrane protein profiles. 
Since an 8-fold increase in resistance to imipenem and 4-fold increase to meropenem 
was seen in the AB153M, it can be deduced that the resistance developed in AB153M 
may not only be due to the movement of ISAba1 upstream of blaOXA-51-like gene but 
also partly due to the reduced expression of three OMPs corresponding to 17kDa, 
23kDa and 25kDa, all of which are poorly expressed in the mutant strain AB153M. 
 
Over expression of OMP’s was seen in AB1225M with drop in MIC values 
suggesting that they might have some implications with respect to the increased 
susceptibility in this strain, which lost the ISAba1 element upstream of blaOXA-51-like 
gene and blaADC  genes. The MICs for ceftazidime and piperacillin/tazobactam in 
AB153 and AB1225 and the mutant strains may provide an insight into the 
development of resistance over a given period of time as no significant changes in 
MICs were seen in the parent and mutant strains.  
 
This study presents an open view that with the moveent of ISAba1 is a strong factor 
for conferring resistance provided it is crucial for the gene action; if there is over 
expression of primary surface structures of the bacterium, it can render the organism 
sensitive to a particular drug or poison and to switch the gene on may be 
advantageous to this bacterium when it is required since OMP changes do act 
synergistically as seen in AB1225s and other strains, a d this would ideally depend on 
the action of promoters present for specific genes and their tight regulation by 
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repressor proteins. This undoubtedly contributes to the organism’s plasticity making it 
resistant to different classes of antibiotics.  
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3.2 SECTION 2:  
ISAba1 and ISAba125 govern the blaADC gene expression in clinical A. baumannii 
isolates. 
3.2.1 Aims and objectives 
To examine the intergenic regions present upstream and downstream of the blaADC 
gene of A. baumannii and to identify any novel insertion sequences, besides ISAba1 
that could be responsible for the over-expression of ampC gene in A. baumannii. 
 
The A. baumannii bacterial strains used this study were A2, A8, A16, and A21 which 
were of clinical origin and were chosen as representatives from a collection of 36 
strains. 
 
The isolates were from the collection of Benjamin Evans (Europe) and had been 
previously identified by the amplified fragment length polymorphism of the 
conserved 16S-23S rRNA intergenic spacer sequences described by Dolzani et al. 
(1995). 
 
3.2.2 Identification and PCR amplification 
All the strains had the intrinsic blaOXA-51-like gene. In addition to the blaOXA-51-like gene, 
strain 2 possessed the blaOXA-58-like gene as identified by multiplex PCR (Woodford et 
al., 2006). The primers oxa-69A and oxa-69B amplified the blaOXA-51-like gene without 
any insertion upstream of the gene in all the strains. Sequencing of the gene revealed 
that strains 2, 16 and 21 had the blaOXA-66 gene. Strain 8 had the blaOXA-69 gene. All 
the strains were also positive for the blaADC gene by the PCR described by Ruiz et al. 
(2007). Strains 16 and 21 showed a positive result for the presence of ISAba1 
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upstream of blaADC. Primers FU and RU used for the detection of sequence upstream 
of blaADC showed the presence of ISAba125 upstream in strain 2 and ISAba1 in strains 
16 and 21. Strain 8 did not have any insert upstream of the blaADC gene. Primers FD 
and RD amplified specific region downstream of blaADC but no insertion was detected 
in any of the strains. 
 
3.2.3 Antimicrobial susceptibility testing  
Table 6.1 shows the MICs of imipenem, meropenem, gatifloxacin, cefepime and 
ceftazidime with and without the efflux pump inhibitor 1-(1-napthylmethyl)-
piperazine (NMP) for the strains used in this study. The MICs of meropenem were 
decreased 4-fold after addition of the efflux pump inhibitor NMP in strains 2, 16 and 
21; however, there was no change seen in MICs of imipenem and all the strains were 
susceptible to this antibiotic. All strains, except 8, were resistant to gatifloxacin 
(BSAC guidelines for Enterobacteriaceae). A two-fold decrease in the MIC of 
gatifloxacin was seen in strain 2 and 21 after addition of NMP. All the strains were 
resistant to ceftazidime and cefepime and there was no decrease in MIC seen after 
addition of NMP. The degree of resistance for ceftazidime and cefepime varied for all 
the strains. The MICs of ceftazidime and cefepime for strain 2 and 16, were greater 









Table 6.1: Antibiotic profile and the fold gene expression of A. baumannii clinical isolates. 
 
● Fold increase/decrease (Standard Deviation ± 1) 
IPM= Imipenem, MEM= Meropenem, CAZ= ceftazidime, FEP= Cefepime, GAT= Gatifloxacin, NMP=1-(1-napthylmethyl)-piperazine, SD= 
SD= Standard Deviation 
Table 6.2: Ethidium bromide accumulation assay for A. baumannii isolates. 
Isolate Ethidium bromide accumulation (arbitrary units) 
 -NMP ± SD +NMP ± SD 
2 16791 ± 106.4 30476 ± 109.0 
8 13113 ± 87.90 12265 ± 90.6 
16 20897 ± 101.3 48769 ± 108.7 




like gene MIC (mg/L) 


















 ± SD 
2 66 0.25 0.25 1.0 0.25 >256 >256 32 32 8 4 - + 6.2 ± 0.05 
8 69 0.25 0.25 0.5 0.25 8 8 8 8 0.12 0.12 - -     1.0 ± 0.10 
16 66 0.5 0.5 1.0 0.25 >256 >256 32 32 16 16 + - 3.0 ± 0.15 
21 66 0.5 0.5 1.0 0.25 32 32 16 16 0.5 0.25 + -     2.4 ± 0.10 
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3.2.4 Detection of extended spectrum β-lactamases (ESBLs) 
Extended spectrum β-lactamases could not be detected by the double disc synergy 
assay as described previously by Livermore and Brown (2001). 
 
3.2.5 Analysis of OMPs (Outer Membrane Proteins) 
There were no significant changes seen in any of the outer membrane proteins 
patterns produced by any of the strains used in this study by the SDS PAGE analysis 
as described earlier by Bossi and Bossi (2007).The changes in carO a 29kDa outer 
membrane protein (OMP), loss of which is responsible for carbapenem resistance 
were also checked by PCR as described earlier by Mussi et al. (2005). Insertional 
inactivation of the carO was not seen in any of the strains, which also concurs with 
the fact that all the strains have very low MIC values of IPM, as one of the factor, 
leading to carbapenem resistance is the loss or disrupt on of this 29kDa OMP and this 
was not observed in any of the strains. 
 
3.2.6 Efflux assay 
The efflux activity of ethidium bromide, a substrate for AdeABC multidrug efflux 
pumps was measured in the presence and absence of th  efflux pump inhibitor NMP 
using the method described earlier by Pannek et al. (2006). It was observed that 
strains 2, 16 and 21 demonstrated active efflux to a certain extent (Table 6.2). The 
fluorescence in strain 2, 16 and 21 increased gradually with respect to time except of 





3.2.7 Analysis of gene expression 
Figure 24 shows the level of expression of blaADC after cDNA synthesis. 
Normalization of DNA was done with 16S-rRNA primers u ed as internal control. 
The expression studies on strain 2, 16, 21 and 8 indicate that strain 2, possessing 
ISAba125 upstream of blaADC, produced a significant over-expression of blaADC which 
was 2.1-fold greater than strain 16 having ISAba1 upstream of blaADC  and 6.2-fold 
more than strain 8, which had no insertion element ups ream of blaADC. Strain 16 had 
an MIC of CAZ > 256mg/L with ISAba1 upstream of blaADC producing an expression 
3-fold greater than strain 8, which had no insertion element upstream of blaADC. Strain 
21 having MIC of CAZ =32mg/L with ISAba1 upstream of blaADC, had an expression 
2.4-fold greater than strain 8, which had no insertion element upstream of blaADC. The 
results recorded are based on the average mean increase or decrease of individual 
strains (SD±1 unit). The gene expression was measurd th ice under the same optimal 
conditions. 
Figure 24: 
Expression of blaADC gene for Acinetobacter baumannii strains 2, 8, 16 and 21. 
 N is the negative control. 
 
Internal 16S-rRNA control for Acinetobacter baumannii strains 2, 8, 16 and 21. 







It has been previously reported by Corvec et al. (2003) and Héritier et al. (2006) that 
ISAba1 causes over-expression of blaADC in Acinetobacter baumannii. All the strains 
reported here were resistant to ceftazidime (CAZ), cefepime (FEP) and gatifloxacin 
(GAT) but sensitive to imipenem (IPM) and meropenem (MEM). There were no 
changes in outer membrane proteins and they did not have high levels of resistance to 
carbapenems. Furthermore the strains did not have any insertion present upstream of 
blaOXA-51-like gene, which explains the low MIC values of IMP and MEM. Since active 
efflux was demonstrated by the efflux assay in strain 2, 16 and 21 (Table 6.2) 
although there was no significant decrease seen in MIC of GAT, they had a 4-fold 
decrease seen in MIC of MEM, which is also a known substrate for efflux pumps as 
described by Szabó et al. (2006). Efflux contributing to reduced ceftazidime and 
cefepime susceptibility was not observed in any of the strains. Furthermore expression 
of the blaADC gene is the key factor in cephalosporin resistance i  A. baumannii and it 
must be recognized that while NMP effects supports the existence of efflux pump, it 
does not necessarily indicate pump over-expression as efflux mediated resistance in 
absolute terms is determined in part by the permeability of the outer membrane.    
 
All the strains had different resistance profiles to the antibiotic ceftazidime. It can be 
seen that strain 2 and 16 are very highly resistant to ceftazidime; on the other hand 
strains 21 and 8 were far less resistant.  
 
Strain 2 had ISAba125 present upstream of the ampC (Figure)and the level of 
expression of the blaADC  gene was 6.2 times greater than strain 8 which has no 
insertion sequence present upstream of blaADC  gene. In contrast, strains 16 (MIC of 
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CAZ>256mg/L) and 21 (MIC of CAZ=32mg/L) had ISAba1 present upstream of the 
blaADC  but the level of expression in these two strain were 3- and 2.4-fold greater than 
strain 8 respectively, which did not harbour ISAba1 upstream of blaADC  gene. This 
indicates that ISAba125 may have a better promoter than ISAba1.  
 
It has been proven that -35 (TTAGAA) and -10 (TTATTT) sequences separated by 
16bp constitute a promoter in ISAba1 and are located 41bp upstream of blaADC 
(Héritier et al., 2006). The intergenic region also harbours -35 (TTGTTA) and -10 
(TTTTTA) sequences separated by 18bp, which constitute a promoter for blaADC gene 
without any insertion sequence (Héritier et al., 2006).  
 
The ISAba125 was found 66bp upstream of the blaADC gene (Figure 25) and was 
oriented in opposite direction against theblaADC gene in strain 2. The right and the left 
inverted repeats showed 14/18 matches. A new -35 box having the sequence TTTACT 
was fused with the left inverted repeat and 17bp downstream the -10 box having the 
sequence TATAAA was seen, which was fused with the -35 promoter of blaADC. The 
blaADC gene was present 39bp downstream of the new -10 box. The ISAba1 sequence 
has a 4/6 and 2/6 match respectively, with the E. coli consensus -35 (TTGACA) and -
10 (TATAAT) whereas ISAba125 has a 4/6 and 5/6 match respectively, with the E. 
coli consensus. This may suggest that ISAba125 is able to provide a better promoter 
than ISAba1. As the -10 box of ISAba125 is fused with the -35 box of blaADC it can 
form a fusion promoter to drive a very strong expression of blaADC and the expression 
results support this claim. ISAba1, which drives the expression of blaADC, is also 
shown to be present in opposite orientation (3’-5’) with the blaADC as proven by 
Héritier et al. (2006). Therefore ISAba125, present in opposite orientation (3’-5’), 
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may also act in a similar way to drive the expression of blaADC gene. It has been 
proved that ISAba125 causes insertional inactivation of the CarO OMP in A. 
baumannii strains leading to a carbapenem resistant profile (Mussi et al., 2005). 
 
Figure 25: Alignment of ISAba125 with various regions upstream and 




 In this study, we demonstrate that ISAba125 can modulate the expression of the 
blaADC gene as shown by the results obtained for strain 2. It is also shown by Evans et
al. (2010) that ISAba125 is responsible for duplication of blaOXA-58-like gene and this 
provides a worrying scenario on the plasmid-borne dissemination of the blaADC gene 
leading to high levels of cephalosporin resistance in other bacterial species. It is 
interesting to note that strain 2 not only has ISAba125 but also possesses the 
blaOXA-58-like gene as detected by the multiplex PCR (Woodford et al., 2006) and there 
may be a high possibility of the upstream integration and expression of the 
blaOXA-58-like gene mediated by ISAba125, which, under carbapenem stress, would 
provide the ideal mechanism of carbapenem resistance s shown for A. baumannii 
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genospecies 3 by Evans et al. (2010).  The results obtained in this study show that IS 
elements such as ISAba125 could modulate cephalosporin or carbapenem resistance 
depending on the antibiotic treatment of the patient as the isolates used in this study 
are of clinical origin. The movement of ISAba125 upstream of an antibiotic resistance 
gene can result in significant over-expression of the target resistance gene. If strong 
promoters are present in the intergenic region, as seen in this study, ISAba125 can 
also form a fusion promoter leading to significant over-expression of the resistance 
gene, as observed in strain 2, which has a very high expression of the blaADC gene. It 
is not surprising that IS elements can cause the spr ad of resistance genes between 
different species of bacteria, as it has been already shown by Mammeri et al. (2003) 
that ISOur1 of Oligella urethralis is believed to have been co-transferred with the 
cephalosporinase gene blaABA-1 from A. baumannii. This study provides an insight into 
a novel insertion sequence ISAba125 belonging to the IS30 family (Siguier et al., 
2005), which is involved in significant over-expression of the blaADC gene, greater 
than that of the previously known sequence ISAba1 found upstream of the blaADC 
gene. These results also suggest that the repressor control in ISAba125 is different 
than that of ISAba1 and hence the contribution towards a greater the cephalosporin 
resistance with strong hydrolytic activity of ceftazidime. 
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3.3 SECTION 3:  
Mechanisms of drug resistance from A. baumannii strains from Bolivia. 
3.3.1 Aims and objectives 
To study the drug resistance profile and the genetic f atures that influence the resilient 
adaptation in Acinetobacter baumannii isolates from Cochabamba, Bolivia 
 
3.3.2 Identification and PCR amplification 
Fifteen isolates thought to have a multiresistant profile were selected for this study. 
All the isolates were isolated from 3 hospitals in Cochabamba in the years 2008-2009 
and were clonally related (Sevillano et al., 2012).  
 
The strains were identified by the blaOXA-51-like PCR described by Héritier et al. 
(2005b) and by sequencing the rpoB PCR product described earlier by La Scola et l. 
(2006).  
 
3.3.3 Antimicrobial susceptibility testing 
Table 7 identifies the blaOXA-51-like enzyme and the MIC values of IPM, MEM, CAZ, 
CIP, CIP+NMP, CN and CN+NMP in each individual isolate. It shows that all the 
strains, except 2, are multi-resistant. The gentamicin MIC values did not change upon 
the addition of NMP whereas a 2 to 4-fold decrease was seen in all the isolates 
resistant to CIP suggesting the contribution of an efflux pump. 
 
3.3.4 Screening for other antimicrobial resistance determinants 
All the isolates were screened by PCR for the presence of genes of the blaOXA-23-like, 
blaOXA-40-like, blaOXA-51-like, blaOXA-58-like and blaOXA-143-like families by the multiplex 
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PCR described earlier by Higgins et al. (2010). All the strains showed the presence of 
blaOXA-51-like gene. All except, isolate 2, were also positive for the blaOXA-58-like gene. 
 
The primers described by Héritier t al. (2005a) amplified the blaOXA-58-like gene, 
which was confirmed by sequencing. The primer SM2 described earlier by Poirel and 
Nordmann (2006b) was used in combination with walk-58-R showed the presence of 
ISAba3-like element upstream of the blaOXA-58-like gene. 
 
The ISAba-3-like element had a codon change at position 25 (GAT to AAT) leading 
to an Aspartic acid to Asparagine amino acid change compared to the ISAba-3-like 
structure deposited in the IS-finder (http://www-is.biotoul.fr/, last accessed 
20/08/2011).  
 
3.3.5 Screening for the disruption of the carO gene 
The carO gene fragment was not disrupted by any insertion elem nt as indicated 
earlier by Mussi et al. (2005), which would lead to reduced carbapenem susceptiblity.  
 
3.3.6 Screening for the presence of aminoglycoside resistance genes 
The mutiplex PCR described by Noppe-Leclercq et al. (1999), revealed that all the 
isolates, except isolate 2, were positive for the aac(6’)-Ib and aph(3’)-VI enzymes. 
Isolate 2 was positive for the aph(3’)-Ia, aac(3)-Ia, and ant(2’’)-Ia genes conferring 
resistance to aminoglycosides. They were negative for the 16s rRNA methylase genes 
such as armA, rmtA, rmtB, rmtC and rmtD. 
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3.3.7 Analysis of the genetic environment of the blaADC gene 
Primers FU and RU were used for amplifying the intergenic region upstream of 
blaADC gene. They detected the presence of ISAba1 upstream of the blaADC gene as 
confirmed by sequencing. Primers FD and RD were used for amplifying the intergenic 
region downstream of blaADC gene which amplified a product of 267bp indicating that 
there was no insert present downstream of the blaADC. 
 
3.3.8 Analysis of the quinolone resistance-determining reion (QRDR) of the gyrA 
and parC genes 
PCRs as described by Valentine et al. (2008), were used for the amplification of the 
QRDR’s of the gyrA and the parC genes. The gene fragments were sequenced and 
checked for specific amino acid changes. The sequencing of the gyrA and parC gene 
revealed Serine-83 to Leucine and Serine-80 to Phenylala ine amino acid changes in 
all the isolates resistant to ciprofloxacin except in isolate 2, which was sensitive.  
 
3.3.9 Analysis of the adeABC and adeRS genes involved in efflux 
The intergenic regions of adeRS were amplified using the primers adeRF and adeSR 
which amplified a 790bp product indicating that there was no insertion. The primers 
adeRA and adeAB amplified a product of 929bp indicating there was no insert 
between these two genes. The primers adeAF, adeAR., adeBF, adeBR., and adeCF, 






3.3.10 Analysis of gene expression 
Expression of the blaADC, blaOXA-58-like, adeA, adeB and adeC gene was studied by RT-
PCR. The primers for the blaADC gene were those defined previously by Ruiz et al. 
(2007) and those used for blaOXA-58-like gene expression were the same as the multiplex 
primers described by Woodford et al. (2006) (Table 7). The gene expression was 
measured thrice with different RNA preps under the same optimal conditions. 
 
The RT-PCR for the blaOXA-58-like gene expression also recorded high levels of gene 
expression in isolates positive for the blaOXA-58-like gene (Table 7). RT-PCR for the 
analysis of the adeA (encoding for the membrane fusion protein) and the ad B 
(encoding the RND-transporter) genes revealed that both the genes were highly 
expressed as they are co-transcribed (Table 7). The adeC (encoding the outer 
membrane protein) was not as highly expressed as adeAand adeB and this may be 
because it has been shown previously that it is not necessary in conferring resistance 
(Marchand et al., 2004) and when absent the bacteria can use altern tive outer 








Gene expression*  
(Standard Deviation of ± 0.57 to 1) No 
IPM MEM CN CN+NMP CIP CIP+NMP CAZ 
OXA-51 





1 8 2 128 128 256 64 128 65 14 15 28 29 15 Leu Phe 
2 0.25 0.5 256 256 1 1 16 66 - 5 24 18 14 Ser Ser 
3 8 2 >256 256 256 64 128 65 14 14 31 31 14 Leu Phe 
4 8 2 256 256 256 64 128 65 14 15 25 29 14 Leu Phe 
5 8 2 64 64 128 32 128 65 15 15 27 29 13 Leu Phe 
6 16 4 64 64 128 32 128 65 14 16 26 28 13 Leu Phe 
7 8 2 128 128 256 64 128 65 15 15 27 30 11 Leu Phe 
8 8 2 64 64 256 64 128 65 15 15 26 29 14 Leu Phe 
9 8 2 >256 256 >256 64 128 65 14 14 31 36 15 Leu Phe 
10 8 2 64 64 128 32 128 65 14 15 26 28 15 Leu Phe 
11 8 2 128 128 256 64 128 65 15 14 27 29 14 Leu Phe 
12 16 2 128 128 256 64 128 65 14 15 27 27 13 Leu Phe 
13 8 2 256 256 128 64 128 65 15 14 28 27 15 Leu Phe 
14 8 2 256 256 128 64 128 65 15 14 27 28 17 Leu Phe 
15 8 2 256 256 128 64 128 65 14 15 28 28 15 Leu Phe 
 
 
* = Relative gene expression was determined by RT PCR and quantified by Bio-Rad quantity-I software  
+ = present 
-  = absent 
Ser = Serine 
Leu = Leucine 




Carbapenem resistance is a growing phenomenon and it is a cause of much concern in 
the past few years. All strains, except isolate 2, xamined in this study were not only 
carbapenem resistant but multi-drug resistant to the antibiotics that have established 
breakpoints according to the BSAC. They were previously confirmed to be clonally 
related according to their PFGE profiles (Sevillano et al., 2012).  
 
The isolates did not have any insertion sequence present upstream of the blaOXA-51-like 
gene. All, except isolate 2, were also positive forthe blaOXA-58-like gene by the 
multiplex PCR. The primers SM-2 and walk-58-R detected the insertion of ISAba3- 
like structure, 17bp upstream of the blaOXA-58 gene. Putative promoters with -35 
(TTTATC) and -10 (TTTCTT) motifs was detected in the ISAba3-like element. The 
promoters have been previously identified by Poirel and Nordman, (2006b). This 
explains the resistance to carbapenems. 
 
The mutiplex PCR described by Noppe-Leclercq et al. (1999) revealed that all the 
isolates were positive for two or more aminoglycoside resistance enzymes. In a 
review by Shaw et al. (1993) the aac(6’)-Ib class of aminoglycoside inactivating 
enzymes has been shown to confer resistance to tobramycin, dibekacin, amikacin, 
5-episisomicin, netilmicin, 2’-N-ethylnetilmicin and sisomicin whereas the aph(3’)-VI 
group of enzyme is characterized by resistance to kanamycin, neomycin, 
paromomycin, ribostamycin, butirosin, amikacin and isepamicin. The aac(6’)-Ib and 
aph(3’)-VI enzymes were found in all the strains except isolate 2.   
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Isolate 2 was positive for the enzymes aph(3’)-Ia, which confers resistance to various 
aminoglycosides including gentamicin, aac(3)-Ia responsible for resistance to 
gentamicin and fortimicin, and ant(2’’)-Ia which hydrolyzes tobramycin, dibekacin, 
sisomicin, kanamycin and gentamicin. The high MIC values of gentamicin in all the 
strains except 2 are due to other unknown mechanisms of resistance. Since the MIC 
values of gentamicin did not decrease after the addition of NMP it can be concluded 
that the multidrug resistance to gentamicin may notbe efflux mediated, as 
aminoglycoside resistance is common in Acinetobacter and results primarily from 
inactivation of the antibiotic by specific modifying enzymes (Magnet et al., 2001). It 
may be beneficial to inactivate and hydrolyse the antibiotic rather than efflux it out of 
the cell as efflux mediated mechanisms are energy dependent and involve proton 
motive force (Magnet et al., 2001).  
 
ISAba1 was found to govern the expression of the blaADC gene in all the strains except 
in isolate 2, which showed a low MIC of ceftazidime. There was no insertion detected 
downstream of the blaADC gene in any of the strains.  
 
Even though ISAba1 was not found upstream of any efflux genes, the most likely 
cause of ciprofloxacin resistance is due to the mutations in the gyrA and parC genes, 
having Serine-83 to Leucine and Serine-80 to Phenylalanine amino acid changes in all 
the isolates resistant to ciprofloxacin with synergistic contribution of the increased 
expression of the efflux genes adeA and adeB. 
 
This work analyzed the genetic environment and the multi-drug resistance profile of 
isolates isolated in Cochabamba, Bolivia. This repot reflects on the emergence of 
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Acinetobacter baumannii as a multi-drug resistant pathogen in Latin American 
countries such as Bolivia. The role of efflux pumps and other antibiotic resistance 
mechanisms in mediating antibiotic resistance is evident in this bacterium and the 
continued study of these systems should contribute towards the better understanding 
of A. baumannii, which is evolving as a major threat. The high proportion of strains 
with resistance genes to the major groups of antibiotics used to control A. baumannii 
must be of great concern.  
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3.4 SECTION 4:  
Study of A. baumannii isolates from Aberdeen Royal Infirmary. 
3.4.1 Aims and Objectives 
To study the resistance profile of A. baumannii strains isolated from Aberdeen Royal 
Infirmary and to classify novel blaOXA-51-like variants. 
 
3.4.2 Identification and PCR amplification. 
Nine distinct A. baumannii strains were isolated from diagnostic clinical specimens 
from patients in Aberdeen Royal Infirmary from the years 2006-2010. The strains 
were identified primarily by the blaOXA-51-like PCR described by Héritier t al. (2005b) 
and by sequencing the rpoB gene as described by La Scola et al. (2006). The source 
of the strains and the dates of the isolation are list d in Table 8. 
 
3.4.3 Antimicrobial susceptibility testing 
Table 8 outlines the MIC values of imipenem (IPM), meropenem (MEM), ceftazidime 
(CAZ), ciprofloxacin (CIP) and gentamicin (CN) in each individual isolate. Table 8 











Table 8: Activities of various antibiotics in A. baumannii clinical strains. 
MIC (mg/L) Strain 
number Source  
Date of 





3 blood 09.09.06 1 0.5 64 256 32 + + + 66 
10 blood 08.06.08 0.06 0.06 1 0.12 0.12 - - - 
65 
(variant) 
12 blood 25.08.08 16 16 64 8 32 + + + 66 
14 blood 21.09.09 0.06 0.06 4 0.03 0.12 - + - 216 
16 sputum 20.02.10 0.5 0.5 4 0.12 0.12 - + - 51 
3n blood 27.04.06 0.5 0.25 2 0.03 0.12 - + - 64 
6n blood 17.07.07 1 0.5 8 0.12 0.5 - + - 217 
10n blood 22.10.08 0.06 0.06 1 0.03 0.12 - + - 
65 
(variant) 
14n blood 14.09.09 0.5 0.25 8 0.12 0.5 - + - 89 
 
 
3.4.4 PCR and sequencing of the blaOXA-51-like gene. 
Two novel variants of the blaOXA-51-like gene were identified by sequencing. Strain 14 
had Serine-14 (TCT) of the blaOXA-180 gene replaced with Phenylalanine (TTT), and is 
now designated blaOXA-216 (Figure 26a, 26b). Strain 6n had Threonine-255(ACA) of 
the blaOXA-78 gene substituted to Isoleucine (ATA), which is now designated blaOXA-217 
(Figure 27a, 27b). Isolates 10 and 10n had variants of he blaOXA-65 gene with silent 
mutations at positions 90 (C to T), 636 (C to T) and 663 (G to A). In addition, strain 










Figure 26a: OXA-216 nucleotide sequence (14 Aberdeen)  
Cytosine=C and Thymine=T 










Figure 27a: OXA-217 nucleotide sequence (6n Aberdeen)  
Cytosine=C and Thymine=T 
 
Figure 27b: OXA-217 amino acid sequence (6n Aberdeen)  
 
 
Threonine (T) to Isoleucine (I) change at position 255 in OXA-217 sequence 
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3.4.5 Screening for other antimicrobial resistance determinants 
All the isolates were screened by PCR for the presence of genes of the blaOXA-23-like, 
blaOXA-40-like, blaOXA-51-like, blaOXA-58-like by multiplex primers described by Woodford 
et al. (2006). The blaOXA-143-like genes were screened for by using primers described in 
the materials and methods section of this thesis. All the strains showed the presence of 
a blaOXA-51-like gene. Isolate 12 was also positive for the blaOXA-23-like gene. ISADC1 
primer used in conjunction with Oxa-23R detected the presence of ISAba1 upstream 
of the blaOXA-23-like gene. 
 
3.4.6 Screening for the disruption of the carO gene  
The PCR for the insertions causing disruption of carO (29kDa OMP) did not detect 
the presence of any insertion element causing disrupt on of the carO, leading to 
carbapenem resistance. This was done to check for any changes in the OMPs of 
strains as one of them was carbapenem resistant and Mussi et al. (2005). have shown 
that the disruption of carO can lead to carbapenem resistance. 
 
3.4.7 Screening for the presence of aminoglycoside resistance genes 
The aac(3')-Ia gene was present in strains 3 and 12 and this was responsible for the 
resistance to gentamicin in these strains. 
 
3.4.8 Analysis of the genetic environment of the blaADC gene 
Primers FU, RU and FD, RD were used for the amplification of the intergenic region 
upstream and downstream of the blaADC gene. Strains 3 and 12 had high MICs of 
ceftazidime, which was due the presence of ISAba1 upstream of blaADC gene. There 
was no insert observed downstream of the blaADC gene making it a defunct 
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transposon. All strains were positive for the blaADC gene, except isolate 10 but, as 
none of these had ISAba1 upstream, their MICs were 8mg/L or less. 
 
3.4.9 Analysis of the quinolone resistance-determining reion (QRDR) of the gyrA 
and parC genes. 
PCRs as described by Valentine et al. (2008) were used for the amplification of the 
QRDRs of the gyrA and the parC genes. The gene fragments of the gyrA and parC 
were sequenced and checked for specific amino acid changes. Changes were seen in 
the gyrA (Serine83-Leucine) and the parC (Serine80-Leucine) genes in strains 3 and 
12. 
 
3.4.10 Detection of the integrase gene 
Strains 3 and 12 were positive for the integrase genes by PCR as described earlier by 
Lévesque et al. (1995). The sequencing of the gene revealed the presence of putative 
glucose dehydrogenase precursor that could be responsible for catabolism of glucose 
by oxidation as shown by Bouvet and Bouvet (1989). 
 
3.4.11 Pulsed Field Gel Electrophoresis (PFGE) 
The PFGE profiles of the strains showed that most were not clonally related as they 
had <80% similarity (Figure 28). Furthermore, they were not related to any of the 
European clones. PFGE analysis revealed that strain 3 and 12 had 83% similarity and 
showed some relationship to each other (Figure 28). Additionally it is important to 
note that strain 3, isolated in the year 2006, was negative for the blaOXA-23 gene 
whereas strain 12 isolated in the year 2008 was positive for this gene and was also 
resistant to imipenem and meropenem. Otherwise, they had very similar drug 
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resistance profiles. This indicates the A. baumannii is actively acquiring resistance 
genes, probably through plasmid transfer. 
 
Figure 28: PFGE profile for A. baumannii strains isolated from the Aberdeen 







EC1= European clone I, EC2= European clone II, EC3= European clone III 
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3.4.12 Conjugation and plasmid detection. 
Transconjugation was performed as described in the materials and methods section 
using E.coli J62-2 (rif) as the recipient and it was unsuccessful.  
 
S1 nuclease digestion described by Findlay et al., (2012). and plasmid extraction 
procedure described by Joly (1996) failed to detect any plasmids. Furthermore, 
elimination studies did not remove the resistance det rminants.  
 
3.4.13 DISCUSSION: 
The two blaOXA-51-like genes 216 (FR865168) and 217 (JN603240) are novel and they 
have arisen from point mutations in the existing blaOXA-51-like variants. They can 
provide a basal level of reduced susceptibility to carbapenems and, although this can 
be enhanced if an insertion is present upstream, this was not seen in our isolates. 
Clinical significance is related to the strain type and establishing clonal relatedness, 
which was seen in two strains, 3 and 12; strain 3 (isolated in 2006) did not have the 
blaOXA-23 gene whereas strain 12 (isolated in 2008) harboured blaOXA-23. There were 
no insertion sequences upstream to regulate the blaOXA-51-like genes and increase their 
resistance to carbapenems. The failure of transconjugation and plasmid extraction 
assays suggests that if blaOXA-23 was plasmid borne, it was now integrated in the host
chromosome of strain 12 endowing it with a stable mchanism of carbapenem 
resistance. Furthermore plasmid curing performed using acriflavine and with elevated 
temperature of incubation (47°C) described by Trevo (1986) failed to eliminate any 
plasmid borne blaOXA-23 gene. Integration of the blaOXA-23 in the host chromosome of 
Acinetobacter baumannii has been reported in strains from Latin America by Villegas 
et al. (2007). These results show that the clinical situat on in the hospital in Aberdeen 
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is in a state of flux. New variant strains are emerging and, most importantly, a 
carbapenem-sensitive strain has become resistant throug  the acquisition of the 
blaOXA-23 gene with an ISAba1 element upstream carrying a promoter allowing 
expression of the β-lactamase. The blaOXA-23 was first found in Scotland more than 20 
years ago (Donald et al., 2000) and it has remained the sole mechanism of 
carbapenem resistance until this point (personal communication S. G. B. Amyes). 
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3.5 SECTION 5:  
ISAba825 controls the blaOXA-65 and blaOXA-58 expression in four clinical isolates of 
A. baumannii. 
3.5.1 Aims and Objectives 
To identify novel insertion sequences that govern the expression of the blaOXA-51-like 
gene and to understand the carbapenem resistance in clinical strains isolated from the 
United States. 
 
3.5.2 Identification and PCR amplification 
Four consecutive distinct clinical strains, isolated in 2004 in the United States were 
confirmed as A. baumannii by PCR and sequencing of the rpoB gene using the 
primers Ac696F and Ac1093R described previously by La Scola et al. (2006). 
 
3.5.3 Antimicrobial susceptibilty 
The MICs of imipenem and meropenem were determined by the agar double dilution 
method and the results were interpreted according to the BSAC guidelines. 
All the strains were resistant to imipenem and merop nem (Table 9).  
 
3.5.4 Pulsed-Field Gel Electrophoresis 
ApaI macrorestriction anaylsis (Seifert e al., 2005) of the four isolates exhibited 
genetic similarities of 99.99% by the unweighted pair group method with arithmetic 







Figure 29:  PFGE profile of A. baumannii clinical isolates from the United States. 
 
3.5.5 PCR for antimicrobial resistance determinants 
Genes encoding known carbapenemases were investigatd as described previously 
and the genes blaOXA-51-like and blaOXA-58-like were detected (Higgins et al., 2010). 
Genes encoding OXA-40-like and OXA-23-like carbapenemases were not detected. 
Neither were metallo-β-lactamases such as IMP, VIM, GIM, SIM, and SPM detected 
by multiplex PCR, as described previously by Ellington et al. (2007) in any of the 
isolates. 
 
The primers FxOxaF and FxOxaR (Lopes et al., 2012) detected the presence of an 
insertion element upstream of the blaOXA-51-like gene in all the four isolates (Figure 30). 
The primers 51F and IntaceR (Lopes et al., 2012) were used for the amplification of 
the blaOXA-51-like gene. The sequencing results showed the presence of ISAba825, 
present upstream of the blaOXA-65 gene in all the four isolates. A putative promoter 
with -35 (TTGTCA) and -10 (TATGAA) were located 17bp apart from each other 
(BPROM, Softberry, Inc., Mount Kisco, NY) and were located 97bp and 74bp 
upstream of the blaOXA-65 gene. A target site duplication of 7bp, AAGTCTT was seen 
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upstream and downstream of the ISAba825 sequence. No insertion was seen 
downstream making the ISAba825 a defunct transposon. The ISAba825 sequence was 
oriented in 5’-3’ direction against the blaOXA-65 gene in all the four isolates. 
 
Figure 30: Genetic arrangement of the blaOXA-65.controlled by upstream 
ISAba825 element. The arrows represent the primers used for detection and 
sequencing of genes (Not to scale). Arrows indicating FxOxaF, FxOxaR, 51F and 





The primers preOXA-58prom+ and preOXA-58B, described previously (Héritier t 
al., 2005a) were used to check for any variations within he blaOXA-58-like gene. The 
primers amplified a 934bp fragment which on sequencing onfirmed that the blaOXA-58 
gene had no nucleotide substitutions. 
 
The SM2 primer (Poirel and Nordmann, 2006a) and the walk-58-R (Lopes et al., 
2012) primer amplified a fragment of ISAba825 oriented in 3’-5’ direction. This has 
been previously reported by Ravasi et al. (2011). Putative promoter -35 (TTGAGA) 
present 148bp upstream of the blaOXA-58 gene and -10 (TTTATA) present 127bp 
upstream of the blaOXA-58 gene were identified 15 bp apart from each other. The
blaOXA-58 gene was highly over-expressed as determined by the RT-PCR assay. 
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Normalization of DNA was done with the 16S-rRNA primers described by Lin et al., 
(2009) with the appropriate amounts of serially diluted RNA used for c-DNA 
synthesis (Table 9). 
 
3.5.6 Analysis of gene expression 
The expression of the blaOXA-65 gene for all the isolates was studied as described 
earlier (Lopes et al., 2010). The internal blaOXA-65 gene primers, 65A and 65B showed 
a significant over-expression of the blaOXA-65 gene expression (Table 9). OXA-58-like 
F and OXA58-like R primers described by Higgins et al. (2010) were used for the 
blaOXA-58 gene expression.  
 
PCR products were quantified using the Bio-Rad Quantity One Software 4.6.1 (Bio-
Rad) (Table 9). Normalization of DNA was done with t e 16S-rRNA primers 
described earlier by Lin et al. (2009) with the appropriate amounts of serially di uted 
RNA used for c-DNA synthesis. 
 
3.5.7 Plasmid profiling 
S1 nuclease digestion was performed for the PFGE plugs according to the 
manufacturer’s instructions. A total of 10 units per lug were used for digestion with 
incubation at 37°C for 45 mins. The plasmid bands of approximately 40kb were 
excised from the gel and purified using the Qiagen l extraction kit. Chromosomal 
DNA contamination if any was checked using the 16S-rRNA primers described 
earlier by Lin et al. (2009). The blaOXA-58 was present to be on this 40kb plasmid. 
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3.5.8 Transconjugation assay 
Transconjugation assays of A. baumannii strains having the blaOXA-58-like gene were 
performed with E.coli J62.2 as described earlier by Findlay et al. (2012). 
Transconjugation assays using E.coli J62.2 could not transfer the 40kb plasmid, which 
had the blaOXA-58 gene.  
 
3.5.9 Plasmid curing 
Plasmid curing was performed using sodium dodecyl sulphate (SDS) with elevated 
temperature of incubation (Trevors, 1989). The strains were incubated in 4.8mL of 
nutrient broth with 200µL of 10% SDS at 46°C/48 hours. The loss of plasmid was 
observed in all the isogenic strains after the blaOXA-58 gene was lost by the plasmid 
curing method as described in the Materials and Methods section. During this curing 
procedure the ISAba825, which was present upstream of the blaOXA-65 gene, was also 
lost, making the isolates carbapenem sensitive (Table 9). A 16-fold decrease in MIC 
of imipenem and an 8-fold decrease in MIC of meropenem were observed for all the 
sensitive isogenic strains. The isolates did retain the basal level of the blaOXA-65 gene 
expression (Table 9).  
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Table 9: Activities of antibiotics and the levels of gene expression in clinical 
isolates of A. baumannii. 
 
-a denotes no transcript due to the absence of blaOXA-58 gene. 
 
3.5j DISCUSSION: 
The transposition of insertion sequence (IS) elements within a genome play important 
roles in the evolution of host cells (Kato et al., 2003, reviewed by Mahillon and 
Chandler, 1998). IS transposition usually completely inactivates a gene at a target site 
due to insertional inactivation (Lopes et al., 2012) but leads to the constitutive 
expression of an adjacently located cryptic or regulated gene by delivering IS-loaded 
promoter sequences (Poirel and Nordmann, 2006b). It has been observed that two or 
more copies of an identical IS element dispersed over a genome promotes various 
genetic rearrangements, including inversion, deletion, and duplication of the 
intervening region and fusion of two replicons residing in the same cell (reviewed by 
Mahillon and Chandler, 1998, Riehle et al., 2001). IS transposition is therefore one of 
the most important driving forces that enhance the variability and consequently the 
adaptive and evolutionary capacities of their hosts. This is demonstrated very well by 
Minimum inhibitory 
concentration (mg/L) 
Quantification of gene expression (arbitrary units) Strain 
Imipenem Meropenem Expression of the 16S 
rRNA gene 
Expression of the 
blaOXA-65 gene 
Expression of the 
blaOXA-58 gene 
Ab202 16 16 16S r-RNA 249 OXA-65 154 OXA-58 194 
Ab203 16 16 16S r-RNA 250 OXA-65 167 OXA-58 189 
Ab204 16 16 16S r-RNA 255 OXA-65 165 OXA-58 187 
Ab205 16 16 16S r-RNA 251 OXA-65 165 OXA-58 189 
Ab202s 1 2 16S r-RNA 240 OXA-65 74.0 OXA-58 -a 
Ab203s 1 2 16S r-RNA 245 OXA-65 72.1 OXA-58 -a 
Ab204s 1 2 16S r-RNA 255 OXA-65 67.5 OXA-58 -a 
Ab205s 1 2 16S r-RNA 255 OXA-65 69.0 OXA-58 -a 
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the acquisition of the plasmid borne blaOXA-58 gene with ISAba825 and the loss of the 
same gene, leading to a sensitive phenotype. 
 
The curing event promoted the loss of the blaOXA-58 gene and its upstream ISAba825 
promoter. However the same event also promoted the loss of the ISAba825 element 
upstream of the chromosomally encoded blaOXA-65 gene thus making the strains 
carbapenem sensitive.  These results suggest that control of the IS elements is 
coordinated by the activators and the repressors as the loss of the IS element occurs at 
the same step as the loss of the plasmid. Transposition activity is generally maintained 
at a low level and the reason for this is that high activities and the accompanying 
mutagenic effect of genome rearrangements would be etrimental to the host cell 
(reviewed by Mahillon and Chandler, 1998). Transposase (Tpase) promoters are 
generally weak, and many are partially located in the erminal IRs, enabling their 
autoregulation by Tpase binding. Many of the classical mechanisms of controlling 
gene expression, such as the production of transcriptional repressors (IS1 and IS2) or 
translational inhibitors (antisense RNA in IS10), are known to operate in Tpase 
expression (reviewed by Mahillon and Chandler, 1998).  
 
The temperature sensitivities of transposition in E. coli have been considered to be the 
intrinsic properties of the transposases (Haren et al., 1997). An increase in the 
transposition activities of the seven IS elements belonging to four different IS families 
of the Burkholderia multivorans ATCC 17616 cells suggested that some common 
host factors affect transposition at high temperatures (Ohtsubo et al., 2005). It is also 
suggested that some unknown factors that inhibit transposition might be depleted at 
higher temperatures (Ohtsubo et al., 2005). Alternatively, other unknown factors 
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might contribute to altering the donor and/or target DNA architecture into a form that 
enables the IS transposition machinery to work more eff ctively (Ohtsubo et al., 
2005). The observed characteristics for the carbapenem resistant and sensitive strains 
indicate that the IS element examined here (ISAba825) plays an important role in cells 
exposed to high temperatures thus generating genetic diversity in a population of A. 
baumannii. Expression studies also show the importance of this element in conferring 
carbapenem resistance by over-expression of the blaOXA-58-like and the blaOXA-65 gene 
and it can be concluded that ISAba825 is also very crucial for the adaptation and 
evolution of carbapenem resistant A. baumannii besides the well-known ISAba1. Our 
results concur with that of Ravasi et al. (2005) and additionally we prove that 
ISAba825 also governs the blaOXA-51-like gene expression and this is an essential 
mechanism of carbapenem resistance in A. baumannii resistant to imipenem and 
meropenem.  
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3.6 SECTION 6:  
ISAba16 disrupts blaOXA-51-like gene in A. baumannii Ab244. 
3.6.1 Aims and Objectives  
This study was undertaken to understand alternative mechanisms of carbapenem 
resistance by the activation of the blaOXA-58 gene in isolate Ab244 which had the 
blaOXA-51-like gene inactivated by a novel IS- element ISAba16. 
 
3.6.2 Identification and typing 
The isolate Ab244 isolated from Carnaxide, Portugal (strain 12) was confirmed as A.
baumannii by restriction of the conserved 16S-23S rRNA intergenic spacer sequences 
as described previously by Dolzani et al. (1995). 
 
3.6.3 Antimicrobial susceptibility testing  
The strain Ab244 had an MIC of imipenem of 4 mg/L and that of meropenem of 16 
mg/L. The strain was classified as resistant to merop nem and intermediately resistant 
to imipenem (BSAC. http://www.bsac.org.uk/Resources/BSAC/version_6.1.pdf, 27 
September 2011, date last accessed).  
 
3.6.4 PCR analysis and sequencing 
The multiplex PCR for the OXA-group of enzymes showed a positive result for 
blaOXA-51-like and blaOXA-58-like genes, but was negative for blaOXA-23-like and blaOXA-40-like 
genes. The expected product size was 889 bp without any insertion present upstream 
of the blaOXA-51-like gene, but the primers FxOxa_F (Figure 31: primer1) and FxOxa_R 
(Figure 31: primer 2) amplified a product of 3449bp.   
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Sequencing revealed that the chromosomal region had the conserved gene encoding a 
putative suppressor of F exclusion of phage T7 (fxsA) as observed by Chen et al. 
(2010) followed by the 399 bp intergenic fragment, followed by a new insertion 
sequence, named ISAba16 , located following the first 15 bp and disrupting the 
blaOXA-51-like gene. The primers ISAba16_F1 (Figure 31: primer 3), ISAba16_R1 
(Figure 31: primer 4), ISAba16_F2 (Figure 31: primer 5) and ISAba16_R2 (Figure 
31: primer 6) were used for sequencing of the insertion element. There was an 8 bp 
target site duplication of the blaOXA-51-like gene encoding the sequence CTCTTACT 
seen at the 5’ and the 3’ end of ISAba16 causing an insertional inactivation of the 
blaOXA-51-like gene (Figure 31). Analysis of the insertion sequence revealed that it had 
the left inverted repeat 5’-GTAAGCATCCGGCTAA-3’ and the right inverted repeat 
5’-TTCAGCGGACGCTTAC-3’. The ISAba16 sequence comprised 3 ORFs encoding 
transposase A, B and C respectively. 
 
 
Figure 31: Genetic arrangement of the disrupted blaOXA-132 gene due to the 
insertion of ISAba16. 
 
 
The primers 51F (Figure31: primer 7) and IntaceR (Figure 31: primer 8) amplified a 
product of 966 bp and the sequencing confirmed thate blaOXA-51-like gene was 
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identical to blaOXA-132. There was no insertion present downstream of the blaOXA-132 
gene. 
 
The primers preOXA-58prom+ (Figure 32: primer 11) and preOXA-58B (Figure 32: 
primer 12), previously described by Héritier t al. (2005a), (Figure 26) amplified a 
product of 934 bp of the blaOXA-58-like gene. The blaOXA-58  gene had no nucleotide 
substitutions and this was confirmed by sequencing. 
 
The primers SM2 (Figure 32: primer 9) and walk-58-R (Figure 32: primer 10) 
amplified a region of 575 bp, present upstream of the blaOXA-58 gene, sequencing of 
which revealed an ISAba3-like structure. A putative promoter with -35 (TTTAC) 
and -10 (TTTCTT) motifs was present 44 bp upstream of the blaOXA-58-like gene as 
described earlier by Poirel and Nordmann (2006b). The ISAba3-like structure had a 
codon change at position 25 (GAT to TAT) causing the amino acid to change from 
Aspartic acid to Tyrosine and a second codon change t position 110 (AAT to AGT) 
leading to Asparagine to Serine change. The primers ISAba1A and ISAba1B detected 
the presence of ISAba1 in Ab244 (Poirel and Nordman, 2006b). 
 





3.6.5 Analysis of OMPs (Outer Membrane Proteins)  
No change was seen in the outer membrane proteins after extraction and isolation on 
SDS-PAGE (Bossi and Bossi, 2007) in comparison with outer membrane proteins of 
A. baumannii (Ab2) (Data not shown). The primers described previously for the 
amplification of the carO gene did not identify any insert disrupting the carO gene 
(Mussi et al., 2005).  
 
3.6.6 Analysis of gene expression 
The expression studies on the blaOXA-51-like gene revealed that the gene in Ab244 was 
not expressed in comparison with strain Ab2 (strain 2), which had no insertion 
upstream of the blaOXA-132 gene (Figure 33, Table 10). On the contrary, the 
blaOXA-58-like gene was highly expressed in Ab244 in comparison to the control strain 
Ab2 which had the blaOXA-58-like gene without any insertion upstream of the gene 
(Figure 34, Table 10).  
 





Quantification of gene expression (arbitrary units) 
(Standard deviation ± 0.95) 
Strain 
Imipenem Meropenem blaOXA-51 gene blaOXA-58 gene 


























N1, 16S-rRNA negative control., 16A, Expression of the 16S-rRNA gene in Ab244., 
16B, Expression of the 16S-rRNA gene in the control strain Ab2., N2, blaOXA-51-like 
negative control., 51A, Expression of the blaOXA-51-like gene in Ab244., 51B, 
expression of the blaOXA-51-like gene in Ab2. The blaOXA-51-like gene is shown at 679bp 
and the 16S-rRNA gene is shown at 426bp 
 
Figure 34: Expression of the blaOXA-58 gene. 
 
N3, 16S-rRNA negative control., 16C, Expression of the 16S-rRNA gene in Ab244., 
16D, Expression of the 16S-rRNA gene in the control strain Ab2., N4, blaOXA-58-like 
negative control., 58C, Expression of theblaOXA-58-like gene in Ab244., 58D, 
expression of the blaOXA-58-like gene in Ab2. The blaOXA-58 gene is shown at 599bp and 
the 16S-rRNA gene is shown at 426bp. 
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3.6.7 DISCUSSION: 
The A. baumannii isolate Ab244 had the conserved F-like structure gene (fxsA) found 
to be present on the chromosome with the intergenic fragment followed downstream 
by ISAba16, which was inserted within the blaOXA-51-like gene causing insertional 
inactivation of the gene. The sequencing of the region between fxsA and the 
phosphinothricin acetyltransferase (GNAT) gene revealed that there was no insert 
present in the intergenic region downstream of the blaOXA-51-like gene. The region 
mapped in this study was 4239 bp encompassing a part of the fxsA, intergenic 
fragment upstream of the blaOXA-51-like gene, the blaOXA-51-like gene itself, intergenic 
fragment downstream of the GNAT and a part of the phosphinothricin 
acetyltransferase. The inactivated blaOXA-51-like gene was identified as the blaOXA-132 
gene. Sequencing studies showed that the ISAba16 inserted after the first 15 
nucleotides of the blaOXA-132 gene, which encode the ‘M N I K T’ amino acid 
sequence. A target site duplication of 8bp having the sequence CTCTTACT was 
observed upstream and downstream of the ISAba16 element. The RT-PCR showed no 
expression of the blaOXA-132 gene and this is because of the interruption caused by 
ISAba16 located following the first 15 bp and disrupting theblaOXA-132 gene. 
 
Analysis shows that the insertion element ISAba16 belongs to the IS66 family. It has 
been reported that the IS66 family elements may comprise of 3 or more ORFs 
(reviewed by Mahillon and Chandler, 1998). ISAba16 has the ability to transpose and 
duplicate an 8 bp target site sequence on its transposition, as observed by target site 
duplications present at the 5’ and the 3’ end of the insertion element. Transposases 
encoded by many IS elements belonging to the members of the IS families other than 
the IS66 family have a DNA-binding domain with an α-helix–turn–α-helix DNA-
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binding motif and a catalytic domain with a DDE motif (Han et al., 2001).  The 
insertion element ISAba16 shows the presence of 3 ORFs where the TnpA protein has 
an α-helix–turn–α-helix DNA-binding motif, and the TnpC protein has  potential 
DDE motif located at the catalytic core domain. The transposases from several 
superfamilies possess a protein domain containing an acidic amino acid triad (DDE or 
DDD) that catalyzes the “cut and paste” transpositin reaction (Yuan et al., 2011).  
 
The TnpB proteins, however, seem to have no homology t  any of the motifs 
identified in the transposases encoded by the IS elem nts of the different IS families 
(Han et al., 2001). Previous studies show that the TnpA, TnpB and TnpC proteins 
may be produced independently in appropriate amounts to form a complex, which acts 
as a transposase promoting the transposition of IS66 family elements like ISAba16 in 
strain Ab244. 
 
As the multiplex PCR was positive for the blaOXA-58-like gene alongside the blaOXA-132 
gene, it was essential to map the sequence of the blaOXA-58-like gene. Therefore a PCR 
was performed by using the primers described by Héritier et al. (2005a), sequencing 
of the amplicon revealed a similarity with the blaOXA-58 gene without any nucleotide 
substitutions. The primers SM2 and walk-58-R amplified 575bp region, sequencing of 
which revealed an ISAba3-like structure. A putative promoter with -35 (TTTAC) 
and -10 (TTTCTT) motifs was present 44 bp upstream of the blaOXA-58-like gene. The 
promoters had been previously identified by Poirel and Nordmann (2006b). The 
RT-PCR proved that the blaOXA-58-like gene was highly expressed. The frequent 
association between blaOXA-58 genes and IS sequences could be associated with the 
low-levels of expression of the blaOXA-51-like genes in a wild-type strain having 
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insertion sequences dispersed in the genome. The mechanism of the insertion 
sequence activation may depend on activation complexes formed by repressor-
inhibitory mechanisms under antibiotic stress conditions (Escoubas et al., 1991). 
Selection for insertion sequences which insert intosi es that allow the bacterium to 
survive the antibiotic stress, such as upstream of β-lactamase genes where the IS 
elements provide strong promoters for β-lactamase gene expression, has provided the 
bacterium with a mechanism for transiently switching on resistance genes in response 
to the stress (Toleman and Walsh, 2011). 
 
Ab244 was resistant to meropenem and intermediately resistant to imipenem although 
no change in the OMP pattern was seen. Furthermore no insertional activation of the 
carO gene was identified.  
 
The results obtained in this study portray Ab244 as a carbapenem resistant pathogen, 
which can employ selective mechanisms of resistance through the expression of 
specific antibiotic resistance genes. The study show  a genetic structure ISAba16 
inactivating the blaOXA-132 gene and this could be due to the fact that the bacterium did 
not require a mechanism of resistance when it was not u der clinical set conditions. 
The acquisition of the blaOXA-58 gene under clinical settings facilitates the survival of 
the bacterium by helping it thrive more effectively under antibiotic stress. This clearly 
demonstrates the acclimatization of Ab244 to various drug environments by 
acquisition of acquired carbapenemases such as the blaOXA-58 gene governed by 
ISAba-3 like elements. 
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This is the first report describing the insertional inactivation of the blaOXA-132 gene by 
ISAba16 (JN415682) and the employment of an alternate resistance mechanism by the 







3.7 SECTION 7:  
Role of IS elements involved in the disruption of the adeR gene in four isolates of 
A. baumannii. 
3.7.1 Aims and Objectives  
To understand the mechanism of resistance to ciprofloxacin mediated by the efflux 
pump genes and by the mutations in the gyrA and parC genes.  
 
3.7.2 Identification and typing 
A. baumannii isolates Ab12, Ab18 and Ab209 were identified by the blaOXA-51-like 
PCR (Héritier et al., 2005b) and rpoB sequencing (La Scola et al., 2006) and were 
used in this study. Ab12M was derived from Ab12 by treating it with sub-inhibitory 
concentrations of acriflavine (Hunt and Sandham, 1969).  
 
3.7.3 Antimicrobial susceptibility testing 
Table 11 outlines the MIC values of ciprofloxacin (CIP) and gentamicin (CN) in each 
individual isolate, with and without the efflux pump inhibitor (EPI) NMP. It was 
observed that strains 12 and 12M were not resistant to gentamicin; on the other hand 
Ab18 was less resistant to gentamicin (MIC=16mg/L) than Ab209, which had an MIC 
of gentamicin of >256mg/L. There was either two-fold decrease or no change seen in 
MIC of gentamicin for all strains in the presence of NMP (Table 11).  
 
3.7.4 Aminoglycoside resistance determinants 
All, but one, of the strains were negative for aminoglycoside resistance genes; the 
exception was Ab209, which was highly resistant to gentamicin and it harboured both 
the ant (2’’)-Ia and aph (3')-Ia genes. It has been shown that ant (2’’)-Ia is able to 
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inactivate tobramycin, dibekacin, sisomicin, kanamycin and gentamicin whereas 
aph(3’)-Ia confers resistance to various aminoglycosides including gentamicin (Shaw 
et al., 1993). All the strains were highly resistant to ciprofloxacin and a ≥ 8-fold 
decrease in ciprofloxacin MIC was seen for all strains in the presence of NMP (Table 
11). 
 
3.7.5 Analysis of the quinolone resistance-determining re ion (QRDR) of the gyrA 
and parC genes 
The amplification of the QRDR’s of the gyrA and the parC genes was performed by 
PCR (Valentine et al., 2008) and amino acids sequence changes were found. All the 
strains had Serine83 to Leucine encoded by a change in th  GyrA protein. Ab18 had 
Serine80 to Leucine change whereas Ab12, Ab12M and Ab209 had a novel mutation 
of Serine80 changing to Tryptophan in the ParC protein. 
 
3.7.6 Screening of genes involved in efflux 
The primers adeRF and adeSR were used to screen the intergenic regions of adeR and 
adeS genes. The intergenic primers adeRF and adeSR detected the presence of ISAba1 
(5’-3’) that disrupted the adeR gene after 530bp in Ab18 and after 588bp in Ab209. 
Ab12M showed the presence of ISAba16 (5’-3’) disrupting the adeR gene after 522bp 
(Figure 35). 
 
The primers adeRA and adeAB were used to screen for the intergenic regions of adeR 
and adeA genes. They detected the presence of another ISAba1 (5’-3’) element 24bp 
upstream of the adeA gene in Ab209. It was located 709bp from the other ISAba1 
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element disrupting the adeR gene. There was no insert seen for any of the other 
strains. 
 
The primers adeA1F, adeA1R., adeBF, adeBR., adeCF, adeCR., adeIF, adeIR., adeJF, 
adeJR., adeKF and adeKR were used for the detection and expression of efflux genes. 
PCR was performed to check for the presence of adeABC, adeRS and adeIJK genes 
detected the presence of all the genes in all the strain  except adeC, which was absent 
in Ab12 and Ab12M. 
 
3.7.7 Fluorescent dye whole cell accumulation assays 
The ethidium bromide (EtBr) dye accumulation assay of Pannek et al. (2006) was 
used. Table 11 outlines the mean quantification of relative expression of various 
efflux genes for all the isolates. It also outlines the mean fluorometric intracellular dye 
accumulation at 30 mins after the addition of EtBr (2mg/L) in the presence and 
absence of the efflux pump inhibitor, NMP. Dye accumulation experiments were 
consistent with EtBr intracellular concentrations. 
 
3.7.8 Analysis of gene expression 
The adeSRAB genes were expressed in Ab12 whereas only adeSB was expressed in 
Ab12M. This is due to the fact that deR was disrupted by ISAba16 in Ab12. We have 
recently shown that ISAba16 is responsible for the disruption and inactivation of the 
blaOXA-51-like gene in isolate 12 (Ab244) (Lopes t al., 2012). It has been shown that 
insertional inactivation of adeS, the kinase component of the adeRS genes, results in 
susceptibility to aminoglycosides and other pump substrates (Marchand et al., 2004) 
and this would be important for the expression of the adeAB efflux pump. Our results, 
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however, suggest that the expression of adeA and adeB are independent, as deB can 
be expressed at an effective level despite lack of expression of adeA. It was previously 
hypothesized that adeAB can recruit adeK in the absence of adeC (Marchand et al., 
2004) and as adeK was very well expressed in Ab12 and Ab12M it could be a 
potential outer membrane protein for the efflux of antibiotics co-ordinated by adeAB. 
 
In Ab18 adeSC and adeIJK were highly expressed, adeR was expressed at low levels 
and this is again due to the disruption of theadeR gene by the insertion element 
ISAba1. Also the adeAB genes were not expressed and this is because in A. baumannii 
adeS may be involved in the transcription regulation of the adeR gene, which in turn 
would be responsible for regulation of the adeA and/or adeB as similarly shown by 
the ompF and ompC regulation by OmpR in E. coli. In E. coli, EnvZ (histidine kinase) 
responds to changes in the extracellular osmolarity of inner-membrane impermeable 
compounds and controls the phosphorylation of the response regulator ompR. Like 
EnvZ, AdeS functions as an autokinase, an adeR phosphotransferase and as a 
phospho-OmpR (OmpR-P) phosphatase (Batchelor t al., 2003). Hence the role of 
regulation by adeS is important. It has been suggested earlier that EvgA (regulator) is 
crucial for the modulation of multi-drug resistant phenotype in E. coli (Nishino and 
Yamaguchi, 2002). The efflux systems have not been extensively studied as it has 
been suggested that disruption of adeS can have serious consequences on the 
antibiotic resistance phenotype (Marchand et al., 2004). Our study shows that the 
disruption of adeR can be indirectly correlated with the decrease in xpression of any 
of the adeABC genes as the primary signal passed on by AdeS is important in the 
auto-phosphorylation of the histidine residue, which can then transfer the phosphate 
group to an Aspartate residue of the response regulator AdeR. AdeR is responsible for 
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the modulation adeABC genes but, if adeS is disrupted, it could lead to the loss in the 
function of adeR and subsequent loss in the expression of one or more genes of the 
adeABC operon. The expression of adeC and adeIJK in Ab18 is suggestive that these 
highly expressed genes in part would contribute towards the ciprofloxacin resistance. 
 
In Ab209, adeR gene was not expressed (Table 11) and this was becaus  of ISAba1 
causing gene disruption (Figure 35). The adeSABC and adeIJK genes were very well 
expressed leading to high levels of pump expression. The adeA gene was highly 
expressed because it had ISAba1 sequence (3’-5’) present in the intergenic region of 
adeR (3’-5’) and adeA (5’-3’), as opposed to Ab18 and Ab12M, which did not show 
any insert. ISAba1 is shown to govern the expression of blaADC and blaOXA-51-like genes 
when present upstream of the antibiotic resistance genes (Gordon and Wareham, 
2010), hence it is not surprising that the adeA gene in strain 209 is so well expressed 





Table 11: Minimum inhibitory concentration (MIC) an d the levels of gene expression for A. baumannii isolates. 
MIC (mg/L) 
EtBr 
accumulationa Gene expression (arbitrary units)b Strain 
No 
CIP CIP+NMP CN CN+NMP -NMP +NMP adeS adeR adeA adeB adeC adeI adeJ adeK 
12 >256 32 1 1 16947 48192 2.42 2.56 2.43 2.29 - 1.35 1.53 1.42 
12M >256 32 1 0.5 15856 56052 2.40 1.23 0 2.31 - 1.27 1.62 1.31 
18 256 32 16 8 20862 43783 2.52 1.44 0 0 2.26 1.55 1.51 1.24 
209 >256 32 >256 >256 14847 49814 2.56 1.14 2.65 2.56 2.42 1.31 1.59 1.41 
19606 0.5 0.12 8 8 16103 15235 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
 
 
aMean average of intracellular ethidium bromide (EtBr) dye accumulation measured by fluorometry at 30 mins (arbitrary units). 
bMean average of gene expression measured by RT-PCR and quantified by Bio-Rad Quantity-I software 
CIP, Cirprofloxacin, CN, Gentamicin, +NMP (in the presence of 1-(1-napthylmethyl) piperazine), -NMP (in the absence of 1-(1-napthylmethyl) 
piperazine ) 
- No transcript detected due to the absence of the gen . 
The values selected are based on the data obtained w thin permissible standard deviation range (±100 to 130 units for EtBr accumulation and 




















Over-expression of the adeABC efflux pump may be caused by the ISAba1 insertion 
to the upstream of adeABC operon (Ruzin et al., 2007). Although this point has been 
stated earlier, it has not been proved (Ruzin et al., 2007). In this study we show how 
insertion elements like ISAba1 and ISAba16 can cause disruption of the adeR gene 
and still lead to high expression of efflux pumps due to the various contributing 
factors highlighted in the Results section. Insertion elements will lead to the over-
expression of a gene only if it can provide a strong promoter upstream of the gene. If 
insertion sequence forward (ISF) and Efflux gene reve se (EGR) primers were 
designed, they would have picked up an insert but the primers designed to span the 
intergenic sequences show how important it is to obtain a definitive result. It has been 
mentioned earlier (Ruzin et al., 2007) that an insert of ISAba1 had been found in the 
adeS gene but, in this study, its potential presence upstream of the gene was not 
studied. We have to consider the point that the ad S gene was disrupted by this 
element (Ruzin et al., 2007) and this should lead either to low levels of expression or 
no expression at all (Lopes et al., 2012) as it has been shown that the disruption of 
adeS can render the bacterium susceptible to a range of antibiotics (Marchand et al., 
2004). 
 
In this study, disruption of adeR gene leads to adeR gene inactivation but the 
expression of adeS shows that the primary signal passed on to adeR by 
phosphorylation is not only important for its transcriptional regulation but also for the 
regulation of adeABC genes.  
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In Ab209, even though the signal is not passed to adeR, because ISAba1 is present 
upstream of adeA, an expression driven by strong promoters of ISAba1 can be seen. 
This is in contrast to Ab12M and Ab18 where adeA gene is not expressed. The over-
expression of the adeB gene in Ab12M may correlate with its high resistance to 
ciprofloxacin, compared with Ab18 where adeB was not expressed. We cannot 
necessarily infer that adeA and adeB are co-transcribed. This could be because of the 
extracytoplasmic function σ factors that are co-transcribed with anti-σ factors located 
in the cytoplasmic membrane and are released upon interaction with an 
extracytoplasmic signal (Marchand et al., 2004). The main contributing factor of 
ciprofloxacin resistance examined for the strains studied is largely due to the 
mutations in the gyrA and parC.  
 
Also none of the point mutations in adeR (Proline116-Leucine) and adeS 
(Threonine153-Methionine or Glycine30-Aspartic acid) genes that have been reported 
previously (Marchand et al., 2004) were seen in any of the strains studied.   
 
Inactivation of adeR does not exert a polar effect on the expression of adeS as shown 
in this study but previous studies have shown that in ctivation of adeS may have a 
significant effect on the susceptibility to various antibiotics (Marchand et al., 2004). 
In two-component regulatory systems it has been establi hed that the sensor kinase 
(adeS) autophosphorylates at an internal histidine (the H box) in response to a 
stimulus, the phosphate group of which is then transferred to an aspartate residue of 
the response regulator (adeR) (Marchand et al., 2004). The phosphorylated regulator 
may also be dephosphorylated by the phosphatase activity of the sensor (Marchand et 
al., 2004). The histidine kinases are bifunctional, in that they phosphorylate and 
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dephosphorylate their cognate response regulator, which leads to a switch between 
these two activities and directs the state of the regulators, thus governing expression 
of the genes on which they act (Marchand et al., 2004). It has been stated that, in 
E.coli, there is evidence that the operon consisting of ompR (regulator) and envZ 
(kinase) is subject to control by integration host factor, cAMP-catabolite activator 
protein, and the histone-like protein HNS (Batchelor et al., 2003). More work is 
needed in order to understand the role of efflux systems in control of resistance to 
various classes of antibiotics. 
 
In this study, we demonstrated that over-expression of the adeABC efflux pump 
resulted in CIP non-susceptibility in the isolates studied by quantifying the transcripts 
of the efflux genes and their regulators. There wasat least an 8-fold decrease in CIP 
susceptibility in the presence of the efflux pump inhibitor NMP. The fluorometric 
assays demonstrated active efflux in all the strains, which contributed, in part, to CIP 
resistance. The remaining contribution was largely due to commonly occurring 
mutations in the QRDR regions of the gyrA and the parC genes. 
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3.8 SECTION 8:  
Multi-drug resistance of A. baumannii in the US and Europe. 
3.8.1 Aims and objectives 
To study the mechanisms of multi-drug resistance from clinical isolates of 
Acinetobacter baumannii isolated in the United States and Europe. 
 
3.8.2 Identification and typing 
The strains used in this study were previously identifi d either by 16S-23S rRNA 
restriction analysis or by the rpoB gene sequencing and by the intrinsic blaOXA-51-like 
gene PCR by Benjamin Evans (isolates from Europe) or by Susan Brown (isolates 
from the US). They were reconfirmed by me by the blaOXA-51-like gene PCR and by any 
of the above methods whenever necessary. 
 
3.8.3 Carbapenem resistance and the detection of blaOXA family genes  
Table 12a and 12b outlines the MIC values of imipenem (IPM) and meropenem 
(MEM) for the 36 isolates from the Europe and 36 from the United States. The 
multiplex PCR was performed for each isolate (Woodfr  et al., 2006) (Figure 36a 
and 36b) and the upstream sequences of the blaOXA-51-like gene, blaOXA-58-like gene were 
determined using established primers (Lopes et al., 2012, Héritier et al., 2005b). The 
whole genes with their upstream sequences, if found, were sequenced. Isolates 2, 14, 
206, 207 and 208 did not yield a positive band despit  the OXA-58 multiplex PCR 
being positive. OXA 143-F and OXA 143-R primers failed to detect the blaOXA-143 
gene in any of the isolates. The primers OXA-24A and OXA-24B (Afzal-Shah et al., 
2001), OXA- 24F and OXA-24R (Jeon et al., 2005), OXA-23F and OXA-23R (Afzal-
Shah et al., 2001) were used for sequencing to detect any variation within the genes. 
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The primer ISADC1 (Ruiz et al., 2007) and OXA-23R were used for detection of 
insertion sequence ISAba1 upstream of the blaOXA-23-like gene, which was detected in 
all strains positive for the gene (Table 12). The primer IntoxaF and IntaceR did not 
detect the presence of insertion sequence downstream in ny of the isolates which had 
an insert present upstream of the blaOXA-51-like gene. The primers ISAba1F and OxaR 
detected ISAba1 and blaOXA-51-like gene on a plasmid in some isolates. The gene was 
found to be present on a 110kb plasmid in strain 1, 90kb in strain 27 and 47kb in 
strain 29. The plasmid of strain 24 could not be isolated even on repeated trials. PCR 
performed with the multiplex primers (Ellington et al., 2007) for metallo-β-lactamases 
detected just two isolates positive for the blaIMP gene. They were Ab25 from the 
















Fig 36a: Multiplex PCR (blaOXA families) for the European isolates 
Fig 36b: Multiplex PCR (blaOXA families) for isolates from the US 
 
blaOXA-51-like gene= 353bp, blaOXA-40-like gene= 246bp, blaOXA-58-like gene= 599bp 
blaOXA-143-like gene= 728bp, blaOXA-23-like gene= 501bp 
(Woodford et al., 2006).
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Table 12a: MIC values, blaOXA genes and gene environment of A. baumannii isolates from Europe (EU). 
EU MIC (mg/L)        
Isolate/Strain IMP MER 
ISAba1-





1 32 64 N N N  66 N Y 
2 0.25 1 N N Y  66 N N 
3 0.25 0.25 N N N  64 N N 
4 8 4 N N N  108 ISAba1 N 
5 1 8 N N N  110 ISAba1 N 
6 1 2 N N N  69 N N 
7 0.25 1 N N N  65 N N 
8 0.25 0.5 N N N  69 N N 
9 16 16 N N N  82 ISAba1 N 
10 4 8 N N N  66 N N 
11 8 16 N N N  107 Y N 
12 4 16 N N Y ISAba3  ∆132 ISAba16 N 
13 0.25 1 N N N  71 N N 
14 0.25 2 N N Y  69 N N 
15 0.12 1 N Y N  68 N N 
16 0.5 1 N N N  66 N N 
17 0.25 2 N N N  71 N N 
18 0.12 1 N N N  112 N N 
19 0.5 1 N N N  106 N N 
20 0.25 0.5 N N N  69 N N 
21 0.5 1 N N N  66 N N 
A22          
23 4 8 N N N  69 N N 
24 32 64 N Y Y ISAba3 64 N Y 
25 2 4 N N N  208 N N 
















MIC (Minimum inhibitory concentration) values of im ipenem (IPM) and meropenem (MEM): Highlighted in red= resistant, 
Highlighted in blue = intermediate, Highlighted in black= sensitive, Y=presence of a gene, N=absence of a gene, IS= Insertion Sequence 
 
EU MIC (mg/L)        
Isolate/Strain IMP MER 
ISAba1-





27 16 32 Y N N  66 N Y 
28 0.25 0.12 N N N  68 N N 
29 16 8 Y N N  144 N Y 
30 2 2 N N N  65 N N 
31 4 4 N N Y ISAba3-ISAba2-ISAba3 66 N N 
32 1 2 N N Y ISAba3-ISAba2-ISAba3 92 N N 
33 4 4 N N Y ISAba3-ISAba2-ISAba3 66 N N 
34 8 16 N N N  107 ISAba1 Y 
35 8 32 N N N  83 ISAba1 Y 
36 0.5 0.5 N N N  66 N N 
37 8 64 N N N  83 ISAba1 Y 
 165 
Table 12b: MIC values of imipenem, meropenem, blaOXA genes and gene environment of A. baumannii isolates from the US 
 
US MIC (mg/L)          
IS upstream 
of   
Isolate/Strain IMP MER 
ISAba1-
OXA-23 OXA-24-like OXA-58-like IS upstream of  OXA-58 OXA-51-like OXA-51-like ISAba1F-51R 
          
Ab25 8 4 N N Y ISAba825 65 N N 
Ab27 16 16 Y N N N 66 N N 
Ab36su 8 4 N N Y ISAba825 51 N N 
Ab37 8 4 N N Y ISAba825 51 N N 
Ab38 4 4 N N Y ISAba825 51 N N 
Ab39 0.25 0.5 N N N N 67 N N 
Ab74 128 64 N Y N N 66 N N 
Ab75 64 64 N Y N N 71 N N 
Ab76 128 64 N Y N N 71 N N 
Ab77 128 64 N Y Y ISAba3-ISAba2-ISAba3 68 N N 
Ab78 16 4 N N Y IS1008 66 N N 
Ab79 4 8 N Y N N 70 N N 
Ab93 8 8 N N Y IS1008 71 N N 
Ab94 8 8 N N Y IS1008 64 N N 
Ab95 8 4 N N Y IS1008 71 N N 
Ab96 1 1 N N N N 71 N N 
Ab97 4 8 N N Y ISAba3 78 N N 
Ab193 8 16 N N Y ISAba3 69 N N 
Ab194 0.25 0.25 N N N N 66 N N 
Ab195 0.12 0.25 N N N N 66 N N 
Ab196 0.25 0.25 N N N N 66 N N 
Ab197 0.5 0.25 N N N N 66 N N 
A198          
Ab199 16 16 Y N N N 69 N N 














MIC (Minimum inhibitory concentration): Highlighted  in red= resistant, Highlighted in blue = intermediate, Highlighted in black= 
sensitive, Y=presence of a gene, N=absence of a gene, IS= Insertion Sequence 
 
 







Isolate/Strain IMP MER 
ISAba1-
OXA-23 OXA-24-like OXA-58-like IS upstream of OXA-58 OXA-51-like OXA-51-like 
ISAba1F-
51R 
Ab201 16 16 N N Y ISAba825 51 N N 
Ab202 16 4 N N Y ISAba825 65 ISAba825 N 
Ab203 16 4 N N Y ISAba825 65 ISAba825 N 
Ab204 16 4 N N Y ISAba825 65 ISAba825 N 
Ab205 16 4 N N Y ISAba825 65 ISAba825 N 
Ab206 4 4 N N Y N 80 ISAba1 Y 
Ab207 4 16 N N Y N 79 ISAba1 Y 
Ab208 8 8 N N Y N 82 ISAba1 Y 
Ab209 16 16 N N N N 66 N N 
Ab210 16 16 N N N N 69 N N 
Ab211 128 128 N Y N N 66 N N 
Ab212 16 4 N N Y ISAba825 68 N N 
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3.8.4 Ceftazidime resistance 
Table 13 outlines the MIC values of ceftazdime (CAZ) for the 36 strains isolated in 
Europe and 36 from the United States. The primers FU, RU detected insertion 
elements such as ISAba1 and ISAba125 upstream of the blaADC gene. ISADC1 and 
ISADC2 primers detected ISAba1 sequence upstream of the blaADC gene. ISADC1 
and ISADC2 PCR was positive for isolate 24, and 29, which had low MIC values 
with no IS element detected by the FU, RU primers. Although the ISADC1 and 2 
PCR for the detection of ISAba1-blaADC was positive for isolate 36su, it had 
ISAba125 detected upstream of the blaADC with FU and RU primers. FD and RD 
primers failed to detect any insert downstream of the blaADC. Multiplex PCR for 
determination of integrase genes was performed (Dillon et al., 2005). Conjugation 
assays performed for isolate 24, 27 and 36su transferred plasmids with OXA-2 and 
OXA-10-like genes present on class one integrons as determined by the CSa and CSb 
primers. Hence this study was not pursued further. Isolates 194 (novel TEM-194), 195 
(novel TEM-195) and 197 (novel TEM-193) did not have ISAba1 upstream of the 
blaADC but tested positive for the blaTEM and blaPER-1 genes. The primers TEMF, 
TEMR and PERF and PERR were used. The alignment of the nucleotides is seen in 
figure 37a and the amino acid translation in figure 37b.  Isolate 196 was positive for 
blaPER-1 gene. Isolates 193 and 195 had cysteine at position 165 that has been known 
to confer high resistance to ceftazidime (reviewed by Bradford, 2001). There were 
other amino acid changes at various different positions that could contribute towards 
resistance to ceftazidime. Isolate 25 having high MIC of ceftazidime had the OXA-2 
gene within the integron structure. 
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Table 13: MIC of Ceftazidime (CAZ), blaADC gene environment 
EU 
MIC 
(mg/L)      US 
MIC 
(mg/L)         
Isolate/Strain CAZ FD/RD FU/RU 
ISADC1 
and 2 integrase Isolate/Strain CAZ FU/RU FD/RD 
ISADC1 
and 2 integrase 
1 16 N ISAba1 ISAba1 N       
2 >256 N ISAba125 N 1 Ab25 8 N N N 2 
3 128 N ISAba1 ISAba1 2 Ab27 128 ISAba1 N ISAba1 1 
4 32 N ISAba1 ISAba1 1 Ab36 128 ISAba125 N ISAba1 1 
5 64 N ISAba1 ISAba1 1 Ab37 64 ISAba125 N N N 
6 128 N ISAba1 ISAba1 N Ab38 64 ISAba125 N N N 
7 32 N ISAba1 ISAba1 2 Ab39 128 ISAba1 N ISAba1 N 
8 8 N N N 1 Ab74 >256 ISAba1 N ISAba1 N 
9 >256 N ISAba1 ISAba1 1 Ab75 >256 ISAba1 N ISAba1 1 
10 32 N ISAba1 ISAba1 1 Ab76 >256 ISAba1 N ISAba1 1 
11 128 N ISAba1 ISAba1 N Ab77 >256 ISAba1 N ISAba1 N 
12 8 N N N 2 Ab78 256 ISAba1 N ISAba1 1 
13 32 N N N 1 Ab79 8 N N N N 
14 16 N N N 1 Ab93 64 ISAba1 N ISAba1 1 
15 32 N N N N Ab94 >256 ISAba1 N ISAba1 N 
16 >256 N ISAba1 ISAba1 N Ab95 64 ISAba1 N ISAba1 1 
17 32 N N N 1 Ab96 64 ISAba1 N ISAba1 1 
18 128 N ISAba1 ISAba1 N Ab97 128 ISAba1 N ISAba1 1 and 2 
19 8 N N N N Ab193 64 N N N N 
20 >256 N ISAba1 ISAba1 1 Ab194 >256 N N N 1 
21 32 N ISAba1 ISAba1 1 Ab195 >256 N N N 1 
A22      Ab196 >256 N N N 1 
23 8 N N N 1 Ab197 >256 N N N 1 
24 8 N N ISAba1 1 A198      
25 >256 N N N 1 Ab199 128 ISAba1 N ISAba1 2 




(mg/L)      US 
MIC 
(mg/L)         
Isolate/Strain CAZ FD/RD FU/RU 
ISADC1 
and 2 integrase Isolate/Strain CAZ FU/RU FD/RD 
ISADC1 
and 2 integrase 
27 >256 N ISAba1 ISAba1 1 Ab201 128 ISAba1 N ISAba1 N 
28 4 N N N N Ab202 128 ISAba1 N ISAba1 2 
29 16 N N ISAba1 N Ab203 128 ISAba1 N ISAba1 2 
30 >256 N N N N Ab204 128 ISAba1 N ISAba1 2 
31 >256 N ISAba125 N 1 Ab205 128 ISAba1 N ISAba1 2 
32 >256 N ISAba125 N 1 Ab206 64 ISAba1 N ISAba1 N 
33 >256 N ISAba125 N 1 Ab207 128 ISAba1 N ISAba1 1 
34 >128 N ISAba1 ISAba1 N Ab208 128 ISAba1 N ISAba1 1 
35 >128 N ISAba1 ISAba1 1 Ab209 128 ISAba1 N ISAba1 2 
36 128 N ISAba1 ISAba1 1 Ab210 128 N N N N 
37 >128 N ISAba1 ISAba1 1 Ab211 >256 ISAba1 N ISAba1 N 
      Ab212 16 N N N N 
 
 
MIC (Minimum inhibitory concentration): Highlighted  in red= resistant, Highlighted in blue = intermediate, Highlighted in black= 




Figure 37a: Nucleotide sequence of TEM-193, 194 and 195 aligned with TEM-1 
 

















Changes at position 165 Arginine (R) to Cysteine (C) seen in TEM-195 and 
TEM-193 enzymes explainin ceftazidime resistance (reviewed by Bradford, 
2001). Gultamine (Q), Proline (P), Alanine (A), Threonine (T), Valine (V), 
Glycine (G), Histidine (H), Glutamic acid (E), lysine (K), Tryptophan (W), 












3.8.5 Ciprofloxacin resistance 
PCR was performed using the primers described by Valentine et al. (2008) for the 
amplification of quinolone resistance determining re ions (QRDRs). Table 14 shows 
the MIC values of ciprofloxacin and the mutations i the gyrA and parC genes. 
Table 14: MIC values of ciprofloxacin and the mutations in gyrA and parC 
EU MIC(mg/L)   US  
MIC 
(mg/L)     
Isolate CIP gyrA parC Isolate CIP gyrA parC 
1 64 S83-L S80-W     
2 16 S83-L S80-S Ab25 128 S83-L S80- Y 
3 64 S83-L S80-L Ab27 64 S83-L S80-L 
4 128 S83-L Q84-K Ab36 128 S83-L S80-L 
5 4 S83-L S80-S Ab37 128 S83-L S80-L 
6 128 S83-L S80-L Ab38 64 S83-L S80-L 
7 2 S83-L S80-S Ab39 64 S83-L S80-F 
8 1 N/D N/D Ab74 128 S83-L S80-F 
9 64 S83-L S80-L Ab75 128 S83-L S80-F 
10 32 S83-L S80-W Ab76 128 S83-L S80-F 
11 8 S83-L S80-S Ab77 128 S83-L S80-F 
12 >256 S83-L S80-W Ab78 32 S83-L S80-S 
13 128 S83-L S80-L Ab79 0.012 N/D N/D 
14 0.25 N/D N/D Ab93 128 S83-L S80-L 
15 0.5 N/D N/D Ab94 4 S83-S S80-S 
16 128 S83-L S80-L Ab95 128 S83-L S80-L 
17 128 S83-L S80-L Ab96 128 S83-L S80-L 
18 256 S83-L S80-L Ab97 8 S83-L S80-S 
19 0.12 N/D N/D Ab193 128 S83-L D84-K 
20 128 S83-L S80-L Ab194 128 S83-L S80-F 
21 4 S83-S S80-S Ab195 128 S83-L S80-F 
22 N/D N/D N/D Ab196 0.5 N/D N/D 
23 64 S83-L S80-L Ab197 8 S83-L S80-S 
24 2 S83-L S80-S A198 N/D N/D N/D 
25 0.12 N/D N/D Ab199 128 S83-L S80-L 
26 64 S83-L S80-L Ab200 128 S83-L S80-L 
27 256 S83-L S80-L Ab201 128 S83-L S80-L 
28 0.12 N/D N/D Ab202 128 S83-L S80-F 
29 64 S83-L S80-L Ab203 64 S83-L S80-F 
30 128 S83-L S80-L Ab204 64 S83-L S80-F 
31 16 S83-L S80-L Ab205 128 S83-L S80-F 
32 0.5 S83-L S80-S Ab206 32 S83-L S80-S 
33 16 S83-L S80-S Ab207 64 S83-L S80-L 
34 8 S83-L S80-S Ab208 16 S83-L S80-S 
35 16 S83-L S80-S Ab209 >256 S83-L S80-W 
36 32 S83-L S80-L Ab210 128 S83-L S80-L 
37 32 S83-L S80-L Ab211 256 S83-L S80-L 
    Ab212 128 S83-L S80-L 
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MIC (Minimum inhibitory concentration) of Ciproflox acin (CIP) 
MIC values highlighted in red: Resistant 
MIC values highlighted in black: Sensitive 
N/D indicates not determined 
parC changes highlighted in light green: novel changes 
gyrA, parC changes in blue: no change in the amino acid 
gyrA, parC changes in black: amino acid changes  
S= Serine, L=Leucine, W=Tryptophan, Q= Glutamine, K=Lysine, D= Aspartate, 
F=Phenylalanine 
The numbers in gyrA, parC denote the position at which the amino acid change 
has occurred. 
Highlighted in Blue: No change in the amino acid. 
It was found that just 16% of the total European isolates and just 5% of the isolates 
from the US were sensitive to ciprofloxacin. Modifications of the DNA topoisomerase 
II and IV, due to in the mutations in the gyrA and parC have been well described in A.
baumannii (Higgins et al., 2004). The AdeABC and AbeM efflux pumps have also 






3.8.6 Gentamicin resistance 
A multiplex PCR described by Noppe-Leclercq et al. (1999) was used for the 
identification of aminoglycoside resistance genes. Table 15 gives the gentamicin 
resistance profile with the detection of one or more aminoglycoside resistance genes. 
 
Table 15: MIC of gentamicin (CN) and aminoglycoside resistance genes. 
EU 
MIC 
(mg/L) aminoglycoside modifying US  
MIC 
(mg/L) aminoglycoside modifying 
Isolate CN enzymes Isolate CN enzymes 
1 0.5 aph(3’)-VI    
2 32 aph(3’)-VI Ab25 >256 aph(3’)-VI  
3 64 ant(2'')-Ia Ab27 128 aac(3)-Ia,ant(2’’)-Ia,aph(3’)-Ia 
4 32 ant(2'')-Ia Ab36 4 aac(3)-Ia,aac(6’)-Ib 
5 128 aac(3)-Ia, ant(3')-VI,aph(3')-Ia Ab37 128 aac(3)-IIa,aph(3’)-VI,ant(2’’)-Ia, 
6 0.25 aph(3’)-VI Ab38 >256 aac(3)-IIa,aph(3’)-VI 
7 >265 ant(2'')-Ia Ab39 128 aac(3)-IIa 
8 >256 N Ab74 32 aac(3)-Ia 
9 >>256 aac(3)-Ia Ab75 128 aph(3’)-VI,ant(2’’)-Ia 
10 32 aac(3)-Ia Ab76 >256 aph(3’)-VI,ant(2’’)-Ia 
11 2 N Ab77 128 aph(3’)-VI,ant(2’’)-Ia 
12 1 N Ab78 2 aph(3’)-VI,ant(2’’)-Ia 
13 >256 ant(2'')-Ia Ab79 0.25 N 
14 4 ant(2'')-Ia Ab93 256 aac(3)-Ia,aph(3’)-VI,ant(2’’)-Ia 
15 8 ant(2'')-Ia Ab94 128 ant(2’’)-Ia 
16 64 aac(3)-IIa Ab95 >256 aac(3)-Ia 
17 256 ant(2'')-Ia Ab96 >256 ant(2’’)-Ia 
18 16 N Ab97 8 aph(3’)-VI,ant(2’’)-Ia 
19 0.06 N Ab193 32 N 
20 256 aac(3)-Ia,ant(2'')-Ia Ab194 16 aac(3)-Ia,ant(2’’)-Ia,aph(3’)-Ia 
21 >256 aac(3)-Ia, aph(3')-Ia Ab195 32 aac(3)-Ia,aph(3’)-Ia 
22   Ab196 4 aac(3)-Ia,ant(2’’)-Ia,aph(3’)-Ia 
23 4 N Ab197 4 aac(3)-Ia,ant(2’’)-Ia,aph(3’)-Ia 
24 1 aac(3)-IIa,ant(2'')-Ia,aph(3')-Ia    
25 0.12 ant(3')-VI,aph(3')-Ia Ab199 256 aac(6')-Ib 
26 >256 aac(3)-IIa,ant(2'')-Ia Ab200 128 ant(2'')-Ia,aac(6')-Ib 
27 4 aac(3)-Ia Ab201 128 aac(3)-Ia,aph(3’)-VI,ant(2’’)-Ia  
28 0.12 N Ab202 0.25 aph(3’)-VI 
29 0.12 aac(3)-IIa Ab203 0.12 aph(3’)-VI 
30 0.5 aph(3’)-VI Ab204 0.25 aph(3’)-VI 
31 8 aph(3’)-VI,aph(3')-Ia Ab205 0.12 aph(3’)-VI 
32 8 aph(3’)-VI,aph(3')-Ia Ab206 1 aac(3)-Ia,ant(2’’)-Ia  
33 2 aph(3’)-VI,aph(3')-Ia Ab207 128 aac(3)-Ia,ant(2’’)-Ia,aph(3')-VI 
34 2 aph(3’)-VI Ab208 >256 aac(3)-Ia,ant(2’’)-Ia,aph(3')-Ia 
35 32 aac(3)-Ia Ab209 >256 ant(2’’)-Ia,aph(3')-Ia 
36 2 aac(3)-Ia Ab210 >256 ant(2’’)-Ia,aac(6')-Ib 
37 4 aac(3)-Ia Ab211 128 aac(3)-Ia,aph(3’)-VI,ant(2’’)-Ia  
   Ab212 128 aph(3’)-VI,ant(2’’)-Ia 
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Minimum inhibitory concentration (MIC) values of gentamicin (CN) 
Highlighted in red= resistant, Highlighted in black= sensitive, N=absence of a 
resistance gene 
The following description from Shaw et al., 1993 
aac(3)-Ia is N-acetyl transferase and confers resistance to astromicin (fortimicin), 
gentamicin and sisomicin 
aac(3)-IIa is N-acetyl transferase and confers resistance to gentamicn, tobramycin, 
dibekacin, 6'-N-ethylnetilmicin, 2'-N-ethylnetilmicin, netilmicin and sisomicin 
aac(6')-Ib is N-acetyl transferase and confers resistance to tobramycin, dibekacin, 2'-
N-ethylnetilmicin, netilmicin, sisomicin, amikacin, 5-episisomicin and isepamicin  
ant(2'')-Ia  is an aminoglycoside adenylyl or nucleotidyltransferase and confers 
resistance to gentamicn, tobramycin, dibekacin, sisom cin and kanamycin 
aph(3')-Ia is a phosphotransferase and confers resistance tokanamycin, neomycin, 
paromomycin, ribostamycin, lividomycin, gentamicin B 
aph(3’)-VI is a phosphotransferase and confers resistance to kanamycin, neomycin, 
paromomycin, ribostamycin, butirosin, amikacin and  isepamicin  
 
The major classes of enzymes conferring resistance to amniglycoside in A. baumannii 
include acetyltransferases, nucleotidyltransferases nd phosphotransferases (Noppe-
Leclercq et al., 1999). Other mechanisms include the post-transcriptional rRNA 
methylation by 16S rRNA methylases such as armA, rmtA, rmtB, rmtC and rmtD (Doi 
et al., 2007; Yokoyama et al., 2003; Yamane t al., 2005). The PCR for 16S rRNA 
methylases was not sought due to time constraints, although the multiplex PCR by 





Forty-seven percent of the strains from the US were carbapenem resistant in 
comparison with 14% resistant strains in Europe; 39% of the strains from the US had 
intermediate levels of carbapenem resistance in comparison to 28% strains isolated in 
Europe. These figures indicate that A. baumannii may be acquiring a resistant state 
slowly, but steadily, by looking at the trends studied for European isolates. The 
population structure of clinical isolates of A. baumannii is dominated by three 
international clonal lineages known as European cloes I, II and III, corresponding to 
CC1 (comprising ST1, ST7, ST8, ST19 and ST20), CC2 (comprising ST2, ST45 and 
ST47) and CC3 (ST3 and ST14) in the MLST scheme of Diancourt et al. (2010), with 
most outbreak strains belonging to the first two of these lineages (Woodford et al., 
2011). We observed that OXA-66 was the most predominant enzyme (28%), followed 
by OXA-69 (11%), OXA-71 (6%) and then other blaOXA enzyme variants in the 
European isolates. 
 
A slightly different trend was observed for isolates from the US where OXA-66 was 
predominant (24%), followed by OXA-71 (14%), OXA-65 (13%), OXA-51 (11%), 
OXA-69 (11%) and other OXA enzyme variants. Seven prcent of the total strains 
harboured the blaOXA-23-like with ISAba1, immediately located upstream of the gene. 
Eleven percent of the strains harboured the blaOXA-40-like gene and 32% of the strains 
harboured the blaOXA-58-like gene linked to different insertion elements (Table12a and 
12b) upstream of the gene. According to Woodford et al. (2011), even if the core 
genome of the clonal lineages is stable, the accessory genome is more fluid and 
carbapenem resistance among these isolates has become mmon, usually by 
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acquisition of OXA carbapenemase genes, although it may simply involve insertion 
sequence-mediated up-regulation of the intrinsic blaOXA-51-like gene, and this was seen 
for 23% of strains, which had their blaOXA-51-like gene upregulated by either ISAba825 
or ISAba1. The isolates with an insert upstream of the blaOXA-51-like gene did not have 
an insert downstream as tested by the intoxaF and intaceR primers. They formed 
defunct transposons. Carbapenem resistance due to metallo-β-lactamases was not 




Resistance to ceftazidime was observed in 81% of European isolates and 94% of 
isolates from the US; 19% of the European isolates had intermediate levels of 
ceftazidime resistance and 6% from the US. There was no isolate sensitive to 
ceftazidime. Most of the isolates had either ISAba1 or ISAba125 governing the blaADC 
gene (Table 13). These insertion elements have been shown to upregulate the 
expression of the blaADC gene (Ruiz et al., 2007, Lopes t al., 2011. P601, ECCMID) 
The strains that did not have any insertion upstream but were still resistant to 
ceftazidime and were positive for at least one or me of either the blaTEM-like, (TEM-F 
and TEM-R primers), blaPER-like (PER-F and PER-R primers) or blaOXA-2-like genes 
(CSa and CSb primers), certain variants of which provide high resistance to 
ceftazidime (reviewed by Bradford., 2001, Pasteran et al., 2006, Danel et al., 1997). 
The same isolates were negative for blaCTX-M families, blaVEB, blaSHV and blaGES 





Resistance to ciprofloxacin was observed in 81% of European isolates and 94% of 
isolates from the US; 19% of the European isolates nd 6% of isolates from the US 
were sensitive to ciprofloxacin. Commonly observed gyrA and parC mutations were 
seen in isolates having a ciprofloxacin resistance profile (Table 14). Fluoroquinolone 
resistance can be attributed to mutations in the gyrA and parC genes (Valentine t al., 
2008) but also to up-regulation of efflux pumps, giving a lower level of resistance 
(Magnet et al., 2001) 
 
Gentamicin resistance 
Resistance to gentamicin was observed in 47% of European isolates and 28% of 
isolates from the US. A previous study by Henwood et al (2002) reports over 75% 
isolates as ceftazidime resistant followed by 30% isolates with gentamicin resistance 
profile and this concurs with the trends observed in this study. Aminoglycoside 
resistance due to acetyltransferases [aac(6’)-Ib, aac(6’)- Ih, aac(3)-I, aac(3)-II], 
nucleotidyltransferase [ant(2’’-I )], and phosphotransferases [aph(3’)-I, aph(3’)-VI] 
has been predominantly identified within clinical A. baumannii isolates, with one or 
more gene(s) conferring aminoglycoside resistance (Noppe-Leclercq et al., 1999). In 
our study, we also observed some of the clinical isolates harbouring one or more 
aminoglycoside resistance but displaying a sensitive phenotype. This also hints 
towards the development of aminoglycoside resistance, which is evolving slowly but 
steadily with time.   
 179 
4.0 DISCUSSION 
The prevalence of insertion elements in A. baumannii is becoming a great concern in 
treating patients with multiresistant isolates. Insertion sequences are motors that 
regulate the expression of genes and drive their exp ession under conditions that are 
stressful for the survival of the bacterium. This study focused on exploring the role of 
insertion elements such as ISAba1, ISAba2, ISAba3, ISAba16, ISAba125 and many 
more which have contributed towards the multi-drug resistant nature of A. baumannii. 
These elements have assisted and enhanced profile of multi-drug resistance of 
Acinetobacter baumannii making it a resilient bacterium and an emerging pathogen. 
Insertion elements have added to the versatility, diversity, evolutionary capabilities, 
and virulence factors of A. baumannii (Bergone-Bérézin, 2008). The expression of 
various β-lactamse genes with the IS loaded promoters help in destroying most of the 
antibiotics. The insertion elements also act as vehicl s of mobilization from one 
bacterial species to another. The entry of Acinetobacter baumannii n the military 
healthcare system and the civilian hospital environme t, leading to numerous 
outbreaks is not surprising (Murray et al., 2008). The implementation of broad 
infection control measures including increased enviro mental cleaning, widespread 
availability and use of hand hygiene, active surveillance, and isolation of colonized 
and infected patients will help to reduce the spread of this bacterium among immuno-
compromised patients (Murray et al., 2008). Novel strategies for control should be 
developed and applied to the combat the increasing rates of infections and the clonal 
spread of this pathogen. It is important to note that such advances in implementing 
infection control will have important implications for both military and civilian 
hospitals and will ultimately lead to better control of infections caused by various 
healthcare-associated pathogens (Murray et al., 2008). The work described in this 
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thesis adds to the better understanding of A. baumannii as the emerging pathogen of 
21st century. It allows the reader to understand the mechanisms of resistance and gives 
an insight about the problems involved in treating multi-drug resistant A. baumannii. 
This study adds to the better understanding of antimicrobial resistance mechanisms in 


















This study aimed to investigate in detail the mechanisms of resistance in A. baumannii 
strains isolated from various parts of the world: 
Various hypotheses were tested and the following questions were successfully 
answered on completion of this study. 
 
Section 1: Can ISAba1 modulate resistant and sensitive phenotypes? Yes. It can 
increase the beta-lactamase gene expression and contribute towards a phenotype that 
is favourable to the bacterium depending on the resistance load. Translational 
frameshifting of ISAba1 has already been shown (Mugnier et al., 2009) and the 
transposition of ISAba1 with frameshift mutants like acriflavine is likely to occur as it 
is a frameshift mutagen. 
 
Section 2: Is there any other insertion element that can regulate blaADC gene 
expression? Yes. In the course of this study ISAba125 was identified. Though it is not 
as common as ISAba1, which is found in most of the isolates, it is provides a very 
strong promoter for the blaADC gene up-regulation. 
 
Section 3: Is A. baumannii emerging as a multiresistant pathogen in countries such as 
Bolivia? Yes. This study found that A. baumannii was resistant to almost all the 
antibiotics tested with the blaOXA-58-like gene, governed by ISAba3-like element, 
conferring carbapenem resistance, and blaADC gene, governed by ISAba1, conferring 
ceftazidime resistance. The mutations in the gyrA, parC were also high, thus 
conferring resistance to ciprofloxacin with synergistic contribution from the AdeABC 
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efflux pump. The mechanisms of gentamicin resistance remains unexplained in some 
of the isolates.    
 
Section 4: What are the trends in Aberdeen Royal Infirmary? In this study we 
observed evolution of new variants of the blaOXA-51-like gene (OXA-216 and 217). We 
also established the clonal relatedness of 2 isolates isolated in different years and 
showed how the integration of blaOXA-23-like gene in the host chromosome can provide 
a stable mechanism of resistance. 
 
Section 5: Are there any other insertion elements that govern the blaOXA-51-like gene 
expression? Yes. We found ISAba825, which governed the expression of blaOXA-58-like 
and blaOXA-51-like genes in clinical isolates isolated in the US. We also demonstrated 
that the loss of this element is co-ordinated by a central mechanism that can render the 
bacterium sensitive to carbapenems. 
 
Section 6: What was the mechanism of carbapenem resistance in strain Ab244 
(isolates 12)? We observed the presence of blaOXA-58-like gene that was governed by 
ISAba-3-like element and this provided intermediate levels of resistance in this 
isolate. We checked for the presence of insertion elem nt upstream of the blaOXA-51-like 
gene to see if that was synergistically related to carbapenem resistance in this isolate 
but instead identified a novel insertion element ISAba16, which disrupted the blaOXA-
51-like gene in this isolate. 
 
Section 7: Are efflux genes controlled by insertion elements? We observed a single 
isolate having ISAba1 sequence upstream of the adeA gene whereas other isolates had 
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disruptions of the adeS gene by insertion elements like ISAba1 and ISAba16. Is 
fluoroquinolone resistance partially contributed by an efflux pump? We concluded 
that efflux does contribute towards multiresistant phenotype but gyrA and parC 
mutations are the primary targets that can make the organism easily resistant to 
fluroquinolones like ciprofloxacin. 
 
Section 8: How do you compare A. baumannii resistance from Europe with that with 
the US? We saw that the emergence of A. baumannii as a multi-drug resistant 
pathogen was at a rapid rate in the US in comparison to Europe.  During the course of 
the study we found that isolates belonging to sequence group 1 and sequence group 2 
appear to be the most successful, certainly across Europe, and within these isolates it 
is the blaOXA-66 and blaOXA-69 genes that are most regularly identified. The trends i  the 
US were a little different where OXA-66 was predominant, followed by OXA-71, 
OXA-65, OXA-51, and lastly OXA-69. The presence of ISAba1 within an isolate is a 
major contributing factor, as it has been shown in this study that isolates which 
encode an ISAba1 element upstream of an OXA-51-like gene have carbapenem MICs 
that are similar to those of isolates that encode an acquired OXA-type β-lactamase of 
the OXA-23, OXA-40 or OXA-58 families. The presence of ISAba1 or ISAba825 
upstream of a blaOXA-51-like gene may thus greatly increase the ability of the isolate to 
survive carbapenem challenge. Our findings indicate that in certain isolates in this 
study the expression of an OXA-51-like enzyme is as important a threat to 
carbapenem use as the acquired OXA enzymes because due to the fluidity of the 
genome, the bacterium can recruit the help of insertion elements in order to enhance 
its gene expression, thus developing resistance to antibiotics. This is of great concern, 
as it presents the scenario that all A. baumannii have the potential to become resistant 
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to the carbapenems without needing to acquire additional β-lactamases. The insertion 
element ISAba1 was the most common element found in at least 60% of the isolates. 
Other elements such as ISAba2, ISAba3, ISAba825, IS1008, ISAba125, ISAba16 were 
found to govern the expression of β-lactamase genes or providing alternate 
mechanisms of resistance for the better fitness of the bacterium. It is noteworthy to 
point out that a variety of elements were associated with the expression the the 
blaOXA-58-like gene. The monitoring of the blaOXA-51-like to identify enzyme variants with 
increased substrate spectrums or higher levels of activity would be crucial if we want 
to preserve and use effectively the few remaining atibiotic treatment options that are 
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Role of ISAba825 in the expression of the blaOXA-51-like gene in clinical strains of 
Acinetobacter baumannii 
 
B. S. Lopes and S.G.B Amyes 
 
University of Edinburgh, UK 
Objective: 
The number of nosocomial Acinetobacter infections has risen in recent years. These 
gram-negative coccobacilli are now major opportunistic pathogens, predominantly 
causing infections of the respiratory and urinary tracts and of the skin, catheter-related 
infections and bacteremias. The aim of this study was to investigate the role of 
insertion sequences involved in the expression of blaOXA-51-like and blaADC gene 
present in A. baumannii. 
 
Methods: 
7 multi drug resistant strains isolated in the United States were screened for the 
presence of insertion sequences and antibiotic resistant genes. The isolates were 
confirmed as A. baumannii by blaOXA-51-like PCR and by restriction analysis using the 
enzymes AluI and NdeII. The isolates were screened for the presence of insertion 
sequence upstream and downstream of blaOXA-51-like and blaADC gene. The MICs of 
imipenem, meropenem and ceftazidime were determined by the BSAC guidelines. 
Multiplex PCR for oxacillinases was performed as decribed previously. 
 
Results: 
All the strains were positive for the presence of blaOXA-51-like gene and blaOXA-58 gene; 
4 isolates showed the presence of insertion sequence ISAba825 upstream of the 
blaOXA-51-like gene and 3 had an insert of ISAba1 upstream of the blaOXA-51-like gene. 
The MIC of IPM strains having ISAba825 was 16mg/L and that of meropenem was 4 
mg/L. The chromosomal blaOXA-51-like genes of these 4 strains were blaOXA-65.  
 
The MIC of IPM ranged from 4-8 and for MEM ranged from 4-16 for the 3 strains 
having ISAba1 upstream of the blaOXA-51-like gene. The 3 strains had blaOXA-79, blaOXA-
80 and blaOXA-82 gene. The blaADC gene was present in all the strains and, in all strains, 
ISAba1 was located upstream of the gene and giving each strain an MIC of 128mg/L 
of ceftazidime. 
 
The ISAba825 sequence was seen 7bp (AAGTCTT) upstream of the blaOXA-51-like 
gene. It was oriented in 5’-3’ direction with respect to the blaOXA-65 gene and putative 
promoters -10 TATGAA and -35 TTGTCA were located 17bp apart from each other 
and were located 74bp and 97bp upstream of the blaOXA-65 gene. There was no 
insertion sequence detected downstream for all strain  making it a defunct transposon. 
 
Conclusions: 
These data indicates a first report on the presence of a novel insertion element 
ISAba825 present upstream of the blaOXA-51-like gene, besides the well known insertion 
sequence ISAba1, that can cause over-expression of the blaOXA-51-like gene. The 




The role of Insertion Elements in control of antibiotic resistance in Acinetobacter 
baumannii isolated from sources throughout the world. 
 
B. S. Lopes and S.G.B Amyes 
 
University of Edinburgh, UK 
 
Background: The aim of this study was to investigate the drug resistance profile and 
the frequency of insertion elements found in A. baumannii strains isolated from 
various sources around the world. 
 
Methods: A collection of 85 epidemiologically unrelated A. baumannii isolates were 
studied. Their identity was confirmed by laOXA-51-like PCR and by restriction analysis 
of the 16S-23S rRNA fragment. The isolates were screned for the presence of 
insertion sequence (IS) upstream of the blaOXA-51-like by PCR amplification and 
sequencing. Primers FU and RU were used to check for the insert upstream of the 
blaADC gene. A multiplex PCR for oxacillinases was also performed. MICs for 
imipenem and ceftazidime were determined by the agar dilution 
method and the results interpreted according to the BSAC guidelines. 
 
Results: All the isolates were positive for blaOXA-51-like gene; 7% of the isolates 
harboured the blaOXA-23 gene, 10% had the blaOXA-24 gene and 36% had the blaOXA-58 
gene. The MIC90 of imipenem was 16mg/L and the MIC90 of ceftazidime was 
>256mg/L. It was observed that, 88% of the isolates w re resistant to ceftazidime, of 
which 63% (8% having ISAba125 and 55% having ISAba1) harboured an insertion 
sequence upstream of the blaADC gene. Furthermore, 26% isolates were resistant to 
imipenem, 33% exhibited intermediate level of resistance of imipenem and 22% of 
the isolates had an insert upstream of the chromosoal blaOXA-51-like gene (5% having 
ISAba825 and 17% having ISAba1).  
 
Conclusions: In this study we report the prevalence of ISAba1 along with the rarer 
ISAba125 and ISAba825, which have been found in clinically relevant strains, 
upstream of the blaADC and blaOXA-51-like gene respectively. In summary, we conclude 
that ISAba125 and ISAba825 may govern the expression of blaADC gene and blaOXA-51-
















Ceftazidime resistance in Acinetobacter baumannii from the 
United Arab Emirates 
 
A. F. Opazo1, B. S. Lopes1, A. Sonnevend2, T. Pal2, A. Ghazawi2, and S.G.B. 
Amyes1. 
 
University of Edinburgh, UK1 and University of United Arab Emirates2 
 
Background:  
Acinetobacter baumannii is one of the most important microorganism causing 
infections in hospitalized patient. The remaining opti ns for the treatment of serious 
infectious diseases causes by multi-resistant A. baumannii are carbapenems, 
cephalosporins and colistin. Resistance to cephalosporins has been associated with the 
insertion sequence ISAba1 providing a strong promoter to ADC-genes.  
 
Methods:  
3 strains of A. baumannii isolated in Al Ain, UAE, named Nm55, Nm57 and Nm128, 
were studied. Nm57 was isolated from an intravenous catheter tip of an adult patient, 
Nm55 and Nm128 were both isolated from sputum samples taken 15 weeks apart 
from a 6 year old patient. They were confirmed as A. baumannii by PCR detecting the 
blaOXA-51-like gene and sequencing the rpoB gene. Genotypic 
characterization was performed by pulsed-field gel el ctrophoresis (PFGE). Antibiotic 
susceptibility and determination of minimal inhibitory concentration (MIC) of 
ceftazidime were performed according to BSAC guideline. Detection of blaOXA genes 




All the strains were designated as identical according to PFGE pattern.All strains were 
resistant to carbapenems, cefotetan, aztreonam, cefoperazone, cefepime, cefotaxime 
and cefpodoxime. Strain Nm55 was resistant to ceftazidime, while Nm57 was 
intermediate and Nm128 was susceptible. All the strains harbour both OXA-64 
chromosomal and the OXA-23 plasmid ß-lactamases. ISAba1 was upstream of the 
blaOXA-23 genes in all three strains and was responsible for carbapenem resistance. All 
the strains harboured the same blaADC gene but in no case was there a defined IS 
element upstream.  
 
Conclusions:  
This study shows a rare example of an A. baumannii strain that was resistant to 
carbapenems but was sensitive to ceftazidime. When the strain progressed to 
ceftazidime resistance this was not by the reported m thod of an insertion of an 









The role of IS30 in the expression of the blaADC gene in Acinetobacter baumannii 
 
B. Lopes, A. Hamouda and S. Amyes. 
University of Edinburgh, UK 
 
Objective: 
Multidrug-resistant Acinetobacter baumannii is a major nosocomial pathogen that is 
rapidly evolving and developing resistance to all major classes of antibiotics. It is 
identified by the presence of intrinsic blaOXA-51-like gene and restriction of 16S-23S 
rRNA intergenic spacer sequences. The aim of this sudy was to investigate the role of 




A panel of 17 geographically diverse A. baumannii isolates was creened for the 
presence of insertion sequence upstream and downstream of blaADC gene.  The 
isolates were confirmed as A. baumannii by blaoxa-51-like PCR and by restriction 
analysis using the enzymes AluI and NdeII. The MICs of ceftazidime were determined 
by the BSAC guidelines. The strains were checked for ESBL production by synergy 
disc assay between cephalosporins and augmentin (co-amoxiclav). 
 
Results: 
The MICs for ceftazidime showed that 4 strains had an MIC of > 256mg/L, 7 strains 
had an MIC of 128mg/L, 1 strain had an MIC of 64mg/L and 5 strains had an MIC of 
32mg/L. None of the strains produced ESBLs as tested by synergy between 
augmentin and cephalosporins such as ceftazidime, cefotaxime, cefipime and 
cefpodoxime. PCR results showed that ISAba1 was present upstream of blaADC gene 
in 12 strains (MICs ranging from 32-128mg/L). Out of he five strains having MIC of 
32mg/L one strain did not have ISAba1 present upstream of blaADC gene. The 4 
strains with MICs >256mg/L harboured IS30 upstream of blaADC gene. There was no 
insertion sequence detected downstream for all 17 strain  making it a defunct 
transposon. The IS30 insert was observed 126bp upstream of blaADC gene. Although 
the region just upstream of blaADC gene had a functional promoter, the IS30 element 
also had a promoter for the transposase it carries and this may also increase the 
expression of the blaADC gene. 
 
Conclusions: 
These data indicate the presence of a novel insertion element IS30 besides ISAba1 
that can cause overexpression of blaADC gene. The isolates with IS30 may encode 
novel ADC variants having significant hydrolysing activity against ceftazidime. The 










The utilisation of gluconic acid in certain strains of Acinetobacter baumannii 
 
B. Lopes, A. Hamouda and S. Amyes. 
University of Edinburgh, UK 
 
Background: 
A characteristic feature of glucose oxidizing Acinetobacters is seen with blood agar 
having aldose sugar. The aim of this study was to evaluate the nature of brown 
pigment produced by Acinetobacter baumannii. 
 
Methods: 
Two (A/B) A. baumannii strains were isolated from diabetic patient and identified by 
blaOXA-51-like PCR and restriction analysis of 16S and 23S r-RNA spacer sequences 
using AluI and NdeII. MICs for to imipenem , meropenem and ceftazidime were 
estimated by BSAC guidelines. Isosensitest (IST)/M9 glucose broth was used for the 
growth of strains. Growth of the strains was monitored over 48 hour period using IST 
broth having gluconic acid concentration range from 0.1 to 4%. The inhibitory 
activity of the pigment produced by strain A was che ked by ditch plate method. 
 
Results: 
The MICs for IPM, MEM, CTZ and FEP were 0.5, 0.5, 8 and 4mg/L respectively for 
strain A and B. Both the strains were positive for blaoxa-51-like and blaADC but negative 
blaoxa-23/40/58 and for metallo-beta-lactamases. It was seen that the strain A produced a 
brown pigment in presence of gluconic acid. It also grew better than strain B over a 
period of 48 hours in the presence of IST broth containing gluconic acid concentration 
ranging from 0.1 to 4%. Both strains did not produce any pigment in Nutrient glucose 
broth. The brown pigment produced by strain A did not have any inhibitory effect 
against S.aureus NCTC6571, Ps. aeruginosa NCTC10662, A. baumannii 
ATCC19606 and E.coli NCTC10418. The glucose dehydrogenase enables both the 
strains to form 6-phosphogluonate which is free to nter the Entner-Doudouroff 
pathway hence there is no pigment production seen in both the strains when M9 
glucose broth is used. On the other side human blood being enriched with nutrients 
including gluconic acid helps strain A to survive btter by converting gluconic acid to 
2,5 diketogluconate which leads to the formation of br wn pigmentation. It is also 
possible that strain B lacks gluconic acid dehydrogenase which could lead to the block 
in successive steps making glycolysis the preferential path for metabolism. In strain B 
it is also possible that the enzyme 2 keto gluconate dehydrogenase is absent which 
converts 2 keto gluconate to 2, 5-diketo gluconate which is responsible for brown 
pigmentation. Strain A can metabolise glucose by glycolysis as well as Entner 
Doudouroff pathway. It is also possible that strain A follows the pathway for brown 
pigment production converting excessive gluconic acd to 2, 5 diketogluconate 
depending on the gluconic acid concentration as the intensity of absorbance increased 
exponentially from lower concentration to higher. 2, 5 diketogluconate being a 
precursor for ascorbic acid production may offer protection against antioxidant stress. 
For strain B glycolysis may be the only option for metabolism unless gluconic acid 
dehydrogenase is present by which it can enter the ED pathway bypassing the step for 




Conclusions:   
The survival of A. baumannii A in gluconic acid enriched medium helps it to survive 
better than A.baumannii B. Excess gluconic acid in strain A leads to brown 
pigmentation which may offer protection against antioxidant stress. The results show 
that strain A has multiple routes of metabolism which offers it better chance for 
survival than strain B.  
 
